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Expansion of a repeat sequence beyond a pathogenic range has been identified as 
the cause of a group of neurodegenerative diseases known as the expanded repeat 
diseases. Disease-associated repeat tracts have been found both within the coding 
region of genes, such as the CAG repeat coding for polyglutamine, or within non-
coding regions. Despite the identification of the mutation involved in these diseases, 
the mechanism by which this type of mutation leads to cell death remains unclear. 
There is a substantial amount of evidence to suggest that RNA-mediated toxicity 
plays a role in pathogenesis of both the polyglutamine diseases and the untranslated 
dominant expanded repeat diseases. A common feature of the expanded repeats 
involved in each of these diseases is the ability of the repeat-containing RNA to form 
a hairpin secondary structure and therefore it has been predicted that similar 
mechanisms may be responsible for initiating cellular dysfunction and death in each 
case. This study uses a Drosophila model to investigate the intrinsic, RNA-mediated 
toxicity of three repeat sequences (CUG, CAG and AUUCU) associated with 
degeneration in human disease. Using a combination of hypothesis-driven and non-
biased approaches, early changes elicited in response to neuronal expression of 
these expanded repeat tracts have been investigated. A hypothesis of a role for RNA 
editing in CAG repeat pathogenesis was explored using this Drosophila model. 
Microarray and proteomic approaches were also utilised to identify pathways which 
are perturbed by the expression of these repeat sequences. The results described in 
this thesis demonstrate a degree of sequence- and context-independent toxicity of 
expanded repeat RNA in this model, suggesting that this kind of effect may also be a 
component of pathogenesis in the disease situation. Pathways commonly perturbed 
in response to expression of these RNA species may represent particularly valuable 
therapeutic targets, since preventing this type of effect could provide positive 
outcomes in a number of diseases.   XX   1 
Chapter 1: Introduction 
 
The identification of disease-causing mutations and investigation of their impact 
on cellular function are vital to the development of therapeutic strategies for human 
disease. Advances in the fields of molecular and cellular biology have greatly 
increased our understanding of the link between genotype and phenotype in disease 
progression however in a number of neurodegenerative diseases, including the 
expanded repeat diseases, the primary cellular dysfunction resulting from the mutation 
has remained elusive. This study uses a Drosophila model of expanded repeat 
disease to investigate early cellular changes which may contribute to pathogenesis. 
 
 
1.0 Expanded repeat diseases 
 
It has been nearly two decades since the first description of human disease 
caused by the expansion of trinucleotide repeats in the genome (1-2). There are now 
at least 17 diseases resulting in neurological or neuromuscular degeneration which 
can be attributed to the expansion of repeat sequences (3-6). The mechanism of 
expansion of these repeats has been suggested to involve slippage during replication 
of the repeat sequences (7). Typically the expanded repeat diseases manifest later in 
life, they show anticipation in families - that is increasing severity of pathology through 
the generations - and they demonstrate repeat number-dependent age of onset (8). 
Instability of the repeats and a tendency towards expansion of repeat number in the 
germ-line has been connected to the phenomenon of anticipation (7). 
 
There is a large amount of overlap in the clinical features of the expanded 
repeat diseases, despite the presence of the repeats in unrelated genes, suggesting 
that the manifestation of expanded repeats in disease is not simply through altered 
expression of the repeat-containing gene. Disease-causing expanded repeats can be 
classified into two categories: those which fall in translated regions of a gene, 
generally consisting of CAG repeats encoding a polyglutamine tract, and those which 
fall in an untranslated region of the genome (7-8). Both translated and untranslated 
repeats generally show dominant inheritance, despite the fact that the untranslated 
repeats do not alter the protein itself.    2 
1.1 Translated repeat diseases  
  
1.1.1 Polyglutamine diseases 
  
To date there are 9 diseases known to be caused by expansion of a CAG 
repeat encoding glutamine (Table 1.1). These diseases are Huntington’s disease 
(HD), spinal bulbar muscular atrophy (SBMA), dentatorubral-pallidoluysian atrophy 
(DRPLA) and a number of spinocerebellar ataxias (SCA1,2,3,6,7&17). Despite their 
presence in entirely unrelated proteins, overlapping features of the polyglutamine 
diseases suggest that there are dominant toxic properties of expanded polyglutamine. 
These features include progressive neurological degeneration which is generally late-
onset, repeat number-dependent age-of-onset and the formation of aggregates by the 
polyglutamine-containing proteins (9). Differences in the specificity of affected cells 
are thought to be a result of the gene in which the repeat falls, however it is unclear 
why mutant forms of ubiquitously expressed proteins should elicit effects on such a 




containing protein  Proposed Function 
CAG Repeat Number 
Disease          Normal 
HD  Huntingtin  Organelle trafficking & axonal transport  36-121  6-34 
SBMA  Androgen Receptor  Ligand-activated Transcription Factor  38-62 
9-36 
 
DRPLA  Atrophin-1  Nuclear receptor Co-repressor  49-88  6-35 
SCA1  Ataxin-1 RNA  processing  39-82  6-44 
SCA2  Ataxin-2 RNA  metabolism  36-63  15-31 




SCA6  CACNA1A  Voltage-gated calcium channel sub-unit  21-33  4-18 
SCA7  Ataxin-7 Transcriptional  regulation  37-306  4-35 
SCA17  TATA box-binding 
protein  Transcriptional initiation  47-55  27-42 
 
Table 1.1: Polyglutamine diseases. HD – Huntington’s disease, SBMA –spinal bulbar 
muscular atrophy, DRPLA - dentatorubral-pallidoluysian atrophy, SCA- spinocerebellar 
ataxia, MJD- Machado Joseph Disease. Larger repeats within the normal range are normally 
interrupted by CAT for SCA1 and CAA for SCA2 while disease-causing alleles consist of 
pure CAG repeats.   3 
Huntington’s disease 
 
Huntington’s disease (HD) is the most common of the polyglutamine 
diseases, and is caused by expansion of a CAG repeat resulting in an expanded N-
terminal polyglutamine tract in the Huntingtin (HTT) protein. The disease presents as 
progressive neurodegeneration resulting in loss of motor and cognitive function. This 
neurodegeneration preferentially affects the medium spiny gamma-aminobutyric acid 
(GABA) neurons in the striatum (9). The function of the 350kDa HTT protein is not 
known, although its association with microtubules and synaptic vesicles suggests a 
role in organelle trafficking and axonal transport (10). A direct association of mutant 
HTT with clathrin-coated membranes has also been demonstrated suggesting that 
perturbation of endocytic pathways may play a role in HD pathogenesis (11). Recent 
studies have demonstrated axonal transport defects in both mammalian neurons 
and a Drosophila model expressing the mutant HTT protein, as well as in HD brains, 
characterised by aggregation of vesicles, mis-localisation of mitochondria and 
apoptosis (12-14).  
 
HTT protein shows ubiquitous expression in neurons and is also expressed at 
low levels throughout the body (15). A number of neuronal cell types which express 
HTT at all times survive in Huntington’s patients – for example the striatal cholinergic 
interneurons – while the striatal spiny neurons most affected in Huntington’s disease 
do not consistently express HTT (16) and it is therefore unclear how selective 
neurodegeneration is elicited. Furthermore, the mutant protein is expressed at 
similar or even slightly reduced levels in comparison to the normal protein in affected 
regions of the brain (9) and therefore there does not appear to be a simple 
relationship between expression of the mutant protein and vulnerability.  
 
 
Spinal bulbar muscular atrophy (SBMA) 
 
  SBMA or Kennedy’s disease is caused by a CAG repeat expansion in the 
androgen receptor (AR) gene on the X chromosome and is the only one of the 
polyglutamine diseases not autosomally dominantly inherited (17). The AR is a ligand 
activated transcription factor which is translocated to the nucleus in response to 
testosterone; a process which is perturbed by the expansion of the glutamine tract in 
the AR (18). It has been suggested that higher circulating androgen and testosterone   4 
levels could explain why only males are affected by SBMA (19). Disease is not simply 
a result of loss-of-function of the AR gene - since mutations to AR do not result in 
SBMA and SBMA individuals show only limited androgen insensitivity - however 
recent reports suggest that loss-of-function may contribute to disease progression, 
since the AR is essential for neuronal health in a YAC mouse model (20). The disease 
predominantly affects spinal and bulbar motor neurons, resulting in muscular atrophy 
and weakness (19). 
 
 
Dentatorubral-pallidoluysian atrophy (DRPLA) 
 
  DRPLA individuals commonly show seizures, involuntary muscle movement 
and chorea as well as dementia (21) as a result of generalised neurodegeneration in 
the cortex, globus pallidus, striatum and cerebellum (22). The polyglutamine tract in 
DRPLA is located in Atrophin-1 (23-24) which has been characterised as a nuclear 
receptor co-repressor and is predicted to interact with a number of transcription factors 
and members of the histone de-acetylase family (25). Expression of expanded 
polyglutamine-containing Atrophin-1 is sufficient to induce symptoms of DRPLA 
through a process which involves proteolytic processing and aggregation of an 120 
kDa fragment containing the expanded polyglutamine tract (26). Pathogenesis does 
not appear to be mediated through a functional interaction of the mutant Atrophin-1 
protein with the wild-type protein, since homozygous deletion of the C-terminal region 
of the wild-type protein does not induce neurodegeneration and also fails to modify 
polyglutamine-induced phenotypes (27). 
 
 
The spinal cerebellar ataxias (SCAs) 
 
  The SCAs are a group of diseases characterised by progressive degeneration 
of the cerebellum resulting in late-onset ataxia and lack of coordination. 70% of SCA 
patients also show degeneration of the peripheral nervous system involving both 
axonal and primary neuropathy (28). There are currently 28 autosomal dominant 
SCAs recognised, 17 of which are caused by a known mutation and 6 of which are 
recognised as polyglutamine diseases (29) as listed in Table 1.1.  
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  SCA1 is caused by a CAG expansion in the Ataxin-1 gene which encodes a 
protein containing an RNA binding motif, with a proposed role in RNA metabolism 
(30). The RNA binding capacity of Ataxin-1 has been shown to be dependent on the 
length of the CAG repeat and therefore it has been suggested that loss of Ataxin-1 
protein function, perhaps resulting in aberrant RNA metabolism, may play a role in 
disease progression (30). The expanded polyglutamine-containing protein is found in 
nuclear aggregates in disease models (31) however, while nuclear localisation of the 
polyglutamine-containing protein is required for disease progression, nuclear 
aggregation is not (31) and it is therefore unclear whether aggregates are a 
component of pathogenesis. While disease-associated Ataxin-1 alleles consist of pure 
CAG repeats, normal alleles of Ataxin-1 contain CAT interruptions in the CAG repeat 
which encode histidine and are thought to reduce aggregation of the protein and 
expansion of the repeat tract (32).  
 
  SCA2 is caused by a CAG expansion within the Ataxin-2 gene. It is 
characterised by degeneration in the cerebellum and brainstem, although it is unclear 
how specificity is elicited since the Ataxin-2 protein is widely expressed in the brain 
(33). The function of the Ataxin-2 protein is unknown although it has been implicated 
in RNA metabolism – a role which is supported by its interaction with cytoplasmic poly-
A-binding protein (34-35) and poly-ribosomes (34) – and a Drosophila orthologue has 
been characterised as a regulator of actin filament formation (36). Both mutant and 
wild-type Ataxin-2 are found exclusively in the cytoplasm and mutant Ataxin-2 does 
not form nuclear inclusions such as those thought to be pathogenic in a number of the 
other polyglutamine diseases (37). Normal alleles of Ataxin-2 are frequently 
interrupted with CAA repeats which, while still encoding glutamine, are thought to alter 
the structure at the DNA and RNA level (33).  
 
  SCA3 or Machado Joseph Disease is the result of a CAG expansion in the 
gene encoding Ataxin-3, MJD1. The phenotype involves progressive ataxia as well as 
peripheral neuropathy which affects both motor and sensory neurons (38). The 
function of Ataxin-3 is unknown, however interactions with DNA repair proteins have 
been reported. HHR23 proteins, which are important in nucleotide excision repair, 
have been shown to be localised to nuclear inclusions in MJD individuals via their 
interaction with the mutant protein (39). Interactions with components of the 
proteasome and ubiquitin-binding factors, which are also present in nuclear inclusions   6 
in MJD, suggest a role for Ataxin-3 in protein turnover (40). More recent studies also 
implicate Ataxin-3 in Ca
2+ signalling via an interaction of the mutant protein with the 
type 1 inositol 1,4,5-trisphosphate receptor, an intracellular calcium channel (41). 
Interestingly, nuclear inclusions in MJD have also been demonstrated to contain wild-
type Ataxin-3 protein which is recruited in a polyglutamine length-dependent manner, 
suggesting that the polyglutamine expansion may affect the normal function of the 
protein (42).  
 
  SCA6 is the result of a C-terminal polyglutamine expansion in the alpha (1A) 
subunit of the neuronal P/Q-type voltage-gated calcium channel encoded by the 
CACNA1A gene (43). Neurodegeneration in SCA6 is primarily localised to the Purkinje 
cells of the cerebellum, which coincides with high expression of the CACNA1A gene 
(44). There are two known disorders caused by missense mutations in the CACNA1A 
gene – episodic ataxia type 2 (EA2) and familial hemiplegic migraine – both of which 
give phenotypes similar to SCA6. It is therefore unclear whether there is toxic gain-of-
function in SCA6, or whether alteration of the kinetic properties of the encoded 
channel is sufficient to explain the neurodegeneration observed (43). This evidence, 
along with the observation that the pathogenic threshold for CAG repeats is much 
lower in SCA6 than the other polyglutamine diseases, has led to questions about the 
classification of SCA6 as a polyglutamine disease (43).  More recently, aggregation of 
the mutant CACNA1A calcium channel has been demonstrated in a knock-in mouse 
model of SCA6, coinciding with age-dependent neurodegeneration without a 
concurrent change in electrophysiological function of neurons (45). This evidence 
suggests that a simple change to calcium channel function is unlikely to explain SCA6 
pathology. 
 
  The polyglutamine tract in SCA7 is located within Ataxin-7. SCA7 individuals 
show neuronal loss in the cerebellum, brainstem and spinal cord, as well as retinal 
degeneration which typically leads to blindness (46). The regions where 
neurodegeneration is observed coincide with regions where Ataxin-7 is expressed. 
Ataxin-7 is thought to play a role in transcriptional regulation since it forms complexes 
with other transcriptional regulators including histone acetyl-transferases (47-48). 
Transcriptional dysregulation has been observed in the absence of ataxia in mice 
expressing expanded Ataxin-7, perhaps suggesting that this is an early component of 
pathology (49).    7 
SCA17 is caused by an expanded CAG repeat in the gene encoding the TATA 
box-binding protein (TBP) which is a transcription initiation factor. TBP is ubiquitously 
expressed, yet pathogenesis in SCA17 is limited to the cerebellum and particularly 
affects the Purkinje cells (50). Expression of TBP containing an expanded 
polyglutamine tract in both cellular and mouse models has been demonstrated to 
result in decreased expression of the nerve growth factor (NGF) receptor, TrkA, which 
is required for Purkinje neuron survival (51). This relationship may go some way to 
explaining specificity of neurodegeneration in SCA17.  
 
Despite the presence of the expanded polyglutamine tract in unrelated genes 
and the degeneration of a specific sub-set of neurons in each disease, there are a 
number of features of the polyglutamine diseases which suggest that common 
pathogenic mechanisms may be involved. Whilst a number of pathways have been 
demonstrated to be perturbed in models of polyglutamine pathogenesis – including 
axonal transport, Ca
2+ homeostasis, transcription, protein turn-over, RNA metabolism 
and mitochondrial function –the primary cause of dysfunction remains unclear.  
 
1.1.2 Pathogenesis and aggregate formation 
 
Aggregates of polyglutamine-proteins are a feature of all of the polyglutamine 
diseases, however their role as a protective or pathogenic agent is contentious. They 
are present in neurons which undergo degeneration in each disease, and are also 
commonly found in neurons which do not undergo degeneration. Both cytoplasmic 
and intranuclear inclusions are seen in HD (52), while only intranuclear inclusions are  
seen in brains of SBMA, DRPLA and SCA1,3,6,7 and 17 patients. In SCA6 and some 
cases of SCA2 only cytoplasmic aggregates have been reported (53).  
 
The role of the nuclear and cytoplasmic aggregates formed by mutant HTT in 
neurodegeneration has been much debated. It has been reported that the N-terminal 
fragment of the mutant HTT protein forms aggregates selectively in striatal neurons 
and is predictive of cell death (54). However, striatal cells transfected with mutant HTT 
in conditions where inclusions cannot form actually show an increase in associated 
cell death suggesting that formation of nuclear inclusions can actually play a protective 
role, perhaps by sequestering soluble forms of the mutant protein (55). There is some 
debate over the validity of cell culture models for neurodegeneration and it has been   8 
suggested that animal models, which typically show increased incidence of cell death 
correlating with formation of aggregates, are more representative of the situation in 
HD individuals (56). Other expanded repeat diseases tell a different story: there is no 
formation of nuclear inclusions in some cases of SCA2 (37), yet many clinical 
manifestations of the disease overlap with the other SCAs where nuclear inclusions 
are observed and in the case of SCA1, are even necessary for pathogenesis (31).  
This observation further supports the idea that aggregates may not actually play a 
causative role in neurodegeneration, however the role of nuclear and cytoplasmic 
aggregates in pathogenesis remains unclear. 
 
 
1.1.3 Polyalanine diseases 
 
There is a class of diseases which are associated with congenital 
malformations which are known to be the result of the presence of polyalanine tracts 
in proteins. The most studied of these is oculopharyngeal muscular dystrophy 
(OPMD), however polyalanine tracts have been found in 494 human proteins and are 
highly polymorphic. They are thought to play a role in transcriptional regulation and 
are known to be regions of DNA binding in many proteins (57). While many 
polyalanine tracts are encoded by GCC or GCG codons, a –1 frameshift of a CAG or 
CUG repeat would also result in translation of alanine and therefore a role for 
polyalanine in pathogenesis of the polyglutamine diseases has been proposed.  
 
It has been shown that the expanded CAG repeat tract in the Ataxin-3 gene is 
prone to –1 frameshifts, resulting in hybrid proteins containing alanine and glutamine 
tracts (58). Frameshifts are thought to be elicited through the formation of secondary 
structures, particularly hairpins, in RNA containing long repeat tracts. In a cellular 
model of SCA3 treatment with anisomycin, a ribosome-interacting drug which reduces 
–1 frameshift, results in a reduction of the cellular toxicity of CAG repeats, suggesting 
a role for these polyalanine tracts in toxicity of polyglutamine diseases (58). Very low 
levels of +1 and +2 frameshifts, which would result in polyalanine or polyserine tracts, 
have been demonstrated in mutant HTT (59). Polyalanine and polyserine containing 
proteins are also among identified modifiers for mutant HTT, further supporting a role 
for frameshift in the pathogenic pathway of HD (60).    9 
However, there is some evidence to suggest that polyalanine tracts are unlikely 
to play a major role in intrinsic toxicity of polyglutamine. Both CAG and CAA-encoded 
polyglutamine tracts have been demonstrated to show a similar range of pathogenic 
phenotypes in a Drosophila model (61), and therefore the ability of the repeat tract to 
undergo a frameshift to encode polyalanine does not appear to play a major role in 
toxicity in all cases. It is not clear whether this result indicates specific properties of 
polyglutamine tracts in Drosophila and therefore the possibility that frameshifts are an 
important component of toxicity in mammalian cells cannot be ruled out.  
 
 
1.2 Untranslated expanded repeat diseases 
 
There are nine diseases currently attributed to the presence of expanded 
untranslated repeats in the genome. Three of these – Fragile X, XE and Friedrich’s 
ataxia – are known to be the result of loss-of-function of the gene in which the repeat 
falls. In the case of Fragile X and XE, methylation of the expanded repeat (CGG and 
GCC respectively) results in transcriptional silencing (62) while in the case of 
Friedrich’s ataxia, a GAA expansion in an intron is thought to prevent transcriptional 
elongation by formation of a secondary structure in the DNA (63). These diseases are 
recessive and are therefore thought to have a different pathogenic mechanism to the 
dominant untranslated repeat diseases.  
 
 
1.2.1 Dominant untranslated expanded repeat diseases 
 
Dominant diseases caused by expanded untranslated repeats are thought to 
result from RNA gain-of-function. Unlike the translated-repeat diseases there is no 
toxic protein encoded by the repeat, yet these diseases show dominance and similar 
neurodegenerative phenotypes to the polyglutamine diseases. Table 1.2 shows a 
complete list of the dominant untranslated repeat diseases.    10 
Disease  Repeat  Gene & region  Mechanism 
Repeat Number 
Disease            Normal 
FXTAS  CGG  FMR1, 5’UTR  Unknown 60-200  6-53 
DM1  CTG  DMPK, 3’UTR  RNA G-O-F  50-3000  5-37 
DM2  CCTG  ZNF9, intron  RNA G-O-F  75-11000  10-26  
SCA8  CTG/CAG  Ataxin-8OS, 3’UTR 
Ataxin-8, polyQ 
Unknown 107-127  16-37 
SCA10  ATTCT  Ataxin-10, intron  Unknown 800-4500 10-29 
SCA12  CAG  PPP2R2B, 5’UTR  Unknown 55-78  9-28 
HDL2  CTG  Junctophilin-3, 
depends on splicing 
Unknown 51-57  14-19 
 
Table 1.2: Dominant untranslated repeat diseases. FXTAS- Fragile X-associated tremor-
ataxia syndrome, DM- Myotonic dystrophy, SCA- spinal cerebellar ataxia, HDL- Huntington’s 
disease-like, G-O-F – gain-of-function. 
 
 
Myotonic dystrophy type 1 and 2 (DM1 and 2) are the best characterised of 
the untranslated repeat diseases. DM1 was the earliest known example of a dominant 
disorder caused by repeat expansion in a non-coding region of a gene. It results from 
a CTG expansion above around 50 repeats in the 3’UTR of the Dystrophia myotonica-
protein kinase (DMPK) gene. The disease manifests as myopathy and progressive 
cardiac defects, often coupled with the formation of characteristic posterior iridescent 
cataracts and insulin resistant diabetes (64). There is also evidence of some CNS 
pathology, including damage to cortical regions of the brain (65), resulting in variable 
and progressive cognitive impairment in individuals with DM1 (66).  It is clear that DM1 
is not simply the result of loss-of-function of DMPK since mouse DMPK knock-out 
models do not recapitulate all aspects of the disease and show much milder cardiac 
and muscular defects even when both alleles are knocked-out (67). A role for loss-of-
function of the nearby SIX5 gene has also been suggested however, while knock-out 
models of SIX5 do have cataracts, they are not the posterior iridescent sort seen in 
DM1 (68-69) and therefore even a reduction in expression of both genes cannot 
explain all aspects of pathology. 
 
Transgenic mice expressing 45 kb of the human DM1 region containing at least 
300 repeats also display symptoms of DM1, including CNS pathology (67), supporting 
a toxic gain-of function mechanism in the disease. The most significant evidence for 
an RNA gain-of-function mechanism in DM1 is that expression of a CUG repeat in a 
completely unrelated mRNA has also been shown to result in myopathy and myotonia   11 
in a mouse transgenic model (70). It has been demonstrated by in situ analysis that 
the expanded repeat in DM1 is transcribed and mRNAs containing the repeat are 
spliced in the normal manner but retained in the nucleus in foci associated with 
nuclear components, including the splicing factor Muscleblind (MBNL) (3). A number 
of targets of MBNL are aberrantly spliced in DM1 individuals including cardiac troponin 
T (TNNT2) (71), insulin receptor (IR) (3, 71), chloride channel-1 (CLCN-1) (3), tau 
(72), myotubularin-related protein-1 (MTMR1), fast skeletal troponin T (TNNT3), N-
methyl-D-aspartate receptor 1 (NMDAR1) (72), amyloid precursor protein (APP) (72), 
ryanodine receptor (RyR) (73) and sarcoplasmic/ endoplasmic reticulum Ca
2+ 
ATPase1&2 (SERCA1&2) (73). These targets normally show developmental or tissue-
specific regulation of splicing which is lost in DM1 individuals such that the adult 
splice-form or correct tissue isoform fails to be expressed. Interestingly, splicing mis-
regulation can be separated from the co-localisation of MBNL, since MBNL has also 
been found in association with CAG-repeat containing foci but is not coupled with mis-
splicing of MBNL targets in this case (71). Some pathologies associated with DM1 are 
directly related to mis-spliced MBNL targets; for example, it has been demonstrated 
that a reduction in CLCN-1 expression equivalent to the loss of expression of the adult 
isoform observed in DM1 results in myotonia (74) and failure to express the correct 
muscular isoform of IR results in failure of skeletal muscle cells to respond to insulin 
(75).  
 
DM2 results from the expansion of a CCTG repeat within an intron of the ZNF9 
gene. In some cases, this expansion can result in a repeat tract which is tens of 
thousands of repeats long (5). Despite the presence of repeats in completely 
unrelated genes, DM1 and DM2 have very similar pathologies and therefore a 
common gain-of-function mechanism of pathogenesis has been proposed. However, 
there are also a number of differences between the diseases: proximal muscles are 
most affected in DM2 and distal in DM1, DM1 shows CNS symptoms while DM2 does 
not and there is no congenital form of DM2 (76). DM1 is also generally associated with 
more severe pathogenesis (76). These disease features may be related to the specific 
function of the gene in which the expanded repeat resides. In support of this idea, a 
role for ZNF9 in regulation of translation has been demonstrated (77). Myoblasts of 
individuals with DM2 show a reduced rate of translation; an effect which appears to be 
mediated through decreased expression of ZNF9 resulting from the presence of the 
CCUG expansion in the mRNA (78). This evidence – along with the observation that   12 
heterozygous ZNF9 mutant mice display muscle phenotypes, cardiac defects, 
cataracts and mRNA mis-regulation similar to what is seen in DM2 (79) – suggests 
that disruption to the normal function of the ZNF9 protein is likely to play a role in DM2 
pathogenesis. Nevertheless, the inability of overexpression of ZNF9 to entirely 
mitigate translation defects in DM2 myoblasts suggests that there is also likely to be a 
dominant toxic effect mediated through the expanded repeat RNA itself (80). Since 
MBNL has also been shown to co-localise to CCUG repeat-containing foci (81) 
resulting in splicing alterations including changes to CLCN-1, TNNT3 and IR splicing 
(82-83), it has been suggested that sequestration of this RNA binding protein is a 
common mechanism of pathogenesis in DM1 and DM2.   
 
A second splicing factor CUG-binding protein-1 (CUG-BP1) has also been 
suggested to play a role in DM1 and DM2 pathogenesis. While CUG-BP1 does not 
associate with repeat containing foci, MBNL and CUG-BP1 have antagonistic roles in 
regulating splicing such that the sequestration of MBNL results in an increase in the 
levels of CUG-BP1 spliceforms, perhaps through an increase in CUG-BP1 activity 
(84). Several lines of evidence support this hypothesis: expression of human CUG-
BP1 in a mouse model is sufficient to induce splicing changes in skeletal muscle and 
the heart, as well as muscular defects reminiscent of those observed in DM1 (84-85). 
In a Drosophila model, neurodegeneration in the eye caused by expression of RNA 
containing a large CUG repeat can be suppressed by human MBNL overexpression 
and is enhanced when human CUG-BP1 is overexpressed (86). This result provides 
further evidence that the expanded repeat RNA itself can explain a large proportion of 
the pathology associated with DM1, since CUG repeat RNA alone is sufficient to 
cause neurodegeneration which can be modified by altering MBNL and CUG-BP1 
protein levels.  
 
Fragile X tremor-ataxia syndrome (FXTAS) is caused by a CGG expansion in 
the 5’UTR of the Fragile X mental retardation 1 (FMR1) gene within the pre-mutation 
range (55-200 repeats) for Fragile X syndrome. Unlike Fragile X - which gives 
characteristic mental retardation and anxiety disorders - FXTAS does not result from 
loss-of-function of the FMR1 gene. Clinical manifestations of FXTAS - including late-
onset neurodegeneration presenting as gait instability, cognitive decline and tremors - 
cannot be explained simply by disruption of the FMR1 gene; indeed levels of FMR1   13 
transcripts are reported to be elevated by up to 8 times normal levels in FXTAS 
individuals and protein levels are reported to be normal (87-88). 
 
Individuals with FXTAS show ubiquitin-positive inclusions in neurons and 
astrocytes throughout the cerebrum and brain-stem which also contain CGG repeat 
RNAs (89). The composition of these inclusions has been investigated and a number 
of proteins identified including the splicing factor MBNL previously implicated in the 
myotonic dystrophies, several intermediate filament proteins including Lamins A/C and 
Internexin and Heterogeneous nuclear ribonucleoprotein A2 (hnRNP A2) (89). The 
FMR1 protein is not present in the inclusions. These observations support a similar 
pathogenic pathway in FXTAS to that described for DM1 and DM2, where 
sequestration of proteins into inclusions with the expanded repeat-containing RNA 
results in loss of the normal function of those proteins which is responsible for disease 
pathogenesis. Expression of ectopic CGG repeat RNA in a mouse model has been 
shown to be sufficient to induce nuclear inclusions and death in Purkinje cells which 
strongly supports this hypothesis (90). 
 
SCA8 is characterised by the slow progressive cerebellar ataxia typical of the 
SCAs (91), but with quite variable degrees of pathology in individual families (92). The 
mechanism of pathogenesis in SCA8 is a source of some debate since the expanded 
repeat region has recently been discovered to be transcribed in a bi-directional 
manner, resulting in the production of both a CUG repeat within the non-coding 
Ataxin8OS gene (also called SCA8) and a nearly pure polyglutamine tract encoded by 
the CAG repeat transcribed from the opposite strand (called Ataxin-8) (93). Ataxin8OS 
also overlaps with another gene on the opposite strand, KLHL1, which does not 
contain the repeat tract. The KLHL1 protein has been shown to be involved in 
regulation of neurite outgrowth via an actin-binding domain and a role in calcium influx 
regulation through P/Q-type calcium channels has also been demonstrated (94). It has 
been suggested that the transcription of the CUG repeat-containing transcript from the 
opposite strand to KLHL1 may be involved in regulation of mRNA levels of KLHL1 
since the two strands both show expression in cells which are involved in processes 
affected in SCA8 individuals (95). Furthermore, deletion of KLHL1 in a mouse model 
has also been shown to result in gait abnormalities and loss of motor control, an effect 
which was also reproduced by targeted deletion in Purkinje cells alone (96), 
suggesting that a reduction in KLHL1 function may play a major role in SCA8   14 
pathology. Polyglutamine-containing inclusions have also been detected in both a 
mouse model of SCA8 and patient tissue, raising the possibility that a mixture of RNA-
mediated and polyglutamine-mediated toxicity may be at play in the disease situation 
(97).  
 
Expression of the non-coding Ataxin8OS transcript alone in the Drosophila eye 
has been demonstrated to elicit a neurodegenerative phenotype, either in the 
presence or absence of an expansion of the CUG repeat to within the human 
pathogenic range (98). A number of modifiers of the phenotype caused by expression 
of the Ataxin8OS transcript were identified in this study, with the majority of these 
being RNA splicing factors, RNA-binding proteins, RNA helicases, translational 
regulators and transcription factors (98). Several of these modifiers also demonstrated 
a change in the strength of interaction dependent upon the size of the CUG repeat 
tract, including the Drosophila orthologue of MBNL and the double-stranded RNA-
binding protein Staufen (98). These results support a role for RNA toxicity in SCA8 
pathogenesis and suggest that this effect may be partly mediated through changes in 
interactions with RNA binding proteins caused by repeat expansion.  
 
SCA10 is the only one of the expanded repeat disorders to be caused by a 
pentanucleotide repeat – ATTCT – of which there can be up to 4500 repeats within 
intron 9 of the Ataxin-10 gene (6). The disease manifests as cerebellar dysfunction 
often involving seizures, with cognitive and neuro-psychiatric impairment (99). AUUCU 
repeat-containing RNA has been shown to form foci when overexpressed in cell 
culture (99) and the repeat tract itself has been demonstrated to have the potential to 
form a hairpin secondary structure under physiological conditions (100). Ataxin-10 
protein has been shown to be essential for the survival of cerebellar neurons, however 
since the disease shows dominant inheritance and Ataxin-10 heterozygous mutant 
mice do not recapitulate features of SCA10, a loss-of-function mechanism cannot 
explain disease pathology (101).  
 
SCA12 is caused by a CAG expansion at the 5’ end of the gene encoding the 
brain-specific regulatory subunit of the protein phosphatase PP2A holoenzyme 
(PPP2R2B). PP2A has been shown to be involved in the DNA repair checkpoint (102) 
and to play a role in induction of neuronal apoptosis via translocation to mitochondria 
(103). Since the repeat can fall either in the 5’UTR or an upstream promoter of   15 
PP2R2B depending upon alternative splicing, it has been suggested that the 
expansion may cause upregulation of PPP2R2B resulting in altered regulation of the 
PP2A enzyme and therefore altered phosphorylation of down-stream targets (104).  
 
Huntington’s disease-like-2 (HDL-2) is one of the clearest examples of 
phenotypic overlap between the translated and untranslated repeat diseases. It is 
caused by a CTG/CAG expansion in a variably spliced exon of Junctophilin-3 (JPH3) 
which results in a disease which is commonly misdiagnosed as HD (105). 
Characteristics of HDL-2 include striatal and cortical neurodegeneration coupled with 
formation of nuclear inclusions such as those typical of HD (106). Alternative 
transcripts contain the repeat either in the 3’UTR or translated as a polyalanine or 
polyleucine tract. The repeat is never translated as polyglutamine and therefore it is 
unclear how the repeat causes a phenotype indistinguishable from HD (105). RNA foci 
have been detected in frontal cortex from HDL-2 brains and expression of an 
untranslated CUG repeat-containing form of JPH3 in HEK293 and HT22 cells also 
resulted in formation of RNA foci which co-localised with MBNL, supporting an RNA 
pathogenesis model for HDL-2 (107).  
 
 
1.3 One pathogenic pathway or many? 
 
There are a number of characteristics of the polyglutamine diseases which 
cannot be explained by loss-of-function of the gene in which the repeat falls. The 
striking overlap in phenotypes associated with the polyglutamine diseases, which has 
led to misdiagnosis of SCA17 and DRPLA as HD, indicates that there are pathogenic 
mechanisms involved which are not gene-specific (108). The most parsimonious 
explanation for such a phenotypic overlap appears to be a common pathogenic 
pathway for the polyglutamine diseases. Several groups have demonstrated that 
expanded polyglutamine peptides are intrinsically toxic both in Drosophila models and 
transfected cells (61, 109-111) and there is evidence to suggest that in HD, DRPLA, 
SBMA and SCA3 at least, caspase cleavage can release the polyglutamine tract from 
the disease protein (112). However, it is likely that the functional properties of the 
expanded polyglutamine-containing proteins also contribute to the pathology, since 
there are unique clinical features associated with each disease.  
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The overlap between the polyglutamine and untranslated repeat phenotypes is 
also striking. Not least, the fact that there are SCAs caused by both polyglutamine and 
untranslated repeats which show the typical set of phenotypes for this group of 
diseases – cerebellar neurodegeneration and progressive ataxia - suggests some 
common causal link between the two sets of diseases. Either there is a common 
pathogenic agent in the two sets of diseases or an entirely separate pathogenic 
pathway is involved in each case, resulting in largely overlapping phenotypes. Since 
the presence of repeat-containing RNA is a common factor between polyglutamine 
and untranslated repeat diseases, it has been suggested that RNA may be a common 
pathogenic agent in the two groups of diseases.  
 
A common feature of all disease-associated expanded repeat RNAs is their 
predicted ability to form stable hairpin secondary structures which increase in stability 
the longer the repeat region grows. This property has been demonstrated for CUG 
(113), CAG (113), CGG (113-115), CCTG (113) and AUUCU (100) repeats and 
appears to be integral to pathogenicity in the untranslated repeat diseases (116). 
Since the expanded CAG repeats which code for polyglutamine in the polyglutamine 
diseases can also form a stable hairpin structure at the RNA level with very similar 
stability to CUG repeats in vitro (113), it seems likely that these repeats may be 
similarly toxic to cells. General acceptance that the polyglutamine proteins themselves 
are the pathogenic agent in the polyglutamine diseases has meant that other 
pathogenic mechanisms have not been thoroughly investigated. There is a large pool 
of evidence for polyglutamine being a pathogenic agent in the translated repeat 
diseases, however there is equally strong evidence of a role for RNA gain-of-function 
pathogenesis in DM1 & 2 (81) and FXTAS (90) which demonstrates the ability of RNA 
to act as a pathogenic agent.  
 
Recent evidence also supports a role for expanded repeat RNA in the 
translated repeat diseases: upregulating expression of the Drosophila RNA binding 
protein Mbl or overexpressing the human orthologue MBNL1 results in the 
enhancement of a neurodegenerative eye phenotype, as well as a decrease in life-
span associated with expression of human SCA3 containing a CAG-encoded 
polyglutamine tract (117). This effect was not seen when the same experiment was 
performed using a polyglutamine tract encoded by a mixed CAG/CAA repeat, which is 
unable to form a hairpin in the same manner as a pure CAG repeat tract, suggesting   17 
that the interaction is occurring at the RNA level and is sequence-dependent (117). 
This result supports the hypothesis that RNA toxicity may at least be one component 
of the pathogenic mechanism in the translated repeat diseases. It seems plausible 
that both polyglutamine proteins and repeat RNA may play a pathogenic role in the 
translated repeat diseases, while repeat RNA alone may be the pathogenic agent in 
the untranslated repeat diseases. 
 
 
1.4 A Drosophila model of polyglutamine and RNA toxicity  
 
Drosophila has been extensively used in studies of neurodegenerative disease 
because of the techniques available to express toxic proteins in a time- and tissue-
specific manner, as well as their amenability for use in genetic and chemical screens. 
There are a large number of articles detailing the use of Drosophila for investigation of 
expanded repeat disease pathology, including models of polyglutamine diseases –  
HD (13-14, 118-121), SBMA (122-123), DRPLA (124), SCA1 (125-127), SCA3/MJD 
(117, 128) and SCA7 (129) – as well as untranslated repeat diseases – FXTAS (130-
132), DM1 (86) and SCA8 (98) – which have revealed key features of these diseases. 
Expanded polyglutamine tracts have also been expressed alone, by us and others 
(61, 109, 133), to demonstrate the intrinsic, length dependent toxicity of these 
peptides.    
 
The Drosophila eye is a convenient system in which to investigate 
neurodegenerative phenotypes, as the ordered structure makes disruptions easily 
observed externally and potentially toxic species can be expressed without generally 
resulting in lethality. The Drosophila eye consists of around 800 ommatidia, each of 
which contains 8 photoreceptors (R1-R8) and a mechanosensory bristle which are 
neuronal, along with cone and pigment cells which are non-neuronal (Figure 1.1).  The 
photoreceptors consist of a rhabdomere – a membrane stack containing photopigment 
– and an axon which projects through the optic stalk to the brain. The rhabdomeres of 
photoreceptors R1-R6 are arranged as a trapezoid structure, while R7 and R8 are in 
the middle with R8 directly below R7. Due to this arrangement, tangential sectioning of 
the eye will only ever reveal 7 of the 8 rhabdomeres, R1-R6 and either R7 or R8 
(Figure 1.1 C and D). Each set of 8 photoreceptors is surrounded by pigment cells 
which contain pigment granules and assist in optical insulation of the ommatidia.   18 
Arranged above the photoreceptors are 4 cone cells which secrete the lens. Each 
ommatidium also contains a single mechanosensory bristle which projects an axon to 
a unique part of the brain (Figure 1.1 D). The ommatidia are arranged in an ordered 
array (Figure 1.1 A&B) making external visualisation of a disruption in patterning of the 
eye relatively simple.  
 
Figure 1.1: The structure of the Drosophila eye. A) Exterior appearance of a wild-type 
Drosophila eye. Reproduced from (133). B) A scanning electron microscope image of the 
Drosophila eye reveals the ordered ommatidial and bristle arrays. C) Tangential section of the 
Drosophila eye showing individual ommatidia, each consisting of 7 visible photoreceptors 
surrounded by pigment granules. D) Illustration of an ommatidial unit. Hexagons show cross-
sections through the ommatidia at different levels, revealing the arrangement of the cone 
cells, and the photoreceptor cells. B=bristle, L=lens, C= liquid-filled pseudocone, PP=primary 
pigment cell, CC=cone cells, SP=secondary pigment cells, TP=tertiary pigment cells, 
Rh=rhabdomeres, A=axons of photoreceptor cells, M=basal membrane, AC=anterior cone 
cell, PC=posterior cone cell, PLC=polar cone cell, EQC=equatorial cone cell, 1-
8=photoreceptor cells 1-8. B-D are reproduced from (134).  
 
 
Tissue-specific expression in Drosophila can be achieved using the UAS-GAL4 
system (135). This system incorporates the yeast GAL4 protein; a transcription factor 
which binds specifically to an upstream activation sequence (UAS). There is no 
orthologue of GAL4 in Drosophila and therefore introduction of ectopically expressed 
GAL4 can specifically drive expression of transgenes under the control of UAS sites. 
The UAS-GAL4 system utilises a “driver” - a promoter region with known expression 
pattern – to temporally and/or spatially control expression of the GAL4 protein which is 
then able to specifically induce expression of a transgene (depicted in Figure 1.2 A). 
Specific expression in the eye can be achieved by using the GMR-GAL4 driver, which 
drives expression in both neuronal and non-neuronal cells. Expression specifically in 
neuronal cells can be achieved using the elav-GAL4 driver, however since this gives   19 
pan-neuronal expression there is a tendency for lethality when it is used for 
expression of toxic species. 
 
 
Figure 1.2: Tissue-specific 
expression in Drosophila using 
the UAS-GAL4 expression 
system. GAL4-UAS expression 
system utilises a tissue- and/or 
developmental time-specific 
promoter sequence which drives 
expression of exogenous GAL4 
protein. A fly line containing this 
promoter, in this case the eye-
specific GMR-GAL4 promoter, is 
crossed to a fly line containing the 
transgene to be expressed. In the 
progeny, GAL4 binds to the 
upstream activation sequence 
(UAS) of the transgene, inducing 




1.4.1 Expanded CAG and CAA-encoded polyglutamine tracts are toxic 
 
In order to address the question of relative toxicity of polyglutamine peptides 
and expanded repeat RNA, transgenic flies were previously generated (described in 
61, 133) containing a polyglutamine tract encoded by either a CAG repeat, which is 
predicted to form a hairpin at the RNA level (Figure 1.3 A), or a CAA repeat, which still 
encodes polyglutamine but is not predicted to form an RNA secondary structure 
(Figure 1.3 B). Crossing these transgenic lines to GMR-GAL4 results in expression of 
the polyglutamine tract specifically in the eye. Repeats either above or below the 
pathogenic threshold in human disease were used in each case. The constructs used 
are represented in Figure 1.3 D&E. In each case, the resulting polyglutamine tract is 
encoded within a short peptide and is tagged with a Myc and FLAG tag. A number of 
independent insertion lines were generated for each construct.  
   20 
 
Figure 1.3: A Drosophila system 
to investigate RNA toxicity as a 
component of polyglutamine 
pathogenesis.  
A&B) Representation of the 
secondary structures formed by 
CAG repeat RNA and CAA repeat 
RNA under physiological 
conditions, as predicted by Mfold. 
In each case 50bp of surrounding 
sequence from the expanded 
repeat constructs used in this 
study was included. CAG repeats 
form a hairpin structure by 
complementary base-pairing 
between G and C residues (A). No 
stable secondary structure is 
predicted for CAA repeat-
containing mRNA (represented by 
a circle (B)). Reproduced from 
(133).C) Design of polyglutamine-
encoding constructs: repeats are 
inserted downstream of a series of 
UAS binding sites which control 
transcription and are encoded 
within a short peptide sequence 
with downstream Myc and FLAG epitope tags to allow detection of the resultant peptide.  
D) CAA repeat tracts of 20 (below the pathogenic threshold) and 94 (above the pathogenic 
threshold) and E) CAG repeat tracts of 30 (below the pathogenic threshold), 52 and 99 (above 
the pathogenic threshold) were generated and inserted into this construct. Previously 




Expression of polyglutamine encoded by either a CAG or CAA pure repeat tract 
with repeat number above the human pathogenic threshold results in severe and 
indistinguishable disruption of the eye (Figure 1.3 C&D). Longitudinal sections of eyes 
from these flies stained with anti-Myc to detect the polyglutamine-containing peptides 
reveal the formation of aggregates in both CAG- and CAA-encoded expanded 
polyglutamine expressing flies (Figure 1.4 C&D). Expression of polyglutamine tracts 
encoded by either CAG or CAA with repeat number below the pathogenic threshold 
does not disrupt the exterior appearance of the eye (Figure 1.3 A&B) or cause the 
formation of aggregates in this system (Figure 1.4 A&B). Therefore it was concluded 
that polyglutamine is toxic in this system irrespective of whether hairpin-forming RNA 
is also present and that this toxicity is repeat length-dependent, as is seen in the 
polyglutamine diseases (61). This result is not consistent with a recent Drosophila 
model of SCA3 pathogenesis in which interruption of the CAG repeat tract with CAA   21 
repeats was observed to abrogate toxicity, resulting in a much milder range of 
phenotypes than expression of the pure CAG repeat when similar levels of protein 
were expressed (117).  It is likely that context of the repeat tract plays a role in 
mediating pathogenesis in the disease situation, a property which is not tested in our 
model of polyglutamine toxicity.  
 
 
Figure 1.4:  Investigation of the effects of expressing polyglutamine in the Drosophila 
eye. All crosses were performed at 25 ° C and constructs driven by GMR-GAL4. A&B) 
Expression of a polyglutamine peptide encoded by either CAG or CAA with repeat number 
below the pathogenic threshold did not result in any alteration to the ordered structure of the 
eye. C&D) Expression of an expanded polyglutamine tract encoded by either CAG or CAA 
with repeat number above the pathogenic threshold results in indistinguishable and severe 
degeneration in the eye. This phenotype is variable between transgenic lines, but 
consistently includes loss of pigment and collapse of the eye. Previously reported in (61, 
133). In order to investigate the ability of polyglutamine tracts encoded by CAG and CAA 
repeats to form aggregates, horizontal cryosections were double-stained with Hoechst (blue) 
to show DNA and anti-Myc (green) which detects the epitope tag of the polyglutamine 
proteins. A’&B’) Polyglutamine tracts encoded by either CAG or CAA with repeat number 
below the pathogenic threshold show a diffuse pattern. C’&D’) Expression of polyglutamine 
tracts with repeat number above the pathogenic threshold results in tight aggregates, 
whether encoded by CAG or CAA repeats. Previously reported in (61, 133). 
 
 
The polyglutamine phenotypes observed when pathogenic length repeats are 
expressed involve severe degeneration of the eye, with pigmentation largely lost and a 
general collapse of structure. These phenotypes are so severe that is difficult to 
determine whether there is any cell-type specificity, however it is clear that non-  22 
neuronal cells, such as the pigment cells, are affected. Since the effect of 
polyglutamine expression in the eye is so severe, it is unlikely that any difference in 




1.4.2 Polyleucine peptides show distinct toxicity in the Drosophila eye 
  
  During the generation of the polyglutamine constructs, an expanded CTG86 
repeat construct, encoding a polyleucine tract was made by inverting an expanded 
CAG repeat (depicted in Figure 1.6 A). While there are no diseases associated with 
expanded polyleucine, studies of expression of polyleucine in cultured cells suggest 
that it is more toxic than polyglutamine (136). Expression of this construct in the 
Drosophila eye resulted in a rough eye phenotype in 5 out of 13 independent lines 
generated, with variable severity (Figure 1.6 B) (133). Interestingly, this phenotype 
was quite distinct from those observed when polyglutamine was expressed in the eye: 
there was no loss of pigment but significant disruption to the ordered arrangement of 
the ommatidia, suggesting that the effect may have different cell-specificity to the 
polyglutamine toxicity (133).  
 
Detection of the polyleucine peptide by staining for the Myc tag showed small 
speckles in the eye, suggesting that the polyleucine peptide is also able to aggregate 
(Figure 1.6 C). Since both the polyleucine and CAG-encoded polyglutamine 
expressing flies are also expressing hairpin-forming CUG or CAG repeat RNA yet 
have very different phenotypes, this result supports the conclusion that the majority of 
the phenotype associated with expression of polyglutamine encoded by either a CAG 
or CAA repeat is likely to be due to the polyglutamine protein and not the hairpin RNA. 
The phenotypes seen in the polyglutamine expressing flies are indistinguishable from 
each other and distinct from the phenotype seen in the flies expressing polyleucine. It 
is also possible that the phenotype seen in the polyleucine-expressing flies is a result 
of the expression of CUG repeat RNA, like that which causes SCA8 and DM1, and not 
the polyleucine peptide.  23 
Figure 1.5: Investigation of the effects of expressing polyleucine in the Drosophila eye. 
Expression of all constructs was driven by GMR-GAL4. A) The construct used to express 
expanded polyleucine in Drosophila is based upon those shown in Figure 1.2. B) Expression 
of polyleucine primarily results in disruption of the ordered ommatidial arrays seen in the wild-
type eye. C) Horizontal cryosections stained with Hoechst (blue) to show DNA and anti-Myc 
(green) which detects the epitope tag of the polyleucine peptide. Small speckles containing 
the polyleucine peptide can be seen, while only diffuse staining is observed in control flies. 




1.4.3 A closer look at RNA pathogenesis 
 
Since the severity of the phenotypes associated with expression of expanded 
polyglutamine tracts made the contribution of RNA to toxicity difficult to determine, 
another set of constructs were generated in which a termination codon was inserted 
upstream of the repeat such that the repeat is effectively shifted into the 3’ 
untranslated region of the product (Figure 1.7 A). Driving expression of this construct   24 
therefore results in the presence of repeat RNA which is not able to be translated. 
Constructs containing pathogenic length untranslated CAG, CUG and CAA repeats 
were generated (called rCAG, rCUG and rCAA respectively) and multiple transgenic 
lines generated for each repeat. There was no consistent phenotype observed when 
any of these constructs were expressed in the eye using GMR-GAL4, however 
expression of 2/14 rCUG insertions did cause a mild disorganization of the eye (133). 
Interestingly, the phenotype associated with polyleucine expression in the eye is a 
similar effect to that observed in the 2 rCUG lines which showed a phenotype which 
may indicate that the phenotypes are a result of the expanded CUG RNA in both 
cases. Expression of a single rCAG transgene was also later characterised to result in 
a very mild rough eye phenotype which was associated with its insertion into the 
5’UTR of the filamin gene (K. Lawlor, unpublished data). Only one of the 2 rCUG lines 
which showed a phenotype is associated with a gene, suppressor 2 of zeste. In this 
case, the insertion appears to be within an intron and may not have an effect on gene 
function and it is therefore unclear whether a positional effect is also responsible for 
the phenotype in this line. Expression of an expanded CUG repeat RNA has 
previously been demonstrated to result in degeneration in the Drosophila eye using a 
construct containing 480 interrupted CUG repeats (86), however the RNA encoded by 
this construct is likely to have a different structure to the pure CUG repeat tract tested 
in this study.  
 
In a recent study, expression of 5 transgene insertions of an untranslated 
CAG repeat tagged with dsRED was demonstrated to cause mild degeneration in the 
brain and reduction in life-span when driven by elav-GAL4 and mild internal 
degeneration in the eye when driven by GMR-GAL4 (117). The requirement for 
expression of multiple insertions before a phenotype is observed in this study 
suggests that there is a dosage-dependent effect of expanded repeat RNA. 
Drosophila lines were subsequently generated which contained up to 4 transgene 
insertions of the rCAG, rCUG and rCAA constructs by recombination, in order to 
increase the amount of expanded repeat RNA being expressed in this system. In this 
experiment, a control carrying four transgene insertions of the same P-element used 
to generate the rCAG, rCUG and rCAA lines but lacking any insert (called “UAS”) 
was also expressed in the Drosophila eye. Free GAL4 has been previously shown to 
induce apoptosis in neuronal cells (137) and therefore this control is important to 
reveal any effect of introducing multiple UAS sites on GAL4-mediated toxicity in the   25 
eye. In this case, the P-element was inserted using the site-specific C31 integration 
system (138). Expression of transgenes generated by this system using GMR-GAL4 
consistently results in flies with distinctly different eye colour compared to 
transgenics generated by random P-element mediated insertion, however the eye 
retains wild-type patterning and organisation (Figure 3.2 A). This effect is likely to be 
a result of the particular sites into which the transgenes have been inserted in this 
case. No phenotype was observed in the eye when four transgene insertions of 
rCAG, rCUG or rCAA repeats were expressed either in the eye with GMR-GAL4 
(Figure 1.7 B-E) or in the nervous system with elav-GAL4, however ubiquitous 
expression (driven by da-GAL4) of either the rCAG or rCUG construct, but not the 
rCAA construct, caused a decrease in viability (K. Lawlor, unpublished data). This 
result supports the idea that expanded repeat RNA can bring about toxicity in a 







Figure 1.6: Expression of four transgene 
insertions of rCAG and rCUG repeats does 
not disrupt the external structure of the 
Drosophila eye. Expression of all constructs is 
driven by GMR-GAL4. Photos were taken by S. 
Samaraweera. A) The construct used to express 
expanded untranslated CAG, CUG and CAA 
repeats (rCAG, rCUG and rCAA) in Drosophila is 
based on the polyglutamine constructs described 
in Figure 1.2 except that a termination codon was 
inserted upstream of the repeat tract. 
Reproduced from (133). B&C) Control flies either 
containing four insertions of the UAS transgene 
without any repeat tract or expressing four 
transgene insertions of the rCAA repeat 
construct, which encodes an RNA lacking a 
secondary structure, have no disruption to the 
appearance of the eye. D&E) Expression of four 
transgene insertions of either rCUG or rCAG 
does not cause a disruption to the appearance of 
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While this model does not recapitulate the neuronal phenotypes associated 
with expression of CAG repeat RNA observed by others (117), there are differences in 
the design of the constructs – including the tag used – which could alter stability and 
localisation of the RNAs. These constructs also differ in the location of the repeat tract: 
in our model the repeats are inserted in the 3’UTR of a short peptide whilst in the 
model which showed degeneration, an insertion of the repeat tract into the 5’UTR of 
the construct was used. Nevertheless, the fact that others observe degeneration as a 
result of expression of similar rCAG (117) and rCUG (86) constructs supports the idea 
that pathways involved in RNA toxicity are present in Drosophila and that both CAG 
and CUG repeat RNAs are able to elicit toxic effects.  
 
Since the expanded repeat diseases are generally late-onset and characterised 
by cellular dysfunction preceding cell death, the ability to express these untranslated 
repeats without causing a large amount of cell death makes this Drosophila model 
ideal for investigating early events in RNA toxicity and progression of the expanded 
repeat diseases. Both the translated and untranslated expanded repeat diseases are 
associated with neurodegeneration of particular subsets of neurons. This study 
focuses on identifying early cellular changes resulting from expression of expanded 
repeat RNA, which is a common agent in both the polyglutamine diseases and the 
untranslated repeat diseases, in the neurons of Drosophila.  Using this approach 
allows the identification of cellular processes which are specifically disrupted by 
hairpin-forming RNA expression and, therefore, may contribute to the onset of 
neurodegeneration in the expanded repeat diseases.   27 





Restriction endonucleases: New England Biolabs (NEB) 
Pfu DNA polymerase – Roche 
Taq DNA polymerase- Invitrogen 
Pfu Turbo
® DNA polymerase – Roche 
Superscript
® III reverse transcriptase – Invitrogen 
RNase H – Invitrogen 
RNAse out™ RNase inhibitor  - Invitrogen 
DNAse I - Invitrogen 
Proteinase K – Sigma Aldrich 
SYBR Green
® PCR master mix – Applied Biosystems (ABI) 
BigDye
® terminator mix – ABI 
T4 DNA ligase – Roche 
T4 polynucleotide kinase, 3’ phosphatase free – Roche 
Shrimp alkaline phosphatase (SAP) – USB 
LR clonase




® gel extraction kit - Qiagen 
QIAquick
® PCR clean-up kit - Qiagen 
GenElute
® plasmid miniprep kit - Sigma 
QIAprep
® spin miniprep kit - Qiagen 
RNeasy
® mini kit – Qiagen 
Expand Long Template
® PCR kit – Roche 
Qiagen DNeasy
® tissue kit – Qiagen 
2D sample cleanup kit – Bio-Rad 
EZQ
® protein quantitation assay – Invitrogen  
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Vectors 
pENTR/D-TOPO
® - Invitrogen 
pGEM
®-T – Invitrogen 
pBluescript KS+ - Stratagene 
pDEST-UAST – generated from pUAST by insertion of the Gateway cloning cassette 
(H. Dalton) 
pUAST-marsh IVM – generated from pUAST by insertion of a short peptide followed 
by a stop codon (C. McLeod) 
pBD1010 – pUAST vector with GFP inserted between the Asp718 and XbaI 




® Top 10 cells – Invitrogen 
SURE2
® cells – Stratagene 






Molecular Weight Marker: 
1kb+ DNA ladder (Invitrogen) 
 
Oligonucleotides 
Oligonucleotides are all standard PCR grade obtained from Geneworks (Adelaide, 
Australia). Sequences are given 5’ to 3’. 
 







SP6 CTATTTAGGTGACACTATAG   29 
SCA10-Fw TGGAAGAGCGCGTCTATGC 
GFP repeat-Rv ATTGGGACAACTCCAGTG 




Primers to amplify and sequence known editing sites in Drosophila (taken from 
(139)). 
Para-dS3 Fw TCATGCACACGACGAGGATATACT 
Para-dS3 Rv GCTGAATTCACCCACGTGTAGTTC 
Para-dS4 Fw GAACTACACGTGGGTGAATTCAGC 
Para-dS4 Rv GTCTAGGACCGCGTTATACGTGTC 
GluCl Fw AACATGGGCAGCGGACACTATTT 
GluCl Rv GACCAGGTTGAACAGGGCGAAGAC 
 
































Primers to generate SCA10 constructs: 
SCA10Intron9-Fw AGAAAACAGATGGCAGAATGA 
SCA10Intron9-Rv GCCTGGGCAACATAGAGAGA 
To amplify the SCA10 repeat region within intron 9 from human DNA. 
 
SCA10 repeat Fw ATTCTATTCTATTCTATTCT 
SCA10 repeat Rv TAAGATAAGATAAGATAAGA 
To expand SCA10 repeat tract in vitro.  
 
SCA10 TOPO-Fw CACCTGGAAGAGCGCGTCTATGC 
SCA10-Rv GCCTGGGCAACATAGAGAGA 
Primers used for PCRIII in the expansion protocol. SCA10 TOPO-Fw adds a CACC 





To add HindIII restriction sites by PCR from pGEM-T. 
 
Nup62 ORF Rw CACCATGGTATTCCAGTTGCC 
Nup62 ORF Rv CTGTGGTTACAATGGAACCATC   31 
Primers to amplify nup62 from Drosophila DNA or cDNA. Nup62 ORF Fw adds a 
CACC non-complementary sequence to the 5’ end of the product to allow direct 
cloning into pENTR/D-TOPO.  
 
Cy3 labelled probes for in situ analysis of repeat-GFP constructs 
This Cy3-labelled oligonucleotide was generated and tagged at the 5’ end by 




Cy2, Cy3 and Cy5 – GE healthcare 
 
Bacterial media: 
All media were prepared with distilled and deionised water and autoclaved or filter 
sterilised, depending on heat lability. Antibiotics were added from sterile stock 
solutions. 
 
L-Broth (LB): 1% (w/v) amine A, 0.5% yeast extract, 1% NaCl, pH 7.0. 
 
SOC: 2% bactotryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, 20mM glucose. 
 
Plates: L-Broth with 1.5% (w/v) bactoagar supplemented with ampicillin (100 mg/mL) 




Fortified (F1) Drosophila medium: 1% (w/v) agar, 18.75% compressed yeast, 10% 
treacle, 10% polenta, 1.5% acid mix (47% propionic acid, 4.7% orthophosphoric 
acid), 2.5% tegosept (10% para-hydroxybenzoate in ethanol). 
 
Grape juice agar plates: 0.3% agar, 25% grape juice, 0.3% sucrose, 0.03% tegosept. 
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Buffers and solutions 
 
2D sample buffer: 7M urea, 2M thiourea, 30mM tris-Cl, 4% CHAPS. 
 
3-11 NL IPG buffer: Immobilised pH gradient buffer, non-linear, pH 3-11 GE 
Healthcare. 
 
Agarose gel loading dye (6x): 30% glycerol, 0.2% (w/v) bromophenol blue, 0.2% 
(w/v) xylene cyanol. 
 
Hybridisation buffer (in situ): 4x SSC, 0.2g/mL Dextran sulphate, 50% formamide, 
0.25 mg/mL polyA, 0.25 mg/mL ssDNA, 0.25 mg/mL tRNA, 0.1 M DTT, 0.5 x 
Denhardt’s reagent. 
 
PBS: 7.5 mM Na2HPO4 , 2.5 mM NaH2PO4, 145 mM NaCl. 
 
PBST: 1x PBS, 0.1% Tween. 
 
Rehydration buffer (for IPG strips): 7M urea, 2M thiourea, 2% CHAPS, 0.5% 3-11 NL 
IPG buffer (GE Healthcare), 1.2% DeStreak™ (GE Healthcare). 
 
SDS Equilibration buffer: 50 mM Tris-HCl, pH 8.8, 6 M urea, 30% glycerol, 2% SDS, 
trace bromophenol blue. 
 
Squishing buffer: 25 mM NaCl, 10 mM Tris-Cl pH 8.2, 1 mM EDTA, 200 μg/mL 
Proteinase K. 
 
1x SSC: 150mM NaCl, 15 mM Na citrate.  
 
TAE: 40 mM Tris-acetate, 20 mM sodium acetate, 1 mM EDTA, pH 8.2. 
 
TBE: 90 mM Tris, 90 mM boric acid, 2.5 mM EDTA, pH 8.3. 
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Drosophila stocks 







c155  458 X  pan-neuronal 
elav-GAL4  8765 II  pan-neuronal 
GMR-GAL4  9146 II  eye 
da-GAL4  8641  III ubiquitous 
 





Gene   Stock number  Source  Description 
adar  -  Palladino et al. 
(2000) (140) 
Allele 1F1, derived by imprecise 
excision of P-element from 
adar
HD57. Null allele. 
adh  v34628 VDRC  RNAi  construct 
akt  v103703 VDRC  RNAi  construct 
CG15862  v34936/v34937 VDRC  RNAi  construct 
CG5669  v45300 VDRC  RNAi  construct 
DPx2540-1  23738 Bloomington    MB01457 Minos insertion •100bp 
upstream of annotated region. 
10989 Bloomington    Allele 01103, P{PZ} insertion into 
intron. Hypomorph.  
hts  
14150 Bloomington    Allele KG06777, P{SUPor-P} 
insertion. Hypomorph. 
insc  v31488 VDRC  RNAi  construct 
mod(mdg4)  v52268 VDRC  RNAi  construct 
mef2  v15550 VDRC  RNAi  construct 
v28731 VDRC  RNAi  construct  mbl 
7318 Bloomington  Allele E27, derived by imprecise 
excision of P-element from 
mbl
k05507b. Removes exons 1&2. 
mGluRA  v1793/v1794 VDRC  RNAi construct (2 different 
insertion sites) 
MBNL1  -  de Haro et al. (2006) 
(86) 




VDRC  RNAi construct (2 different 
insertion sites) 
nup62 
- This  study  Open reading frame, cloned from 
cDNA. Overexpression construct. 
5435 Bloomington  Overexpression  construct.  sgg 
v7005/v101538 VDRC  RNAi  constructs. 
 
Table 2.2: Candidate gene lines used in this study. VDRC is the Vienna Drosophila RNAi 





Standard molecular genetic techniques were performed as described in (141). 
 
Restriction enzyme digestion of DNA 
Digests were carried out according to manufacturer’s instructions. Where possible, 
enzymes were heat inactivated prior to use of digested product in further cloning. 
Enzymes that could not be heat inactivated were removed by agarose gel 
electrophoresis and gel extraction with the QIAquick
® gel extraction kit according to 
manufacturer’s instructions before further use. 
 
Dephosphorylation of restriction enzyme digested vector DNA 
Vector DNA to be used for cloning was dephosphorylated to prevent self-ligation.  
Following restriction enzyme digestion, 1-2 units of SAP were added directly to the 
reaction and it was incubated at 37 °C for at least 1 hr. The enzyme was then 
inactivated by incubating at 65 °C for 15 minutes. 
 
Ligation of DNA fragments 
Ligations of PCR products into pGEM
®-T were performed according to 
manufacturer’s instructions. Other ligations were generally carried out in a volume of 
10 μL with 1 unit of T4 DNA ligase and 1x ligation buffer. Ligations were incubated 
overnight at room temperature (approximately 22°C). 
 
Agarose gel electrophoresis 
Molten 1% agarose dissolved in either 0.5% TBE or 1% TAE was supplemented with 
ethidium bromide and poured into a plastic gel-cast and allowed to set with well 
combs in place. The gel was submerged in the appropriate buffer and DNA samples 
mixed with agarose loading buffer were loaded into wells with one well loaded with 1 
kb+ DNA markers. DNA was size-separated by applying 80-120 V to the tank. The 
gel was then visualised by UV light exposure using Gel-Doc™ apparatus (Bio-Rad). 
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Purification of DNA from agarose gels 
DNA bands were excised from agarose gels and purified using the QIAquick
® gel 
extraction kit according to manufacturer’s instructions except that purified DNA was 





Transformation of plasmids into bacteria and plating on selective media 
Transformation was carried out by heat shock of DH5-α chemically competent cells 
for standard transformations, of ONE SHOT
® Top 10 cells when greater efficiency 
was required or of SURE2
® cells to prevent recombination of large repeat constructs. 
 
Chemically competent cells stored at -80 °C were thawed on ice and 50 μL added to 
2-10 μL of each ligation reaction and the mixture incubated on ice for 20-30 minutes 
before heat shocking at 42 °C for 45-50 seconds. The mixture was then returned to 
ice for 2 minutes before 2-300 μL of SOC + 0.8 % glucose was added. The tube was 
inverted and incubated at 37 °C for at least 1 hour, pelleted at 600 g for 5 minutes 
and 200 μL of SOC removed. The cells were then re-suspended in the remaining 
SOC and plated on LB media supplemented with Kanamycin or Ampicillin as 
appropriate (see materials). Where selection for β-galactosidase activity (blue-white 
colour selection) was required, 56 μL of 100mM IPTG and 16 μL of 50 mg/mL X-gal 
per plate were plated along with bacteria. Plates were allowed to dry at room 
temperature before incubation at 37 °C overnight. 
 
Isolation of plasmid DNA from bacteria 
Preparation of plasmids was performed using the Sigma GenElute™ kit or Qiagen 
spin miniprep kit according to manufacturer’s instructions except that elution was 
performed using 50 μL of MQ water rather than buffer. 
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Genomic preps from Drosophila 
 
Single female flies were collected and incubated at -20 °C for at least 1 hour. Flies 
were then squashed with a 200 μL pipette tip, 50 μL of squishing buffer was added 
and the reaction was incubated at 37 °C for 30 minutes. The proteinase K was then 
inactivated by heating to 95 °C for 2 minutes. 2 μL of the prep was used as a PCR 
template to amplify transgenes.   
 
 
PCR amplification of DNA 
 
PCR reactions were cycled in an MJ Research PTC-200 Peltier Thermal cycler.  
 
Colony PCR 
Selected colonies were tested for presence of the recombinant plasmid by PCR. The 
colony was transferred with a sterile toothpick to a master plate with appropriate 
selection then the toothpick was swirled in 10 μL of PCR mix (0.25 units Taq 
polymerase, 1x supplied buffer, 0.2 mM dNTPs, 2 mM MgCl2 and 2.5 ng/μL of each 
primer) to release a small number of bacteria. Cycling conditions were 10 cycles of 
94 °C for 30 seconds, 60 °C for 30 seconds, 72 °C for 90 seconds then 25 cycles 
with annealing temperature dropped to 55 °C followed by 72 °C for 10 minutes.  
 
PCR from Drosophila genomic DNA 
For verifying insertion of transgenes in SCA10 flies, PCR was performed using the 
expand long template PCR kit with buffer 3 according to the manufacturer’s 
instructions except that cycling conditions were 94 °C for 2 minutes then 29 cycles of 
94 °C for 20 seconds, 45 °C for 30 seconds, 60 °C for 2 minutes followed by 60 °C 
for 7 minutes. The very low annealing and extension temperatures were necessary 
since the ATTCT repeat in these constructs makes them very AT rich. Primers were 
either pUAST-Fw and Rv or pUAST-Fw and GFP-Rv depending on the construct.    37 
Sequencing 
 
DNA was sequenced using the ABI Prism™ Big Dye Terminator v3.1 Cycle 
Sequencing Ready Reaction Mix (Perkin-Elmer) as described in the manufacturer’s 
protocol except that half the described amount of reaction mix was used. Generally 
20 μL reactions were performed with 400-800 ng of double-stranded DNA used as a 
template and approximately 100 ng of primer. Reactions were performed using an 
MJ Research PTC-200 Peltier Thermal cycler. Cycling conditions were: 25 cycles of 
96 °C for 30 seconds, 50 °C for 15 seconds and 60 °C for 4 minutes. Samples were 
then precipitated with 80 μL 75% isopropanol for at least 15 minutes at room 
temperature (approximately 22 °C) before the sequencing product was pelleted by 
centrifugation for 20 minutes at 13,000 rpm and the supernatant removed. The pellet 
was then washed in 250 μL of 75 % isopropanol and pelleted for another 10 minutes 
before the supernatant was removed and the pellet dried on a 95 °C heating block 
for approximately 5 minutes. Sequencing analysis was performed at the Institute of 
Medical and Veterinary Science (IMVS) Frome Road, Adelaide. 
 
 
Generating SCA10 repeat constructs 
 
Cloning the repeat tract of human ataxin-10 
The original PCR product used for the SCA10 expansion contained 13 ATTCT 
repeats and was kindly donated by S. Dayan. The SCA10 repeat region was 
amplified with Taq polymerase using SCA10Intron9-Fw and Rv from HeLa DNA 
purified using the Qiagen DNeasy tissue kit according to manufacturer’s instructions. 
PCR conditions were 94 °C for 3 minutes followed by 12 cycles of 94 °C for 30 
seconds, 66 °C – 1 °C per cycle for 45 seconds then 23 more cycles with annealing 
temperature of 55 °C followed by 72 °C for 10 minutes. The product from this PCR 
was gel purified and sequenced using the SCA10Intron9-Fw primer. The product 
was ligated into pGEM-T according to manufacturer’s instructions.   
 
Expansion of the SCA10 repeat tract 
Expansion was adapted from methods outlined in (142). Approximately 100 ng of the 
pGEM-T vector containing the SCA10 repeat region was linearised with ApaI or NotI 
in separate reactions. Digested vector was gel purified to ensure that no uncut vector   38 
remained and the purified products diluted 1/20 and 1 μL used as a template for 
PCR.  
 
PCR I and II 
The ApaI digested vector was used as a template in PCRI with T7 and SCA10-
repeat-Rv as primers and NotI digested vector was used in PCRII with SP6 and 
SCA10-repeat-Fw as primers. PCRI and II were carried out with the expand long 
template PCR kit according to manufacturer’s instructions except that annealing 
temperature was lowered to 45 °C and extension temperature was lowered to 60 °C. 
The products of PCRI and II were then gel purified to remove any non-expanded 
product or template to ensure that these were not preferentially amplified in PCRIII.  
 
PCRIII 
2 μL of gel purified PCRI and PCR II were mixed and heated to 94 °C for 5 minutes 
then incubated at 65 °C for 2 mins to allow products from PCR I and II to anneal. 1 
μL of this mix was then used as a template for PCRIII without further dilution. Primers 
for PCRIII were SCA10 TOPO-Fw, which adds a CACC to the 5’ end of the product 
to allow direct cloning into the pENTR-D/TOPO
® vector, and SCA10 Rv. PCR 
conditions were identical to PCRI and II. This product was used directly for ligation 
into the pGEM
®-T vector, since the Expand Long Template™ enzyme mix also adds 
the A-overhang required for this ligation. SURE2
® cells were used for transformation 
of the expanded SCA10 repeats to avoid recombination. Positive clones were 
identified by restriction digest. During the expansion procedure it appears that 
several interruptions were introduced to the repeat tract, despite the use of an 
enzyme mix which had proof-reading capabilities.  
 
A number of clones were sequenced using the SCA10-Fw primer and a clone of 65 
repeats was chosen for sub-cloning into the pBD1010 vector and the pUAST-marsh 
vector previously generated by C. McLeod (133). 
 
Ligation into pBD1010 to generate SCA10-GFP lines 
The expanded SCA10 repeat tract was re-amplified using the Expand Long 
Template™ kit according to manufacturer’s instructions except that annealing 
temperature was reduced to 45 °C and extension temperature to 60 °C. Primers 
were SP6 and T7-HindIII to introduce a HindIII site to the 5’ end of the product. The   39 
product was then restriction enzyme digested with NotI and HindIII to generate sticky 
ends that could be used to ligate into pBD1010 vector digested with NotI and HindIII. 
The digested vector was de-phosphorylated prior to ligation and the insert was 
column purified using the QIAquick
® PCR purification kit to remove the fragments 
cleaved off by the restriction enzymes. Cloning into pBD1010 in this way results in 
insertion of the repeat tract into the 5’UTR of the GFP transcript. During this process 
the repeat tract changed size, generating a variety of different repeat lengths. Clones 
with 67 and over 100 repeats were chosen for microinjection to generate transgenic 
Drosophila.   
 
Ligation into pUAST-Marsh IVM to generate SCA10-Marsh lines 
This vector, based on a set of constructs originally described in (143), contains a 
short peptide sequence followed by a stop codon such that insertion of a repeat tract 
downstream of the stop codon results in an untranslated 3’ repeat tract. The 
expanded SCA10 repeat tract was inserted into a HindIII site within this short peptide 
sequence. To achieve this, the expanded product was re-amplified from pGEM
®-T 
using the Expand Long Template™ kit and SP6 and T7 primers with HindIII sites 
added. This results in a small amount of extra sequence surrounding the repeat tract 
including the MCS from the pGEM
®-T vector. The product of this PCR was then 
digested with HindIII before purification with the QIAquick
® PCR purification kit. The 
pUAST-marsh IVM vector was digested with HindIII and de-phosphorylated before 
ligation with the PCR product. Colonies obtained in this way were screened for 
presence and direction of the insert by diagnostic restriction enzyme digestion and 
sequencing with the Marsh TOPO-Fw primer.  
 
 
P-element mediated transformation of Drosophila 
 
DNA for microinjections was prepared using the GenElute
™ plasmid miniprep kit or 
the Qiagen spin miniprep kit according to manufacturer’s instructions.  
 
Microinjection  
Microinjections were kindly performed by J. Milverton. An injection mix with 0.5 – 1 
mg/mL transformation vector and 0.3 mg/mL delta 2-3 transposase plasmid 
(pp25.7wc) was prepared in 1x embryo injecting buffer. A drawn out capillary was   40 
used to back-fill the injection needle with 2 mL of this mix, which had been 
centrifuged to remove any particulate matter. W
1118 embryos were collected from 30 
minute lays on grape juice agar plates at 25 °C, dechorionated for 3 minutes in 50% 
bleach then rinsed thoroughly in MQ water. The embryos were then aligned on non-
toxic rubber glue and a drop of liquid paraffin was placed on them. A 
micromanipulator was used to position the needle and the microscope stage moved 
to bring the embryos to the needle for injection such that a very small amount of DNA 
was injected into the posterior cytoplasm. 
 
Identification of transformants 
Injected embryos were grown at 25 °C on the injection slide in a petri dish containing 
moist paper towel with some yeast paste. After 2 days, larvae were collected onto 
Whatman paper and placed into vials containing F1 medium and allowed to develop 
to adulthood at 25 °C. Eclosed adults were crossed to w
1118 flies and transformants 
identified amongst the progeny of these crosses on the basis of the presence of 
colour in the eye bestowed by the white mini-gene present in the construct. A 
number of independent transformants for each construct were then mapped to 
determine the chromosome of insertion using the CyO and Tm6B dominantly marked 
balancer chromosomes present in the Bl/CyO; Tm2/Tm6B stock. Balanced stocks 





Flies were generally raised at either 18 °C or 25 °C with 70% humidity on F1 
medium. Crosses were performed at 25 °C unless otherwise stated. 
 
 
Fly crosses and strains 
 
To generate flies carrying two independent insertions on the same chromosome, two 
lines of flies carrying balanced independent insertions were crossed and trans-
heterozygous female virgins selected, since recombination between chromosomes 
only occurs frequently in female Drosophila. These females were then crossed to 
male w
1118 flies and progeny with the two insertions recombined onto the same   41 
chromosome were selected based on darker eye colour than either one of the single 
insertion lines. The recombinant chromosomes were then rebalanced with either Cyo 
or Tm6B dominantly marked balancer chromosomes. Flies carrying two independent 
insertions on the 2
nd chromosome could then be crossed to flies carrying insertions 
on the 3
rd chromosome to generate flies with four independent insertions, which 
could again be selected by eye colour. This method was used to generate two and 




RNA extraction and purification 
 
For microarray analysis and Q-PCR of microarray candidates 
Approximately 100 male Drosophila heads were collected for each genotype and 
stored at -80 °C until extraction. 100 μL of Trizol™ (Invitrogen) were then added and 
the heads homogenised with a pestle before a further 900 μL of Trizol™ was added. 
The homogenate was passed through a 20 gauge needle several times and 
centrifuged at 13, 000 rpm for 10 minutes at 4 °C to remove cellular material. 
Supernatant was decanted into a sterile, RNAse free tube and incubated at room 
temperature (approximately 22 °C) for 10 – 15 minutes. An additional 300 μL of 
Trizol™ was then added and the mixture was vortexed for 1 minute before 
centrifugation for 15 minutes at 13, 000 rpm. The upper aqueous phase was 
collected (approximately 500 μL, taking care to avoid the interphase) and transferred 
to a sterile RNAse free tube. An equal volume of 100% ethanol was added and the 
mix vortexed briefly to precipitate DNA. The resultant mix was then loaded onto an 
RNeasy column and the remainder of the purification carried out according to the 
RNeasy mini kit instructions except that elution was with 50 μL of 0.1% DEPC 
treated de-ionised water. Preps were stored at -80 °C until use. 
 
Transportation of RNA for microarray analysis 
RNA to be used for microarrays was precipitated by adding 0.1 volumes of 3 M Na 
acetate, pH 5.2 and 2.5 volumes of ice cold 100% ethanol and incubating at -20 °C 
for at least 10 minutes before centrifuging at 10,000 rpm for 10 minutes at 4 °C. The 
resulting RNA pellet was then washed twice with 250 μL of 75% ethanol before   42 




Microarrays were performed by Dr Gareth Price and in collaboration with Professor 
Deon Venter at Mater Hospital, South Brisbane. Affymetrix Drosophila GeneChip
® 
2.0 arrays were used and preparation, hybridisation and detection were performed 
according to manufacturer’s instructions.  
 
Preparation of cDNA 
 
cDNA was prepared from 1 μg of total RNA using Superscript
® III RNase H
-  
according to manufacturer’s instructions. 500 ng oligo(dT)18 was generally used per 
20 μL reverse transcription reaction. 
 
Quantitative real-time PCR (QPCR) 
 
cDNA was diluted 1/5 and 5 μL used as a template for each 25 μL reaction with 1.26 
pmol of each primer and SYBR
® green master mix diluted to 1x. A standard curve 
was prepared by further serial dilution of cDNA (1/2, 1/5, 1/10) and used for each 
primer set. Each reaction was performed in triplicate in a 96 well plate. Cycling 
conditions were 50 °C for 2 minutes, 95 °C for 10 minutes then 40 cycles of 95 °C for 
15 seconds and 60 °C for one minute on an ABI Prism
® 7000 sequence detection 
system (Applied Biosciences). A dissociation curve was produced for each primer set 
to ensure that only one product was amplified in each reaction. The ABI Prism
® 7000 
SDS program was used to analyse data and produce the standard curve from the 
serial dilutions of cDNA to which each sample was then compared to determine the 
relative amount of product in each. Data was then exported to Microsoft Excel for 
further statistical analysis. The quantity of product for each sample with each primer 
pair was normalised to the quantity of product with Rp49 primers for the same 
sample to give an idea of relative expression levels between samples. 
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Editing Assays 
 
RNA for editing assays was prepared as described for microarray and QPCR except 
that 5 adult flies were used. RNA to be used in the reverse transcription was treated 
with DNase I according to manufacturer’s instructions before reverse transcription 
was performed using Superscript
® III RNase H
- also according to manufacturer’s 
instructions. 1 μL of the 20 μL reverse transcription reaction was then used as 
template for PCR with the Expand Long Template
® kit. PCRs which gave a single 
product were selected for sequencing analysis, with 1 μL of the PCR product used 
as a template in the sequencing reaction. In each case, the forward primer for the 





Protein samples were prepared from 30 male Drosophila heads for each genotype. 
Protein preparation, 2D gel electrophoresis and mass spectrometry were all 
performed by the Adelaide Proteomics Centre. The following is an abbreviated 
version of the methods used.  
 
Sample preparation 
Samples were homogenised with a micro-pestle on liquid nitrogen before addition of 
100 μL of 2D sample buffer and incubation for 1 hour on ice. Samples were then 
centrifuged for 30 minutes at 13,000 rpm and supernatant collected. This supernatant 
was purified using a 2D sample clean-up kit. Pellets obtained were washed in 1mL 
cold acetone, centrifuged again for 30 minutes at 13,000 rpm and supernatant was 
removed. Purified protein pellets for each sample were pooled and dissolved in 30 μL 
2D sample buffer. Protein concentrations were determined using an EZQ
® protein 




Powdered CyDyes (Cy2, Cy3 and Cy5) were dissolved in anhydrous 
dimethylformamide (DMF) to generate 200 pmol/μL solutions which were stored at -
80°c under argon until required. 100 μg of total protein was labelled with 1 μL of Cy3   44 
or Cy5 for each sample. An internal standard was prepared by pooling 50 μg of 
protein from each sample. The resulting 800 μg total protein was labelled with 8 μL 
of Cy2. Samples were incubated for 30 minutes on ice in darkness before the 
labelling reaction was stopped by addition of 1 μL of 10 mM lysine per 100 μg 
protein. Sample volumes were made up to 93 μL with 2D sample buffer before 
addition of DTT to final concentration of 65 mM and carrier ampholytes (3-11 NL IPG 
buffer) to a final concentration of 0.5%. 
 
Isoelectric Focusing 
24cm pH 3-11 non-linear immobilised pH gradient strips (GE Healthcare) were re-
hydrated overnight in 450 μL rehydration buffer. Samples were applied to the strips 
by cup-loading. Isoelectric focusing was performed on an IPGphor™ II (GE 
Healthcare) at 20°C using a 6 step program (300 V for 2 hours, 500 V for 2 hours, 
1000 V for 2 hours, a gradient of 1000-8000 V for 5 hours, 8000 V for 40,000 Vhours 




Following isoelectric focusing, strips were equilibrated in equilibration buffer 
containing 100 mg/mL DTT for 15 minutes, then equilibration buffer containing 250 
mg/mL of idoacetamide in place of DTT. SDS-PAGE was carried out using 12.5% 
polyacrylamide gels and an EttanDalt 12 unit in Tris-gly buffer at 15 °C at 95V for 
approximately 21 hours.  
 
DIGE imaging and analysis 
Gels were scanned using an Ettan™ DIGE imager (GE Healthcare) and cropped to 
show relevant regions. Image analysis was performed using the Differential In-Gel 
Analysis (DIA) module of the DeCyder™ 2D software (Version 6.5, GE Healthcare). 
Exclusion filters were set to reject spots with a slope of >1.1, an area of <600, a 
volume of <10,000 and a peak height of <80 and >65,000. The resulting spot maps 
were then inspected manually and poorly resolved areas excluded. Spot matching 
and comparative analysis were performed using Biological Variation Analysis (BVA).  
 
Liquid chromatography-ESI mass spectrometry (MS & MS/MS) 
Spots of interest were excised from the gels and digested with 100 ng of trypsin per 
sample. The sample was chromatographed using an Agilent Protein ID Chip column   45 
assembly housed in an Agilent HPLC-Chip Cube Interface and connected to an HCT 
ultra 3D-Ion-Trap mass spectrometer (Bruker Daltonik GmbH). The column was 
equilibrated with 4% acetonitrile/0.1% FA and eluted with an acetonitrile gradient 
(4%-31%). Ionisable species were trapped and the most intense ions eluting were 
fragmented by collision-induced dissociation (CID) and electron-transfer dissociation 
(ETD).  
 
MS & MS/MS Data analysis 
Spectra were subjected to peak detection using DataAnalysis (version 3.4, Bruker 
Daltonik GmbH) then imported into BioTools (Version 3.1, Bruker Daltonik GmbH). 
An in-house Mascot database-search engine (Version 2.2, Matrix Science) was then 
used to identify proteins present within the sample.  
 
 
In situ hybridisation of AUUCU repeat RNA 
 
Cryosections of Drosophila larvae 
Whole larvae were positioned in optimal cutting temperature (OCT) medium, frozen 
on dry ice and stored at -80 ºC until cutting. Sectioning was performed by K. Lawlor 
using a Leica CM1900 cryostat, with both the chuck and the chamber set to between 
-16 and -19 ° C. 10m sections were cut and collected on poly-lysine slides to be 
stored again at -80 ºC until staining. 
 
In situ hybridisation 
Sections were fixed in fresh 4% paraformaldehyde for 15 mins, washed 3x 5 mins in 
PBS at room temperature and then briefly rinsed in 100% ethanol. After drying, 
slides were incubated with 0.5 ng/L probe in hybridisation solution for at least 2 
hours at 37 ºC in a humid chamber. Slides were then washed twice in 2x SSC and 
twice in 0.5x SSC for 15 mins each at 37 ºC. Slides were then mounted with 
vectashield™ (Vector Laboratories) and 1 ng/L DAPI. 
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Microscopy 
Image preparation was performed using Adobe Photoshop 6.0.  
 
Light microscopy 
Light photos were taken with an Olympus SZX7 dissection microscope fitted with an 
SZX-AS aperture. Images were captured with a Colorview IIIu camera and 
AnalysisRuler image acquisition software. In all cases, anterior is to the left. 
 
Fluorescent microscopy 
Fluorescent microscopy was performed using a Zeiss Axioplan 2 upright microscope 
with 63x PlanApo objective. Images were captured with an Axiocam MRm camera 
and AxioVision 4.5 image acquisition software.  
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Chapter 3 – The RNA editing hypothesis 
 
 
3.0 Roles for RNA as a pathogenic agent 
 
The mechanisms proposed for expanded repeat RNA toxicity have been 
informed by the investigation of pathogenic pathways in DM1. In DM1, the presence 
of an expanded CUG repeat within the DMPK transcript causes an inappropriate 
interaction with the MBNL1 splicing factor which results in mis-splicing of a number 
of downstream targets (3). Many of the pathologies associated with DM1 can be 
directly attributed to these splicing changes (74-75). The ability to form double-
stranded regions of RNA is a common characteristic of all of the expanded repeats 
associated with disease to date (100, 113) and therefore it has been predicted that 
altered interactions with double-stranded RNA binding proteins, like those seen in 
DM1, may also be a general disease feature. This sort of phenomenon has been 
demonstrated for both CAG and CUG repeats with the double-stranded RNA 
regulated protein kinase (PKR) and with MBNL splicing factor (71, 76, 144-145), 
although the interaction of CAG repeats with MBNL1 does not appear to have the 
same effects on splicing as CUG repeats (71).  
 
Many RNA binding proteins play roles in regulation of gene expression and 
therefore can have profound effects on cell survival. For example, PKR is able to 
inhibit translation in the presence of dsRNA via phosphorylation of the eukaryotic 
initiation factor 2 (eIF2) (146). This effect demonstrates how RNA hairpins formed by 
repeats could alter gene expression at a global level in the cell. PKR has been 
shown to preferentially bind large CAG repeats in mutant HTT RNA in vitro and is 
activated in affected regions of HD brains (144). It has been predicted that the 
presence of basal levels of activated PKR in neurons and axons of regions which are 
highly affected in HD could result in sensitivity to the presence of CAG repeats and 
therefore may explain the specificity of cell death in HD individuals (144). CUG 
repeat RNA-containing foci in DM1 also contain PKR (147) and PKR is also 
activated in the presence of expanded CUG repeat RNA (145), however it is unclear 
whether this is a component of pathogenesis since DM1 model mice lacking PKR 
still show phenotypes of DM1(76).  
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Another important family of dsRNA binding proteins is the RNAse III family 
which includes the Dicer and Drosha ribonucleases, best characterised for their role in 
RNAi and miRNA pathways. These ribonucleases specifically bind duplex regions of 
RNA and play a role in regulation of RNA turn-over and protect the cell against viral 
and transposon insults (148). In the RNAi pathway, long perfect duplexes of RNA are 
cleaved to 21-24bp small interfering RNAs (siRNAs) and incorporated into the RNA-
induced silencing complex (RISC) resulting in sequence-specific cleavage of target 
RNAs. MicroRNAs (miRNAs) are of similar length but regulate translation of 
transcripts with imperfect complementarity. In each case Dicer and Drosha are 
involved in the cleavage of larger RNAs to the smaller siRNAs or miRNAs (148). 
These pathways play a major role in the regulation of gene expression in the cell. The 
presence of long dsRNAs in the cell could feed into these regulatory pathways, 
possibly resulting in altered expression of a large number of down-stream targets. The 
ability of Dicer to cleave both CUG (149) and CCG (150) repeats has been 
demonstrated and may indicate a role for this pathway in pathogenesis of at least 
some of the expanded repeat diseases. 
 
 
3.1 RNA editing: roles and consequences 
 
RNA editing is the post-transcriptional modification of bases within mRNA and 
is used primarily to increase the coding-power of the genome by creating alternative 
transcripts which may result in effects such as altered splice-site choice (151-152), 
increased degradation rate, altered protein binding sites (153) or incorporation of an 
alternative amino acid at the protein level (154). One particular RNA-editing enzyme, 
adenosine deaminase acting on RNA (ADAR), is specifically involved in the de-
amination of adenosine (A) residues to inosine (I), which is in turn recognized by the 
translational machinery as guanosine (G) (154). The majority of specific targets of 
ADAR in mammals are neuronally-expressed ion-gated channels or receptors 
involved in neurotransmission; for example the serotonin and glutamate receptors 
(155) .  
 
ADAR has both site-specific and promiscuous de-aminating ability, depending 
on the structure of the mRNA being edited. Site-specific de-amination is thought to 
be achieved through a very short tract (9-15 bases) of complementary RNA 
embedded in an intron adjacent to the exon in which editing is required, such that an   49 
imperfect duplex is formed around the adenosine which is to be edited (154). ADAR 
also plays a role in viral defense where perfectly double-stranded RNAs greater than 
100 base pairs long are promiscuously hyper-edited, with up to 50% of A residues 
being edited in some cases (156). Hyper-edited RNA associates with a number of I-
RNA binding proteins which play roles in gene-regulation (see Figure 3.1 B). ADAR 
itself has been reported to co-localise with splicing factors and to sites of 
transcription, further supporting a role for editing in regulation of gene expression 
(156).  
 
There are three fates for edited RNAs in the cell, depending upon their level of 
editing. Firstly, RNAs which are selectively edited are simply exported to the 
cytoplasm where they are translated and a protein incorporating amino acid changes 
is produced (see Figure 3.1 A). Alternatively, hyper-edited transcripts can be bound 
by either Vigilin or the p54nrb complex (see Figure 3.1 B). The p54nrb protein (NonA 
in Drosophila) has been shown to associate with a range of other RNA and DNA 
binding factors including poly-pyrimidine-tract associated splicing factor (PSF), which 
is a negative regulator of transcription, and Matrin 3, which is thought to be a 
transcriptional enhancer. In complex, p54nrb and PSF have been demonstrated to 
interact with the C-terminus of the large RNA polymerase II subunit co-
transcriptionally (157). Binding by p54nrb may alter export of some transcripts from 
the nucleus via association with Matrin 3, a component of the nuclear matrix (156), 
however it is unclear whether this is a general effect of hyper-editing. Vigilin has 
been predicted to play a role in regulation of gene expression via an association with 
heterochromatin and also plays a role in cytoplasmic stability of mRNA (156). 
Furthermore, Vigilin is found in complex with ADAR itself as well as RNA helicase A. 
This complex is thought to recruit kinases which phosphorylate targets including 
RNA helicase itself and histones and is therefore predicted to be involved in gene 
silencing (158).  
 
Hyper-edited RNA is also cleaved by Tudor Staphylococcal Nuclease 
(TudorSN), a component of the RISC complex, suggesting that promiscuous RNA 
editing feeds into RNAi pathways (159). The ability of TudorSN to bind and cleave 
edited RNAs is dependent upon a high percentage of IU and UI base pairs since 
these are less stable than the normal AU and UA pairings and result in localized 
distortions to RNA (159). Since the majority of large, perfectly double-stranded RNAs   50 
in the cell are viral in origin, this is likely to be a protective mechanism to shut down 
viral gene expression. There is some evidence for an antagonistic role for RNA 
editing and miRNA processing by Dicer. Promiscuous editing of double-stranded 
RNAs may prevent further processing to produce miRNAs – either by structural 
changes to the RNA or because other proteins such as TudorSN bind to transcripts 
containing a high proportion of inosine residues - and, conversely, slicing by Dicer 
may result in fragments too short to be editing substrates (153, 160). Editing of 
specific sites on miRNA precursors has also been demonstrated to play a regulatory 
role by preventing Dicer processing, suggesting a more elegant role for RNA editing 
































































































Figure 3.1: Proposed outcomes of site-specific and promiscuous RNA editing. A) The 
downstream effects of site-specific RNA editing by ADAR can include splice-site changes or 
single amino acid changes in the resultant protein. Since the majority of ADAR targets are 
channels and receptors, this has implications for the efficacy of channel and receptor 
function and therefore can be used as a regulatory mechanism by the cell. B) The 
downstream effects of promiscuous RNA editing by ADAR can include nuclear retention of 
the transcript resulting in translational silencing or heterochromatin formation resulting in 
transcriptional silencing. There is also thought to be an antagonistic relationship between 
miRNA pathways and RNA editing.  
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3.2 ADAR editing and disease 
 
Although ADAR is fairly ubiquitous, expression in the CNS is much higher 
than elsewhere and expression in muscle is quite low; approximately 1/8 of that of 
the MBNL1 splicing factor which plays a role in DM1 and 2 (76). Site selective A to I 
editing has been widely studied in mammalian systems, where editing plays a vital 
role in the regulation of neurotransmission pathways through targets which include 
the glutamate receptor family and G-protein-coupled serotonin receptors. ADAR 
activity has been shown to be developmentally regulated in mammalian brains (163) 
producing different forms of a number of ion channels at different developmental 
stages: for example the GABAA-α3 channel is edited only around 40% of the time in 
newborn mice compared to 100% in adults (152). This editing is linked to the switch 
from an excitatory role for GABA in the developing brain, to an inhibitory role in the 
adult brain via alteration of the chloride permeability of the channel on GABA 
binding. Loss of this editing would be predicted to result in a continuous large 
chloride influx, which could be damaging to the neuron over a long period of time.  
 
The editing of the AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole 
propionateglutamate) receptor B subunit (GluR-B) at a single position, resulting in a 
substitution of arginine for glutamine, controls the Ca
2+ permeability of the channel 
and this position has been found to be edited 99.9% of the time in humans. Mutant 
mice expressing unedited GluR-B at even low levels with the edited form are prone 
to epileptic seizures and premature death due to toxic effects of increased Ca
2+ 
influx into neurons (164). Substitution of the normal allele for one encoding the 
edited form of GluR-B rescues this phenotype (165). It is unclear why such a vital 
amino acid substitution is not simply encoded but requires editing; however there 
may be some degree of spatial and temporal specificity of editing which simply 
altering genomic sequence does not allow. Mice mutant for ADAR2, the isoform 
responsible for the editing of this GluR-B site, show similar phenotypes to mice 
expressing the unedited form and can also be rescued by the substitution of an allele 
encoding the edited form of GluR-B (165). A reduction of editing of this site has also 
been observed in the motor neurons of amyotrophic lateral sclerosis (ALS) patients, 
suggesting that this may be sufficient to result in neuronal death (166).  
 
 Amongst neurons which express the GluR-B receptor are the medium spiny 
neurons of the striatum which are most vulnerable in Huntington’s disease. Loss of   52 
these neurons has been shown to result in movement control defects in animal 
models (167). It has also been demonstrated that there is a reduction of GluR-B Q/R 
site editing in the striatum from 99.5% in controls (normal and schizophrenic) to 
approximately 95% in HD brains (168). Intriguingly, ADAR has been shown to edit 
the cytoplasmic FMR1 interacting protein 2 (CYFIP2) in a mouse model (169). 
CYFIP2 has been proposed to play a role in neuronal path-finding and axonal growth 
(170) and interacts with and regulates expression of the FMR1 protein, suggesting 




3.3 Drosophila Adar 
 
One ADAR orthologue has been identified in Drosophila by sequence 
comparison with mammalian and C.elegans ADAR. Editing is highly developmentally 
regulated – via use of alternative promoters and splice sites such that activity is low 
in embryonic stages and high in adults – and seems to occur at a much higher rate 
in the CNS than in other tissues, since the inosine content of RNA in the brain is 
much higher (171). Adar loss-of-function mutants show complete loss of editing of 
the sodium channel paralytic (para), the Dmca1A calcium channel (cac) and 
glutamate-gated chloride channel-α (DrosGluCl-α) all of which are vital for neuronal 
function in Drosophila (172). The mutant flies display a number of interesting 
phenotypes including age-dependent neurodegeneration, reduced neuronal 
tolerance to anoxia (172), an overall reduction in life-span under competitive 
conditions and temperature sensitive seizures or paralysis (140).  
 
The specific targets of Adar currently known in Drosophila are not orthologues 
of the known targets in mammals, although they play functionally similar roles. It is 
probable that there are more targets in both mammals and Drosophila which have 
not yet been identified. A recent study comparing sequences in Adar mutants to wild-
type Drosophila revealed that a number of transcripts which are edited play roles in 
neurotransmission and synaptic growth, including AP-50 which plays a role in 
secretory pathways for neurotransmission and the Boss glutamate receptor (173). 
This suggests that there is a common regulatory role for mammalian ADARs and 
Drosophila Adar in neurotransmission. Adar mutant flies also show statistically 
significant upregulation of reactive oxygen species (ROS) scavengers including the   53 
thioredoxin homologue deadhead (Dhd) and the cytochrome p450 family member 
Cyp4g1 (174). It is therefore suggested that Adar plays a role in oxidation pathways 
and regulates ROS scavengers, although it is not clear how this fits with the 
neurotransmission regulation roles already established for Adar. 
 
 
3.4 A role for RNA editing in the dominant expanded repeat diseases? 
 
The downregulation of RNA editing of GluR-B specifically in the striatum seen 
in individuals with HD suggests an intriguing link between RNA editing and expanded 
repeat disease. Furthermore, the observation that the majority of specific targets of 
RNA editing are neurotransmitter receptors and voltage and ligand-gated ion 
channels appears consistent with a model where long-term disruption to editing 
could result in progressive cellular dysfunction. We therefore hypothesise that 
expanded CAG repeats may be sequestering ADAR, whether or not they are edited 
themselves, resulting in a reduction in editing of ADAR targets. This could represent 
a common pathogenic mechanism in both the untranslated CAG repeat and 
polyglutamine diseases similar to the sequestration of MBNL1 observed in DM1 and 
DM2. Both the high expression of ADAR in the CNS and the dependence of neural 
circuits on the normal function of these targets suggest that neural systems would be 
highly affected by a reduction in ADAR editing activity. 
 
There are various mechanisms by which ADAR could influence disease 
progression in the dominant expanded repeat diseases. Firstly, there could be a 
direct interaction between ADAR and the expanded repeat tract, either involving 
editing by or simply sequestration of the ADAR enzyme. It has been shown that the 
location of mammalian ADAR2 within the nucleus has a profound effect on the 
overall editing level of endogenous transcripts (175), therefore the presence of 
ADAR in repeat-containing foci could prevent the enzyme from performing its normal 
function. While studies using tissue from DM individuals revealed that ADAR does 
not co-localise with either CUG or CCUG repeats in muscle (76), the localization of 
ADAR with CAG repeats has not been investigated.  
 
It is also possible that either the expansion of the repeat tract results in it 
being edited in a promiscuous manner – a process which could have regulatory 
outcomes for the entire repeat-containing transcript – or that the presence of an   54 
expanded repeat tract disrupts the normal editing that occurs in the non-expanded 
transcript, resulting in aberrant processing. The repeat regions involved in the 
expanded repeat diseases are all predicted to form large, imperfect hairpin 
structures at the RNA level. In the case of CAG repeat RNAs, this hairpin contains a 
mis-match every third base between two adenosine residues (as depicted in Figure 
1.3 A). It is known that ADAR is able to promiscuously edit long, perfectly double-
stranded RNAs (145, 176) and that ADAR editing in the human brain and in C. 
elegans frequently occurs in hairpin-forming non-coding regions of the RNA (177), 
however it is not clear whether structures such as those predicted to be formed by 
CAG repeats are likely targets of ADAR editing. Alternatively, there could be an 
antagonistic effect on the RNA editing pathway by repeat-mediated over-activation of 
other RNA processing systems such as the miRNA pathway. Our Drosophila model 
is an ideal system to investigate the contribution of Adar to repeat pathogenesis, 
since it enables the use of rapid genetic techniques to look for both direct and 
indirect interactions between Adar and expanded CAG repeat RNA. 
 
 
3.5 Investigation of the effects of altering Adar expression in Drosophila 
expressing expanded repeat RNA 
 
Since there is no phenotype in Drosophila expressing up to four transgene 
insertions of rCAG or rCUG repeats under the control of either a pan-neuronal driver 
(elav-GAL4) or an eye specific driver (GMR-GAL4), it is not possible to test for 
modification of an RNA-induced phenotype. Adar mutant Drosophila are viable and 
fertile, with temperature-dependent locomotion defects (140). They do not show a 
disruption to the exterior organisation of the eye, either when an RNAi construct 
targeting Adar is driven specifically in the eye by GMR-GAL4 or when a null allele of 
Adar (Adar
) is introduced, resulting in a 50% reduction in Adar expression in all 
tissues. Expression of up to four transgene insertions of either rCAG, rCUG or rCAA 
repeats in the eye in a heterozygous Adar
 background similarly does not result in a 
disruption to the exterior organisation of the eye (Figure 3.2 B-D).   55 
 
 
Figure 3.2: Effect of expression of rCAA, 
rCUG or rCAG repeats in a heterozygous 
Adar null background. Expression of 
untranslated repeat tracts is driven by GMR-
GAL4. In each case, female flies heterozygous 
for Adar
 were photographed. A) Eyes of 
heterozygous Adar
 females are wild-type in 
appearance. In this case, the flies also carry 
GMR-GAL4 and four transgene insertions of the 
UAS region from the repeat constructs, but with 
no repeat tract. B-D) Expression of four 
transgene insertions of the rCAA, rCUG or rCAG 
repeat constructs in the eye of Adar
 
heterozygous female flies does not alter the 





Expression of a polyglutamine tract encoded by either CAG or CAA repeats in 
the Drosophila eye has been shown to cause a severe disruption to the eye, 
resulting in loss of pigment and in some cases necrotic patches (61) (described in 
1.4.1). While these polyglutamine phenotypes are visually indistinguishable, only the 
flies expressing the CAG-encoded polyglutamine tract are also expressing CAG 
repeat RNA. Therefore the identification of genes which modify the eye phenotype in 
the CAG repeat expressing flies but not the CAA repeat expressing flies could 
indicate an interaction with the CAG hairpin RNA. Using this reasoning, the effect of 
a reduction in Adar levels on the polyglutamine eye phenotypes was investigated. 
Introducing one null allele of Adar (Adar
)
 into flies expressing polyglutamine 
encoded by a CAA repeat appears to slightly suppress the eye phenotype: there is a 
slight increase in the size of the eye and a slight reduction in the extent of the loss of 
pigment (Figure 3.3 B compared to E). This effect is not seen in flies expressing 
polyglutamine encoded by a CAG repeat (Figure 3.3 A compared to D).    
 
In support of a sequence-dependent interaction between Adar and CAG 
repeat RNA, the mild disruption to patterning of the eye caused by expression of a 
translated CUG repeat encoding polyleucine (shown in Figure 3.3 C and described in 
section 1.4.2) is also suppressed by loss of one copy of Adar, resulting in a marked 
reduction in the area of roughness and an increase in the size of the eye (Figure 3.3 
F). Since CAG and CUG repeat tracts are both predicted to form RNA hairpins, this   56 
result indicates that the difference in secondary structure between the CAG and CAA 
repeat RNAs is not solely responsible for the difference in observed interaction. It is 
unclear how the suppression of the CUG-encoded polyleucine and CAA-encoded 
polyglutamine phenotypes is mediated, however the inability of a reduction in Adar to 
modify the CAG-encoded polyglutamine phenotype may suggest that this repeat 
sequence is unique. 
 
 
Figure 3.3: Effect of reducing 
Adar levels on Drosophila eye 
phenotypes elicited by 
expression of CAG or CAA-
encoded polyglutamine or CUG-
encoded polyleucine. Flies were 
grown at 25°C and repeat 
expression driven by GMR-GAL4.  
Adar
 flies are heterozygous
 female 
flies in all cases. (A&B) Expression 
of either CAG or CAA-encoded 
polyglutamine results in a loss of 
pigment eye phenotype. (C) 
Expression of CUG-encoded 
polyleucine results in roughening of 
the surface of the eye without loss 
of pigment. (D) The exterior 
appearance of the eye does not 
change when a heterozygous Adar
 
mutation is introduced into flies 
expressing CAG-encoded 
polyglutamine. (E) Suppression of the loss of pigment eye phenotype and an increase in the 
size of the eye is observed when a heterozygous Adar
 mutation is introduced into flies 
expressing CAA-encoded polyglutamine. (F) Suppression of the disorganisation of 
patterning and an increase in the size of the eye is observed when a heterozygous Adar
 




3.6 Investigation of the editing status of ectopically expressed CAG and CAA 
repeat tracts in Drosophila 
 
One difference between CAG repeat RNA and either CUG or CAA repeat RNA 
is its ability to form a hairpin secondary structure containing multiple mis-matched 
adenosine residues. It is possible that these residues could themselves be targets of 
Adar editing or could result in the sequestration of Adar, in a similar manner to the 
sequestration of MBNL splicing factor by expanded CUG repeats in DM1, without 
themselves being edited. To determine whether expanded CAG repeats are edited in   57 
Drosophila, translated and untranslated CAG and CAA repeats were expressed in 
the nervous system (elav>GAL4), total RNA was extracted and the ectopically 
expressed repeat tracts were reverse transcribed and sequenced. There was no 
detectable A to I editing in either CAG or CAA repeat tracts in this model (Figure 3.4). 
While this result does not support a role for Adar in editing expanded CAG repeat 
transcripts in Drosophila, it does not rule out the possibility that Adar is sequestered 
by the presence of expanded CAG repeat RNA.  
 
 
Figure 3.4: There is no 
detectable editing of pure 
CAG or CAA repeats 
expressed pan-neuronally 
in Drosophila. Untranslated 
rCAG (A) and rCAA (B) 
repeats were expressed 
specifically in the nervous 
system with elav-GAL4 and 
total RNA from 
approximately 100 heads 
was purified for reverse 
transcription and 
sequencing.  
A&B) Sequenced rCAG and 
rCAA repeat tracts show no 
sign of editing, which can be 
observed as a mixed A/G signal at the edited residue. Translated CAG or CAA repeats 
expressed pan-neuronally were also sequenced and similarly showed no evidence of A 




3.7 Investigation of the effect of expression of CAG repeat RNA on editing of 
endogenous Adar editing targets in Drosophila  
 
A situation where Adar is sequestered through a direct interaction with repeat-
containing transcripts would be expected to result in a reduction in observed editing 
of the normal targets of the enzyme, as is observed when Adar levels are reduced by 
genetic means. In order to test whether a reduction of Adar activity occurs in CAG 
repeat-expressing Drosophila, four transgene insertions of the rCAG repeat construct 
were expressed pan-neuronally with elav>GAL4 and the editing status of a set of 
sites known to be highly edited in Drosophila was determined by reverse transcription 
of the mRNA and sequencing. Two adenosine residues for the GluCl-∝ channel 
(Figure 3.5 A) and five sites for the para sodium channel (Figure 3.5 B & C) were 
A    elav>rCAG 
B    elav>rCAA   58 
tested in this manner, chosen because these sites are known to be normally edited at 
levels detectable by sequencing and this editing is reduced or completely lost in Adar 
mutant Drosophila (172). A significant decrease or complete loss of editing was seen 
at all sites in Adar
 flies, while no consistent decrease in editing was observed in 
rCAG repeat expressing flies. It therefore does not appear that the expression of 
CAG repeat RNA is able to reduce Adar editing levels in Drosophila, at least not at a 




Figure 3.5: There is 
no detectable 
decrease in editing 
of normal Adar 




nervous system of 
Drosophila.  Sites 
known to be edited 
with high frequency in 
Drosophila were 
selected and 
sequenced in male 
Drosophila. Since 





tested do not have a 
functional Adar allele. 
A clear reduction in 
the level of RNA editing at known editing sites is observed in ADAR null flies (Adar
) 
compared to either wild-type flies (not shown) or the out-crossed elav-GAL4 driver line 
(elav>+). There is no reduction in editing when four transgene insertions of the rCAG 
construct are expressed throughout the nervous system (elav>rCAG). A) Sites known to be 
edited in the Drosophila GluCl-∝ channel mRNA. B&C) Sites known to be edited in the para 
channel mRNA. Black arrow heads indicate sites that show a substantial proportion of 
editing, observed as a mixture of A and G signals in the sequencing chromatograph, while 
red arrow heads show sites that appear to have a reduction or loss of editing. Interestingly, 
there is one site reported to be highly edited in Drosophila (172) which does not show 
evidence of editing in any genotype in this assay (C- red arrow heads).  
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3.8 Summary of investigation of RNA editing as a component of CAG repeat 
RNA pathogenesis. 
 
  There is a large amount of data demonstrating the pathogenic nature of CUG 
repeat RNA in DM1, however the possibility of CAG repeat RNA being pathogenic 
and the mechanisms by which this might occur have not been extensively explored. 
We propose a mechanism whereby the expansion of a CAG repeat tract might result 
in sequestration of the RNA editing enzyme ADAR in much the same manner as 
MBNL is sequestered in DM1. ADAR appears to be a good candidate for a role in at 
least some of the expanded repeat diseases because of its demonstrated importance 
in maintaining function in a specific subset of neurons which includes those most 
affected in HD.  
 
  There are several mechanisms by which expansion of CAG repeat tracts 
might be envisaged to disrupt ADAR activity, two of which were investigated in this 
study. Firstly, the expanded repeat tracts themselves might be editing targets for the 
enzyme and therefore expansion beyond a particular repeat number may have a 
rate-limiting effect on editing of normal ADAR targets in the disease situation. 
Alternatively, expanded CAG repeat tracts may sequester ADAR without themselves 
being edited. Despite observing a difference in interaction between Adar and either 
CAA-encoded polyglutamine or CUG-encoded polyleucine compared to CAG-
encoded polyglutamine in the eye, no evidence was obtained that Adar is able to edit 
neuronally expressed CAG repeat RNA in Drosophila, or that the presence of CAG 
repeat RNA in neurons results in a reduction in editing of the normal targets of 
Drosophila Adar; an effect which could be indicative of sequestration of the enzyme. 
It was therefore concluded that Adar is unlikely to be binding to the expanded CAG 
repeat tract in our Drosophila model and that the difference in interaction between 
Adar and expanded CUG or CAA repeats and CAG repeats in the Drosophila eye is 
not the result of a direct physical interaction between Adar and the repeat tract, but is 
most likely mediated through an indirect mechanism.  
 
The expanded repeat disease model investigated in this study examines only 
the intrinsic toxicity of expanded repeat tracts and therefore the possibility that 
expanded CAG repeats are able to be edited and/or sequester ADAR in the context 
of the disease-associated transcripts cannot be ruled out. The Drosophila Adar   60 
enzyme may also have different binding preferences than the human enzymes; a 
possibility which could be tested in this model by generating Drosophila lines 
containing insertions of the human ADAR genes. Therefore, while the results 
presented in this study do not support a role for Adar in pathogenesis in this 
Drosophila model, a role for RNA editing in the expanded repeat diseases may 
warrant further investigation.  
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Chapter 4: Identifying pathogenic pathways of expanded repeat disease by 
proteomic analysis 
 
The experiments described in Chapter 3 of this thesis investigated a role for 
the editing enzyme Adar in pathogenesis in flies expressing expanded CAG repeat 
RNA. While this kind of directed investigation of pathogenic pathways can provide 
biologically relevant information, one advantage of exploring disease pathways in 
Drosophila is the ability to perform large scale screens of candidate genes with 
relative ease. This property makes genetic validation of candidates identified by 
techniques such as microarray and proteomic analysis, which typically produce large 
amounts of data, a viable option.  
 
There are indications from both mouse and Drosophila models of DM1 that 
CUG repeat RNA alone is intrinsically toxic and can elicit many of the pathological 
features observed in the disease (70, 86). More recently, the toxicity of untranslated 
CAG repeats has also been demonstrated in Drosophila (117), however the primary 
cellular changes responsible for neurodegeneration are not yet clear. In order to 
investigate the pathogenicity of repeat-containing RNA specifically in neurons, 
transgene insertions of the rCAA, rCAG and rCUG repeat constructs were expressed 
under the control of the pan-neuronal elav-GAL4 driver (as depicted in Figure 4.1). 
Flies expressing up to four transgene insertions of these constructs are viable and 
show no obvious phenotypes (K. Lawlor, unpublished data). Expression of these 
untranslated repeats in the nervous system therefore allows the investigation of the 
effects of expression of hairpin repeat RNA (rCUG and rCAG) in cells which are not 
dying, but are likely to demonstrate early hallmarks of expanded repeat pathogenesis. 
Given that CAG and CUG repeat RNAs form structurally similar hairpin structures, it 
has been proposed that similar mechanisms may be involved in pathogenesis of 
disease caused by each of these repeats. Therefore common changes observed in 
both CAG and CUG repeat expressing flies are of particular interest in this study. The 
rationale for this methodology is summarised in Figure 4.2.  
 
Using this Drosophila system, in vivo perturbations to neuronal pathways 
caused by expression of expanded untranslated repeats have been investigated by 
looking at both proteomic and transcriptional changes. In order to identify early 
events in expanded repeat pathology – which are more likely to represent causative   62 
changes rather than the down-stream effects of cellular perturbation – newly eclosed 
flies were used in these analyses. By investigating changes occurring at both the 
protein (using 2D-DIGE followed by MS) and transcript (using microarrays) levels, a 
broader view of the sorts of pathways which are disrupted by repeat expression can 
be obtained. It is predicted that amongst the proteins and transcripts altered as a 
result of hairpin repeat expression in this model will be mediators of pathogenesis 
and therefore these analyses should provide information about the primary steps in 
pathogenic progression. In order to validate results obtained from these studies, the 
Drosophila eye was then used as a tool to look for modification of phenotypes 
associated with expanded repeat expression. The results of these experiments are 
described in Chapters 4-6 of this thesis. 
 
Figure 4.1: Obtaining Drosophila 
expressing untranslated repeats 
pan-neuronally for microarray and 
proteomic analysis. A) Constructs 
used to express expanded 
untranslated CAG, CUG and CAA 
repeats pan-neuronally in Drosophila. 
CAG, CUG and CAA repeat tracts 
are inserted into the 3’ untranslated 
region of a short peptide (called 
rCAG. rCUG and rCAA respectively). 
B) Expression can be induced by 
GAL4 protein binding to the upstream 
activation sequence (UAS) region. In 
this case, pan-neuronal expression of 
each of the untranslated repeat 
constructs was achieved by driving 
expression with elav-GAL4. Crossing 
elav-GAL4 flies to flies carrying the repeat insertions results in progeny expressing the 
expanded untranslated CAG, CUG or CAA repeats specifically in the nervous system. 
 
 
Figure 4.2: Rationale for use of this 
Drosophila model for investigation of 
early changes in expanded repeat 
disease. Expression of rCAG/rCUG 
repeats in this model should allow the 
identification of early changes caused by 
expression of hairpin repeats (red arrow). 
In the disease situation, there are likely to 
be many steps between the initial 
dysfunction and cellular death which take place over many decades. Many of these 
processes are unlikely to occur within the life-span of Drosophila, however by comparing 
the transcriptomes and proteomes of flies expressing rCAG/rCUG hairpin RNAs with those 
of flies expressing rCAA RNA, which cannot form a hairpin, or flies not expressing any 
ectopic RNA species (elav>+), early changes that represent causative pathways leading to 
this long-term pathogenesis should be identified.  63 
4.1 Identification of proteomic changes in neuronal cells expressing expanded 
repeat tracts 
 
  Proteomic analysis has not been extensively used in models of expanded 
repeat pathogenesis to date, with emphasis in many of the existing studies being on 
proteins found to aggregate with polyglutamine (178-179). We used a proteomic 
approach to identify changes caused by expression of rCAG and rCUG repeat RNAs 
in neurons of Drosophila with the aim of distinguishing hallmarks of expanded repeat 
pathogenesis. Proteomic analysis has the advantage that it can detect changes to 
both the abundance and post-translational state of proteins, therefore giving insight 
into mechanisms such as oxidative damage of proteins which have been proposed to 
play a role in polyglutamine disease (180).  
 
Proteomic analysis was performed by the Adelaide Proteomics Centre 
(University of Adelaide, Australia). For each sample, total protein was extracted from 
heads of male flies. Samples were prepared from four biological replicates for each 
genotype and spread across a total of 8 2D mini gels, such that each genotype was 
represented on 4 separate gels as shown in Figure 4.3 A. Details of lines used can 
be found in Appendix A, Figure A1. Differential in-gel electrophoresis (DIGE) analysis 
was used to identify protein spots with a difference in abundance between 
genotypes. The comparisons performed between genotypes are represented in 
Figure 4.3 B&C. Two-tailed Student’s t-tests were initially performed to identify spots 
with a significant difference in protein abundance in rCAG, rCUG and rCAA repeat 
expressing flies compared to elav>+ control flies (Figure 4.4 A). A single spot which 
showed a significant change in abundance in rCAG and rCUG repeat expressing flies 
compared to the elav>+ control but not in rCAA repeat expressing flies compared to 
the elav>+ control was then selected from this list (Figure 4.4 B). Since there is some 
evidence to suggest that GAL4 is itself toxic to cells when it accumulates and can 
trigger apoptosis (137), the elav>rCAA comparison provides a control where the 
GAL4 present in the cells of the nervous system should be able to bind to the UAS 
sites of the rCAA construct, preventing accumulation. We therefore predict that 
driving expression of this CAA repeat RNA, which is unable to form a hairpin 
structure like the CAG and CUG repeats, should provide a control for the effects of 
GAL4 toxicity. The elav>+ sample is included as a control for any effects that the 



















Figure 4.3: Overview of 2D-DIGE experiment procedure and analyses performed. 
A) IPS= Internal pooled standard. This sample is an equal mix of proteins from each of 
the 16 samples analysed on the gels (elav>+ A-D, elav>rCAA A-D, elav>rCAG A-D and 
elav>rCUG A-D) labelled with Cy2 and was run on every gel to allow comparisons and 
spot-matching to be performed between gels. Protein was extracted from 4 biological 
replicates for each genotype and 2 samples were labelled with Cy3 and 2 with Cy5. 
These samples were then spread across a total of 8 gels as shown. Gel 4 was selected 
as the master gel for this experiment, since it showed the largest number (2753) of 
properly resolved protein spots. Protein spots on all other gels were spot matched to the 
master gel.  B) Initially, average spot ratio calculations and two-tailed Student’s t-tests 
were performed for the four replicates for each of elav>rCAA, elav>rCUG and 
elav>rCAG compared to elav>+. A single spot that showed a significant change in 
abundance in both elav>rCUG and elav>rCAG but not elav>rCAA flies compared to 
elav>+ was then identified by MS/MS (Figure 4.4). C) Average spot ratio calculations 
and two-tailed Student’s t-tests were also performed directly comparing the elav>rCUG 
and elav>rCAG samples to elav>rCAA. This analysis also identified a single spot with a 







Gel Number  Cy2  Cy3  Cy5 
1  IPS   elav>+ (A)  elav>rCAG (C) 
2  IPS  elav>rCAA (B)  elav>rCUG (D) 
3  IPS  elav>rCUG (B)  elav>+ (D) 
4  IPS  elav>rCAA (D)  elav>rCAG (B) 
5  IPS  elav>+ (C)  elav>rCUG (A) 
6  IPS  elav>rCUG (C)  elav>rCAA (C) 
7  IPS  elav>rCAG (A)  elav>+ (B) 






elav>rCAA (A-D)  elav>rCAA (A-D) 
elav>rCAG (A-D) 
elav>rCUG (A-D) 















Figure 4.4: Summary of changes in protein abundance detected in flies expressing 
rCAG, rCUG and rCAA RNA when compared to elav>+ control flies. A) Number of spots 
with a detected change in abundance when compared to the elav>+ control. In each case, 
two-tailed students t-tests were performed on biological replicates and spots chosen with 
P<0.05. Spot IDs are listed in Appendix A as indicated. B) Spot 1978 showed a change in 
abundance in flies expressing rCAG and rCUG repeats but not rCAA repeats. Fold change 
was calculated from the average change in spot intensity compared to elav>+ across the four 
gels for each genotype. Spots were selected for P<0.05. C) Spectra obtained from MS/MS 
were submitted to a MASCOT database search-engine. Two proteins, DPx-2540-1 and 
Alcohol dehydrogenase, returned combined ion scores above the cut-off, indicating 95% 
confidence in these proteins matching the MS/MS spectra and therefore suggesting that both 
proteins are likely to be present as a mix in this spot. Combined ion scores are calculated by 
summing the statistical score for each individual peptide match and excluding any redundant 
matches. DPx-2540-1 returned a combined ion score and % sequence coverage nearly twice 
that for Alcohol dehydrogenase and was also predicted to be nearly three times more 
abundant, as indicated by the exponentially modified protein abundance index (emPAI) 
scores. This suggests that DPx-2540-1 is more likely to be responsible for the observed 






T-test  Fold 
Change 
elav>rCAG 0.005  1.22 
elav>rCUG 0.002  1.27 
Spot 
number  Protein ID  Human 
orthologue 
Accession 































elav>rCUG  elav>rCAG 
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4.2 Identification of proteins altered in Drosophila expressing rCAG or rCUG 
repeats pan-neuronally 
 
Only one detected spot was significantly altered in flies expressing rCAG and 
rCUG repeats, but not rCAA repeats, compared to elav>+ (Figure 4.4 B). This spot 
was excised from the master gel and identified by MS/MS (Figure 4.4 C). Two protein 
matches were found for the MS/MS spectra obtained for this spot by MASCOT search 
– Dpx-2540-1 (CG12405) and Alcohol dehydrogenase (CG3481) – both of which had 
combined ion scores that greatly exceeded the cut-off score of 58 required for 95% 
confidence in the match. This suggests that both proteins are likely to be present in 
spot 1978. The combined ion score is calculated by summing the statistical probability 
associated with all of the non-redundant peptide queries assigned to that protein 
match and therefore is a measure of the total level of support for that match. The 
sequence coverage and exponentially modified protein abundance index (emPAI) 
score give a measure of the percentage of the matched protein sequence covered by 
the peptides identified in MS/MS and a measure of the relative abundance of the 
protein predicted from the relative amount of each peptide identified by MS/MS 
respectively. The relative abundance score (emPAI) for DPx-2540-1 was more than 
double that of Alcohol dehydrogenase, suggesting that this protein is more likely to be 
responsible for the observed increase in spot intensity.  
 
PRDX6, the human orthologue of DPx-2540-1, has been previously shown to 
protect against apoptosis (181), as well as assisting in maintenance of Ca
2+ 
homeostasis (182). Induction has been demonstrated in both Alzheimer’s patient 
brains – although in this case induction is seen only in astrocytes and not neurons 
(183) –  and HD patient brains (180). It is a particularly unique member of the 
peroxiredoxin family in that it has both peroxidase and phospholipase activities; 
functions which may be particularly important in the brain because of its high lipid 
content (184). While regulation of human PRDX6 has been demonstrated to occur at 
the transcriptional level (185), there was no increase in DPx-2540-1 mRNA expression 
in flies expressing rCAG or rCUG repeats by quantitative real time PCR (data not 
shown), suggesting that transcriptional regulation is not responsible for the observed 
change in protein abundance. It is therefore likely that stabilisation or modification of 
the Dpx-2540-1 protein is responsible for any change in abundance in expanded 
repeat expressing flies.   67 
  In order to confirm a role for DPx-2540-1 in expanded repeat disease 
pathogenesis, we obtained a fly line which contains an insertion within the region of 
DPx-2540-1. This insertion, called MB01457, is a Minos element insertion from 
Drosophila hydei (186) located approximately 100 bp upstream of the annotated 
DPx-2540-1 gene. The ability of the MB01457 insertion to reduce DPx-2540-1 
expression has not been demonstrated, however there is currently no RNAi line and 
no other insertion associated with DPx-2540-1 available in Drosophila. Since 
expression of up to four transgene insertions of the untranslated repeat constructs 
(rCAG, rCAA and rCUG) in the eye does not elicit a phenotype, we examined the 
ability of the MB01457 allele to alter the phenotypes seen in the eye when a 
polyglutamine tract encoded by either a CAG or CAA repeat or a polyleucine tract 
encoded by a CUG repeat are expressed using the eye-specific GMR-GAL4 driver 
(described in Chapter 1.4.1 and 1.4.2). Where altering expression of a candidate 
gene results in a modification of the phenotypes caused by all three of these 
repeats, we predict that this interaction is unlikely to be due to a specific interaction 
with hairpin repeat RNA since the CAA RNA is unable to form a secondary structure. 
A similar methodology has been successfully used to identify mbl as a candidate 
gene which is able to modify the phenotype caused by a polyglutamine tract 
encoded by a pure CAG repeat but not a mixed CAG/CAA repeat (117).  
 
The phenotypes associated with expression of CAG or CAA-encoded 
polyglutamine or CUG-encoded polyleucine did not appear to be dramatically altered 
in flies heterozygous for the MB01457 insertion (Figure 4.5). Subsequent analysis of 
DPx-2540-1 expression levels in the MB01457 insertion line revealed that levels of 
DPx-2540-1 RNA are not reduced in this stock compared to the wild-type w
1118 stock 
used to generate the expanded repeat lines; in fact expression is consistently higher 
in the insertion line (Appendix A, Figure A5). A hypomorphic or null allele of DPx-
2540-1 could be generated by remobilising the Minos element to excise surrounding 
DNA (as described in (186)) however this was not pursued further in this study. 
Upregulation or modification of DPx-2540-1 may play a protective role in cells 
expressing expanded repeat RNA however, given that induction of PRDX6 is also 
seen in Alzheimer’s patients, it seems unlikely that this is a primary change elicited 
specifically by expanded repeat RNA.  
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The effect of altering levels of the other protein identified in spot 1978, Alcohol 
dehydrogenase, on the expanded repeat phenotypes was also tested (Figure 4.5 G-I). 
In this case, an RNAi construct targeting Adh was co-expressed with CUG, CAG or 
CAA repeats in the eye. A slight change in the phenotype resulting from expression of 
polyglutamine encoded by either CAG or CAA was seen when these repeats were co-
expressed with the Adh RNAi construct in the eye, consisting of a slight improvement 
in the ordered structure of the ommatidia but a decrease in pigmentation. A slight 
suppression of the rough eye phenotype resulting from expression of polyleucine 
encoded by CUG repeat was also seen. This effect is unlikely to be mediated through 
an interaction with hairpin RNA, since it is observed in flies expressing CAA repeat 
RNA which is unable to form a secondary structure. 
 
 
Figure 4.5: Modification of phenotypes 
resulting from expression of translated 
CUG, CAG and CAA repeats by insertion 
of a Minos element upstream of 
DPxr2540-1 or knocking down 
expression of Alcohol dehydrogenase. 
In all cases, repeat expression was driven 
by GMR-GAL4. A&B) Expression of 
polyglutamine encoded by either CAG or 
CAA results in loss of pigment in the eye. 
C) Expression of polyleucine results in a 
very mild rough eye phenotype. D-F) 
Expression of translated CAG, CUG or CAA 
repeats in a heterozygous MB01457 
insertion background does not result in a 
dramatic alteration to the exterior 
appearance of the eye. G-H) A slight 
change in the polyglutamine phenotype is 
seen when an RNAi construct targeting Adh 
is co-expressed with either CAG or CAA 
repeats. I) Co-expression of an RNAi 
construct targeting Adh slightly suppresses 
the ommatidial disorganisation in flies 
expressing CUG-encoded polyleucine. 
 
 
4.3 Identification of proteins altered in flies expressing rCAG or rCUG repeats 
compared to rCAA repeats. 
 
Since analysis of spots altered in both elav>rCAG and elav>rCUG flies 
compared to the elav>+ control resulted in detection of only 1 spot with a change in 
abundance which was not also altered in elav>rCAA flies, the 2D-DIGE data was re-  69 
analysed comparing rCAG and rCUG repeat expressing flies directly to rCAA repeat 
expressing flies (comparison depicted in Figure 4.3 C). The resulting number of 
spots for each genotype compared is shown in Figure 4.6 A. This comparison also 
identified only one spot showing a change in abundance common to flies expressing 
rCAG and rCUG (Figure 4.6 A&B). The low number of changes identified common to 
flies expressing rCAG and rCUG repeats compared to either elav>+ or elav>rCAA 
flies was unexpected. However, since these 2D mini-gels were only able to resolve 
between 2513 and 2753 spots per gel and Drosophila are predicted to have 
somewhere in the vicinity of 50,000 protein variants, the detected changes in spot 
abundance are likely to represent only a small proportion of changes to the 










Figure 4.6: Summary of changes in protein abundance detected when rCAG and rCUG 
repeat expressing flies were compared directly to elav>rCAA flies. A) Number of spots 
altered in elav>rCAG and elav>rCUG compared to elav>rCAA. In each case, two-tailed 
Student’s t-tests were performed on replicates and spots chosen with P<0.05. All spots 
meeting these criteria are listed in Appendix A, Table A6-A7.  B) Only one spot with changed 
abundance in both elav>rCAG and elav>rCUG flies compared to elav>rCAA was detected, 
which showed significantly decreased abundance. C) Summary of MASCOT search results 
for spectra obtained by MS/MS for spot 1101. Two proteins, Nup62 and cAMP-dependent 
protein kinase R2, returned combined ion scores above the cut-off, indicating >95% 
confidence in the protein match. Combined ion scores are calculated by summing the 
statistical score obtained for each individual peptide match and excluding any redundant 
matches. Nup62 was predicted to have greater relative abundance based on the frequency 
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elav>rCAG 0.001  -1.51 
elav>rCUG 3.5E-4  -1.51 
Spot 
number  Protein ID  Human 
orthologue 
Accession 





(CG6251)  NUP62 gi|20130049  0.26  8.4  183/48 
1101  cAMP-dependent 
protein kinase R2 
(CG15862) 
PRKAR2A gi|17647815  0.08  7.7  128/48 
A 
C 
elav>rCUG  elav>rCAG 
1  2  26 
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The single spot detected which showed a common change in abundance in both 
rCAG and rCUG expressing flies compared to rCAA expressing flies was also excised 
from the master gel and identified by MS/MS (Figure 4.6 B&C). There was a 1.51 fold 
decrease in abundance of this spot in both elav>rCAG and elav>rCUG flies. Two protein 
matches were found for the MS/MS spectra by MASCOT search – Nucleoporin 62 
(Nup62) and cAMP-dependent protein kinase R2 (CG15862) – both of which greatly 
exceeded the cut-off score of 48 required for 95% confidence in the match. This suggests 
that spot 1101 contains a mixture of both proteins, however the emPAI score for Nup62 
was much higher than for cAMP-dependent protein kinase R2 (0.26 compared to 0.08) 
indicating that this protein is likely to be more abundant in the spot. Given the higher 
relative amount of Nup62 in spot 1101, a decrease in abundance of this protein would be 
predicted to be more likely to be the cause of the observed change in spot intensity. 
 
 
4.4 Evidence for involvement of nuclear transport in expanded repeat disease 
pathogenesis 
 
NUP62 is a central component of the nuclear pore complex (NPC), the 
protein channel which spans the nuclear envelope and regulates transport in and out 
of the nucleus. Mutations in components of the NPC have been implicated in a 
number of diseases, known as the laminopathies, which have diverse symptoms 
depending upon the affected tissues (reviewed in (187)). Mutations in NUP62 have 
been demonstrated to result in infantile bilateral striatal necrosis; a condition caused 
by degeneration of the basal ganglia and characterised by symptoms including 
involuntary movements, mental retardation, seizure and abnormal eye movements 
(188). NUP62 has also been reported to localise to protein aggregates in 
Alzheimer’s disease (189) and polyglutamine expressing cells (190), suggesting that 
altered nuclear transport pathways play a role in some neurological diseases. 
Irregular localisation of the NPC, including NUP62, has also been described in 
anterior horn cells from spinal cords of patients with sporadic or familial ALS (191), a 
neurodegenerative disorder characterised by death of motor neurons. This 
observation supports a role for the NPC and nuclear transport in neuronal survival.  
 
The nuclear pore also plays a role in stress response through extensive 
modifications and degradation of components of the NPC including NUP62 (192).   71 
These modifications, which include phosphorylation and O-glycosylation, alter the 
interactions of the NPC with proteins both within the nucleus and the cytoplasm and 
thus inhibit nuclear export (192). In Drosophila, Nup62 has been shown to co-
localise with the RNA binding protein Staufen2 (193) which has been implicated in 
nuclear export of mRNA (194). Data from Xenopus showing a direct interaction 
between mRNA and Nup62 during export (195) further supports a central role for 
Nup62 in mRNA export from the nucleus. A role for Nup62 in transcriptional 
regulation has also been suggested through an interaction with the transcription 
factor SP1 (196). Recent evidence from Drosophila suggests a central role for 
nucleoporins, including Nup62, in gene activation and silencing through interactions 
with chromatin. While these interactions can occur at the NPC, they have also been 
found to occur in the nucleoplasm (197-198) suggesting that nucleoporin function is 
not limited to the nuclear envelope.    
 
  In order to verify an interaction between Nup62 and CAG and CUG repeat 
RNA, the ability of an RNAi construct targeting nup62 or an overexpression 
construct encoding the Drosophila nup62 cDNA to alter the appearance of the eye 
when introduced into flies expressing a polyglutamine tract encoded by either a CAG 
or CAA repeat or a polyleucine tract encoded by a CUG repeat was tested.  
Expression of an RNAi construct targeting nup62 with GMR-GAL4 did not cause a 
phenotype in the eye alone, but consistently caused a mild enhancement of the 
phenotypes resulting from expression of CAG-encoded polyglutamine and CUG-
encoded polyleucine (Figure 4.7 A&C compared to D&F). No significant change to 
the exterior appearance of the eye was observed when the same RNAi construct 
was co-expressed with polyglutamine encoded by a CAA repeat (Figure 4.7 B 
compared to E). This suggests that Nup62 is able to modify expanded repeat 
pathology in our Drosophila model and that, since this interaction is not observed 
when the non-hairpin forming CAA repeat is expressed, this is likely to be sequence-
dependent effect occurring at the RNA level. In further support of a role for Nup62 in 
expanded repeat pathogenesis, expression of an RNAi construct targeting the 
transcript encoding the other protein identified in spot 1101, cAMP-dependent 
protein kinase R2 (CG15862), did not cause a significant change to the appearance 
of the eye in flies co-expressing polyglutamine encoded by a CAG or CAA repeat or 
polyleucine encoded by a CUG repeat (Figure 4.7 G-I). This suggests that while 
there may be a change in expression or modification of both Nup62 and cAMP-  72 
dependent protein kinase R2 in flies expressing expanded repeat RNA, Nup62 is 
likely to be involved in a rate-limiting step in pathogenesis in this model.  
 
 
Figure 4.7: Co-expression of an 
RNAi construct targeting nup62 
enhances CAG and CUG but not 
CAA eye phenotypes. Both RNAi 
construct expression and repeat 
construct expression are driven by 
GMR-GAL4. Two independent 
insertion lines were tested for this 
RNAi construct and the same result 
was observed in both cases. A&B) 
Expression of polyglutamine encoded 
by either CAG or CAA results in a 
loss of pigment eye phenotype. C) 
Expression of polyleucine results in a 
mild rough eye phenotype. D) Co-
expression of an RNAi construct 
targeting nup62 with polyglutamine 
encoded by a CAG repeat results in a 
consistent increase in the area of the 
eye displaying loss of pigment. E) Co-
expression of the same RNAi with 
polyglutamine encoded by a CAA 
repeat does not cause a change to 
the exterior appearance of the eye. F) 
Co-expression of the nup62 RNAi 
construct enhances the polyleucine 
eye phenotype, resulting in an 
increased area and severity of 
roughness, a decrease in the size of the eye and the appearance of necrotic patches. 
G&H) Co-expression of an RNAi construct targeting CG15862 (cAMP-dependent protein 
kinase R2) with polyglutamine encoded by either a CAG or CAA repeat results in 
indistinguishable eye phenotypes. I) Co-expression of an RNAi construct targeting 
CG15862 with polyleucine encoded by a CUG repeat does not significantly alter the 
exterior appearance of the eye.  
 
 
Since Nup62 is involved in RNA export from the nucleus, the modification of the 
eye phenotype in Drosophila may be mediated via a direct interaction between Nup62 
and the CAG and CUG repeat RNA. Nuclear retention of CUG repeat-containing RNA 
has been described in models of DM1 as well as in patient tissue (72, 76, 81) and is 
thought to be necessary for pathogenesis. In support of this, the formation of 
cytoplasmic foci has been shown to be insufficient to elicit toxicity in a mouse model 
(199) and forcing RNA out of the nucleus in myoblasts in a cellular DM1 model is able 
to reduce some of the muscle differentiation phenotypes associated with CUG repeat 
expression (200). It is unclear whether nuclear retention is the cause of sequestration   73 
of key RNA binding proteins including MBNL1, or a result of these interactions. One 
key piece of evidence to support a role for RNA binding proteins in preventing CUG 
repeat RNA from leaving the nucleus is that reducing levels of one component of 
these foci, the RNA binding protein HnRNP-H, rescues nuclear retention in DM1 cells 
(201). Interestingly, HnRNP-H itself has been shown to play a role in shuttling 
between the nucleus and cytoplasm (202). The finding that altering Nup62 levels 
modifies phenotypes associated with expanded repeat expression in Drosophila 
supports an important role for nuclear retention in expanded repeat disease 
pathogenesis. 
 
In order to further investigate the sequence-dependent interaction of Nup62 
and CAG and CUG repeat RNA, an overexpression Nup62 construct was generated.  
GMR-GAL4 driven overexpression of Nup62 alone did not result in any disruption to 
the Drosophila eye. Interestingly, overexpression of Drosophila Nup62 in flies co-
expressing CUG, CAG or CAA repeats resulted in a reduction in the severity of the 
eye phenotype in all cases (Figure 4.8 D-F). This result is not consistent with the 
sequence-dependent effect seen when levels of Nup62 were reduced. To confirm 
that the absence of a phenotypic modification in flies co-expressing polyglutamine 
encoded by a CAA repeat with the nup62 RNAi construct was not a result of an 
insertional effect in a single transgenic line, an independent CAA repeat line was 
subsequently tested. Expression of the CAA-encoded polyglutamine tract in this line 
with GMR-GAL4 gives a strong loss of pigment eye phenotype and no change in the 
appearance of the eye was seen when a nup62 RNAi construct was co-expressed 
(data not shown). Similarly, a second candidate gene line with an independent 
insertion of the nup62 RNAi construct was tested and also slightly enhanced the 
CAG and CUG repeat phenotypes but not the CAA repeat phenotype. This suggests 
that the absence of an interaction with CAA-encoded polyglutamine when Nup62 
levels are reduced is not due to an insertional effect of a single transgenic line, but a 
more general property of this repeat tract. The interaction with CAG and CUG 
repeats is therefore likely to be occurring at the RNA level and is dependent upon 
the ability of the expanded repeat RNA to form a hairpin secondary structure, a 
property which CAA repeat RNA lacks. 
 
The localisation of Nup62 to protein aggregates in polyglutamine diseases 
(190) suggests that there may be a direct physical interaction between polyglutamine   74 
tracts and nuclear pore components. Since increasing levels of Nup62 in Drosophila 
expressing polyglutamine tracts reduces toxicity in the eye, it appears that the 
localisation of Nup62 to polyglutamine aggregates may play a role in pathogenesis. 
This does not rule out a separate role for Nup62 in RNA-mediated toxicity; a role 
which is strongly supported by the fact that the alteration in Nup62 levels was 
originally observed in Drosophila expressing untranslated expanded repeat tracts. In 
order to further investigate the interaction between expanded repeat RNA and Nup62, 
the effect of reducing Nup62 levels in flies expressing expanded untranslated rCAG, 
rCUG and rCAA repeats was also tested. Co-expression of the nup62 RNAi construct 
with four transgene insertions of the rCAG, rCUG and rCAA constructs did not result in 
a disruption to the exterior appearance of the eye (data not shown) and therefore the 
effects of altering Nup62 levels on the polyglutamine component of pathogenesis and 
RNA-mediated toxicity were not able to be further separated using this approach.  
 
 
Figure 4.8: Overexpression of 
Nup62 in the Drosophila eye 
suppresses both polyglutamine 
and polyleucine eye 
phenotypes. Both Nup62 
overexpression and repeat 
construct expression are driven by 
GMR-GAL4. B) Expression of 
polyglutamine encoded by either 
CAG or CAA results in a loss of 
pigment eye phenotype. C) 
Expression of polyleucine results 
in a very mild rough eye 
phenotype. D-E) Ectopic 
expression of Nup62 in the eye 
resulted in a considerable 
suppression of both the CAG and 
CAA-encoded polyglutamine eye 
phenotypes. In both cases, there 
is a reduction of the area and 
severity of loss of pigment. F) 
Ectopic expression of Nup62 with polyleucine completely suppressed the rough eye 
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4.5 Summary of proteomic changes elicited by expression of CAG and CUG 
repeats in neurons of Drosophila 
 
A small number of changes in protein abundance were observed which were 
common to flies expressing rCAG and rCUG repeat RNA compared to rCAA repeat 
expressing flies and the elav>+ control. This may be a result of the limited number of 
proteins properly resolved and of sufficient abundance to be detected on the 2D mini 
gels used for this experiment. There were also a number of protein spots which 
showed unique changes in abundance in either rCAG or rCUG repeat expressing 
flies which may represent sequence-dependent components of RNA pathogenesis, 
however these proteins were not further investigated in this study.  
 
MS/MS analysis of the 2 spots which showed a common change in 
abundance in rCAG and rCUG repeat expressing flies identified 2 candidate proteins 
in each case. Further genetic analysis of one candidate protein, Nup62, showed that 
a reduction in expression was able to modify phenotypes resulting from expression 
of translated CAG and CUG repeats but not CAA repeats in Drosophila. This 
suggests that this interaction may be occurring at the RNA level, since both CAA 
and CAG repeats code for polyglutamine at the protein level but only the CAG 
repeat RNA is able to form a hairpin secondary structure. The identification of 
Nup62, a central component of the nuclear pore, as a modifier of expanded repeat 
pathogenesis in Drosophila suggests that nuclear transport may play a central role in 
pathogenesis. Since Nup62 is known to play a role in mRNA export from the 
nucleus, reducing levels of Nup62 could modify the toxicity of expanded repeat RNA 
by altering its localisation and therefore the proteins with which it interacts.  
 
The observation that overexpression of Nup62 is able to suppress both CAG 
and CAA-encoded polyglutamine phenotypes may indicate that the nuclear pore 
also assists in clearance of polyglutamine aggregates from the nucleus. This does 
not appear to be a rate-limiting step in pathogenesis, since the CAA-encoded 
polyglutamine phenotype was not altered when Nup62 levels were reduced. These 
results point to a central role for nuclear transport pathways in pathogenesis of the 
expanded repeat diseases which, in the case of the polyglutamine diseases, may 
involve components of both polyglutamine and RNA-mediated toxicity. However it is 
also possible that the effects observed in this assay are specific to the eye, which   76 
consists of a mixture of both neuronal and non-neuronal cells, and therefore a role 
for nuclear transport in pathogenesis should also be validated in a neuronal assay. 
Since very few protein spots were detected which showed a change in abundance in 
both rCAG and rCUG repeat expressing flies, identification of proteins which are 
altered in either rCAG or rCUG will also be a focus of further experiments.    77 
Chapter 5: Identifying pathogenic pathways of expanded repeat disease by 
microarray analysis 
 
A number of studies have attempted to establish common and unique 
pathways of expanded repeat pathogenesis through microarray analysis of various 
disease models (203-208). In most cases, these studies have aimed to identify 
disease-specific transcriptional changes through the use of repeat tracts in the 
context of the different expanded repeat disease genes. There is evidence that in 
both the polyglutamine diseases (109-110) and untranslated repeat diseases (117), 
the repeat-encoded peptides or expanded repeat RNAs respectively are intrinsically 
toxic, suggesting that there are likely to also be context-independent pathways of 
pathogenesis in the expanded repeat diseases.  
 
Our model differs from those previously studied by microarray analysis in that 
the repeat tracts are encoded within a short peptide and are not in the context of the 
transcripts in which they are normally found. This study tests the outcomes of 
expression of hairpin-forming repeat sequences (rCAG and rCUG), with the aim of 
identifying components of expanded repeat pathogenesis which are the result of 
RNA toxicity of the repeat sequences themselves. This approach also allows direct 
comparison of the cellular outcomes resulting from expression of different repeat 
sequences, which will provide information on both sequence-dependent and 
sequence-independent features of expanded repeat disease pathogenesis. Another 
difference between this model and many that have been previously analysed is the 
lack of severe degeneration apparent in this model. This analysis should therefore 
allow the identification of transcriptional changes which are hallmarks of early cellular 
dysfunction in disease, rather than the result of induction of apoptotic pathways, and 
therefore should represent causative components of pathogenesis rather than the 
downstream effects (as depicted in Figure 4.2). 
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5.1 Identification of transcriptional changes in neuronal cells expressing 
expanded repeat tracts: microarray experiment 1 
 
Microarray experiments were performed using Affymetrix Drosophila 2.0 
arrays on RNA extracted from the heads of newly eclosed male Drosophila 
expressing the rCAG, rCUG and rCAA constructs. Crosses to generate these flies 
were performed as depicted in Figure 4.1. In microarray experiment 1, repeat 
constructs were under the control of the same elav–GAL4 driver used in proteomic 
analysis (elav
c155–GAL4) which consists of a P-element insertion within the promoter 
of the endogenous elav gene, such that GAL4 is expressed in the same pattern as 
the endogenous ELAV protein (209). To increase repeat RNA expression levels, 
recombinant chromosomes were generated each carrying two UAS-repeat transgene 
insertions. Three fully independent transgenic lines were tested for each of the repeat 
sequences (rCAG, rCUG and rCAA) to overcome the possibility of insertional effects 
in individual lines impacting on the results. Details of lines analysed in this 
experiment are shown in Appendix B, Table B1. All microarray experiments were 
kindly performed by Gareth Price and in collaboration with Deon Venter (Pathology, 
Mater Health Services, South Brisbane QLD).  
 
Comparisons of microarray data were performed as represented in Figure 5.1. 
In each comparison, genotypes were filtered for transcripts which returned a 
“present” call as determined by the Affymetrix Expression Console™ Software. To 
return a present call, the hybridised spot must show significantly higher signal than 
the background measured across the entire chip (P-value <0.001). While these 
criteria are likely to result in the exclusion of some genes which are very lowly 
expressed, including genes in analysis which do not return a present call can result in 
a false representation of the degree of change between samples when fold change is 
calculated, since the signal is likely to be more variable at the lower end of the 
detectable scale. Excluding genes which do not give a signal above the Affymetrix 
detection threshold should decrease the false-positive detection rate and produce a 
more robust data set for further analysis. Nevertheless, it is likely that performing the 
analysis in this way will exclude genes which are completely “off” in either genotype 
being compared. This set of genes may warrant further investigation in a secondary 
analysis of the data. 
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Two-tailed Student’s t-tests were then performed for each comparison 
represented in Figure 5.1 and lists compiled of genes which showed significantly 
altered (P<0.05) expression in rCAG or rCUG repeat expressing flies compared to 
either elav>+ (the elav–GAL4 driver out-crossed to the w
1118 wild-type line) or 
elav>rCAA flies. Expression ratios of these genes were then calculated based on the 
average Affymetrix chip signal which was determined from all 3 lines (or 2 biological 
replicates in the case of elav>+) analysed for each genotype. This list was then 
further filtered for genes which gave a value for log2 of the expression ratio – defined 
as “log2(ratio)” – >0.5 or <-0.5; that is genes with a fold change greater than 
approximately ±1.4. The resulting number of genes for each comparison is 
represented in Figure 5.3 A.  
 
Figure 5.1: Overview of microarray experiments. Fly 
lines used for each genotype are listed in Appendix B, 
Table B1. Comparisons were performed between 
elav>rCAG and elav>rCUG flies and each of elav>rCAA 
and elav>+ as shown. In all cases, only probe-sets which 
were called “present” in both genotypes under 
comparison were included in further analysis. For each 
comparison, Log2 of the ratio for each probe-set - 
log2(ratio) - was calculated from the average chip signal 
of all lines tested for each genotype. Final lists of genes 
with a Student’s t-test value of P<0.05 and log2(ratio)>0.5 
or <-0.5 were then generated for each comparison.  
 
 
As described for the proteomic analyses (Chapter 4), transcriptional profiles of 
rCAG and rCUG repeat-expressing flies were compared to both elav>+ and 
elav>rCAA flies in order to account for both toxicity resulting from accumulation of 
GAL4 protein in the nervous system and any effects that expression of the rCAA 
RNA may have. The complete gene lists for each of these analyses can be found in 
Appendix B (Table B3-B6). Gene ontology analysis was then performed on each of 
these gene lists to identify cellular pathways which may be disrupted by the 
expression of rCAG or rCUG hairpin repeats (Figure 5.4 A-D).  
 
 
5.2 Validation of cellular changes by independent microarray experiment: 
Microarray experiment 2 
A second microarray experiment was performed to provide an independent 
validation of transcriptional changes in flies expressing expanded repeat RNAs. 
elav> rCAG  elav> rCUG 
elav> +  elav> rCAA   80 
Analysis was performed as described for microarray experiment 1, except that in this 
case flies were expressing four transgene insertions of rCAG, rCUG or rCAA under 
the control of a different elav-GAL4 driver. This elav-GAL4 line consists of a P-
element insertion on the second chromosome encoding GAL4 under the control of 
the promoter region of the Drosophila elav gene (210), and therefore these flies have 
a normal endogenous copy of elav on the X chromosome (represented in Figure 5.2). 
Two completely independent four transgene insertion lines were available for each 
repeat (listed in Appendix B, Table B2). Comparisons were made using both this 
elav-GAL4 driver out-crossed to the wild-type w
1118 line as a control (elav>+) and 
elav-GAL4 driving an untranslated CAA repeat (elav>rCAA), as described in 5.1. The 
number of genes significantly altered in each comparison (log2(ratio)>0.5 or <-0.5, 
P<0.05) is shown in Figure 5.3 B. Complete lists of genes for each comparison can 
be found in Appendix B (Table B7-B10). Gene ontology analysis was again 
performed on each of these gene lists (Figure 5.4 E-H). 
 
Figure 5.2: comparison of 
the two elav-GAL4 driver 
lines used in this study. 
Pictures represent the 
chromosomes of a male 
Drosophila. A) The elav-GAL4 
line contains an insertion 
within the endogenous elav 
gene such that GAL4 is 
expressed in cells where elav 
would normally be expressed. 
B) The elavII-GAL4 line has 
an insertion on chromosome 
II which contains the elav promoter controlling expression of GAL4. In this case, the flies 
have a normal copy of the elav gene.  
 
 
5.3 Comparison of microarray experiment 1 and 2 
A similar number of genes are altered in each comparison in microarray 
experiment 2 as in microarray experiment 1 (Figure 5.3 A compared to B), however 
there is no overlap in genes changed when flies expressing the rCUG repeat are 
compared to both elav>rCAA and elav>+ control flies, as compared to 26 changing 
genes for the same comparison in the first microarray experiment. The corresponding 
comparison for elav>rCAG results in detection of 8 transcripts in both microarray 
EXPERIMENT 1  EXPERIMENT 2 
GAL4 
GAL4   81 
experiment 1 and 2, however none of these transcripts are common to both 
experiments (Table 5.1 and 5.5 respectively).  Furthermore, only 9 genes are 
changed in both elav>rCAG and elav>rCUG flies compared to elav>rCAA in 
microarray experiment 2 while 38 changing genes were detected for the same 
comparison in microarray experiment 1. Genes common to microarray experiment 1 
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Figure 5.3: Overview of total 
number of genes significantly 
altered in each microarray 
experiment and genes which 
were significantly altered in 
both experiments. In each 
case, numbers are the number 
of transcripts detected meeting 
the criteria log2(ratio)> 0.5 or  
<-0.5, P<0.05. A) Overview of 
microarray experiment 1 as 
described in 5.1. B) Overview of 
microarray experiment 2 as 
described in 5.2. C) Summary 
of genes significantly altered in 
both experiment 1 and 2 (Listed 
in Table 5.1-5.4) Asterices 
indicate genes which have been 
previously implicated in 
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There are several possible explanations for the differences seen between the 
two experiments. Firstly, it is likely that there are some transcripts being detected as 
significantly altered in one experiment which fall below the set detection threshold for 
the other experiment and are therefore not included in analysis. It should also be 
noted that the driver line used to express the repeats could have an impact on the 
changes seen, since we have some evidence to suggest that the two elav-GAL4 
drivers used in this study have slightly different expression patterns (K. Lawlor, 
unpublished data). Since we are increasing the amount of repeat RNA expression in 
experiment 2 by driving expression of four insertions of the repeat constructs 
compared to two insertions in experiment 1, it is also possible that these differences 
demonstrate real dose-dependent effects of repeat RNA expression. The purpose of 
these analyses was not to produce a comprehensive list of all changes resulting from 
expanded repeat expression, but to gain insight into the “categories” of changed 
transcripts and therefore pathways which may be important in expanded repeat 
disease pathology.  
 
 
5.4 Gene ontology analysis of genes altered in rCAG and rCUG repeat-
expressing flies compared to elav>rCAA flies 
 
Lists were compiled of genes with altered expression in flies expressing either 
rCAG or rCUG repeats compared to rCAA repeats in both experiment 1 and 2 as 
described in 5.1 (Full gene lists can be found in Appendix B, Table B3-B4 & B7-B8), 
with the aim of identifying key cellular processes which are specifically perturbed by 
the expression of hairpin-forming repeat RNA. Genes were then grouped into 
categories based upon their known or predicted function. Each comparison resulted 
in lists in which more than 30% of the detected genes have unknown function and 
therefore do not provide additional information on cellular pathology. There are also a 
considerable number of genes which were placed in the “other” category, indicating 
that they do not fit into one of the gene ontology pathways listed. Together, the 
“unknown” and “other” categories make up nearly 50% of the listed genes when 
elav>rCAG flies are compared to elav
 >rCAA flies and more than 50% of the listed 
genes for the other comparisons (Figure 5.4 A,B,E&F). 
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Virtually all gene ontologies listed overlap between comparisons performed on 
elav>rCUG flies in both experiments and elav>rCAG flies in experiment 1, suggesting 
that there are repeat sequence-independent effects of hairpin RNA expression. 
Analysis of the transcriptional profile of elav>rCAG flies in experiment 2 resulted in 
detection of less than half the number of genes altered as was seen for the 
elav>rCUG genotype in either experiment or elav>rCAG in experiment 1. This 
suggests that there was a large amount of variation in the transcriptional profiles 
resulting from pan-neuronal expression of the independent four transgene insertion 
rCAG lines analysed in experiment 2, which may indicate location-dependent effects 
of the transgene insertion sites. Nevertheless, expression of rCAG RNA did 
consistently result in altered expression of genes involved in “lipid 
synthesis/metabolism”, “cytoskeleton/ vesicle trafficking” and “RNA binding/ 
metabolism” which may indicate that these are components of CAG repeat RNA 
pathogenesis. 
 
There are a large number of gene ontologies represented in each experiment 
when transcript levels in elav>rCUG flies are compared to elav>rCAA, each 
constituting only a small percentage of the total genes. The largest group of genes 
changed in each experiment belongs to the “redox regulation” category and of the 
nine genes common between the two experiments, most are also involved in stress 
response (Table 5.2) further suggesting that some of the primary cellular changes in 
these cells may involve a response to cellular stresses caused by the presence of the 
rCUG RNA. “Transcriptional regulation” is also highly represented in both experiment 
1 and 2 when elav>rCUG flies are compared to elav>rCAA, but only in experiment 1 
when elav>rCAG flies are compared to elav>rCAA (Figure 5.4 A, B & F). 
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EXPERIMENT 1 
elav>rCAG v elav>rCAA  elav>rCUG v elav>rCAA 
elav>rCAG v elav>+  elav>rCUG v elav>+   85 
Figure 5.4: Gene ontology analysis of genes which were significantly altered in 
Drosophila expressing rCAG or rCUG RNA pan-neuronally. Genes were selected 
for Log2(ratio) >0.5 or <-0.5, P<0.05. The number of genes placed in each category 
and the percentage of the total number of genes which they represent are indicated. 
Categories are as listed in figure legend. Genes in the “unknown” category have no 
known function. Gene ontology was determined either from known phenotypic data or 
homology with other genes of known function. Genes in the “other” category have a 
known or suspected function that does not fit into one of the listed categories. 
EXPERIMENT 2 
elav>rCAG v elav>rCAA  elav>rCUG v elav>rCAA 
elav>rCAG v elav>+  elav>rCUG v elav>+   86 
5.5 Gene ontology analysis of genes altered in rCAG and rCUG repeat-
expressing flies compared to elav>+ flies 
  
Analysis of changes detected in flies expressing rCAG and rCUG repeats 
compared to elav>+ flies was also performed for both experiment 1 and 2 (full lists 
can be found in Appendix B, Table B5-B6 & B9-B10). This comparison should also 
identify changes specifically caused by expression of hairpin-forming CAG and 
CUG repeat RNA, however it is possible that some changes that are detected may 
also be the result of accumulation of GAL4 protein. In experiment 1, a similar 
pattern of categories of altered genes was detected when the transcriptional 
profiles of elav>rCAG and elav>rCUG flies were compared to elav>rCAA flies as 
was seen in the comparison to elav>+, with over 50% of genes falling into the 
“unknown” or “other” categories (Figure 5.4 C & D). Of the remaining genes, 
“transcriptional regulation” was again highly represented, with 8.3% of the total 
genes altered in elav>rCAG flies and 12.5% of those altered in elav>rCUG flies 
falling into this category (Figure 5.4). Again, there was nearly complete overlap 
between categories of genes altered in rCAG and rCUG repeat-expressing flies 
compared to elav>+, supporting the idea that there may be a component of repeat 
sequence-independent pathogenesis in this model. 
 
A number of studies have identified transcriptional dysregulation as a feature 
of the polyglutamine diseases including HD (203, 205), SCA7 (206), DRPLA (203) 
and SCA3 [8, 9]. Other categories of genes identified in this study, including 
“mitochondrial processes” (211-212), “RNA processing/metabolism” (73, 213), 
“cytoskeleton/vesicle trafficking” (11, 13, 205, 214-217), “lipid metabolism” (205) and 
“neuronal transmission” (206-207, 218-219), have also been previously implicated in 
pathogenesis in polyglutamine models. It therefore seems likely that there is a 
significant degree of sequence-independent pathogenesis occurring in the expanded 
repeat diseases, since both rCUG and rCAG repeat RNAs are able to induce 
alterations to these pathways. This result also suggests that the expanded repeat-
containing RNA itself may be involved in inducing at least some of the early changes 
observed in the polyglutamine diseases. The reported ability of the untranslated CUG 
repeat RNA in DM1 to induce transcriptional dysregulation (220) further supports the 
ability of repeat-containing RNA alone to induce significant perturbations to cellular 
homeostasis.    87 
Analysis of categories of genes altered in elav>rCAG flies compared to 
elav>+ in experiment 2 provided limited information as nearly 2/3 of the listed genes 
fall into the “unknown” or “other” categories (Figure 5.4). Of the remainder, “lipid 
synthesis/ metabolism” and “protein modification/metabolism” are most highly 
represented, however each of these groups only contains four genes (6.2% of the 
total number) and therefore this is fairly inconclusive. The corresponding 
comparison of elav>rCUG flies to elav>+ (Figure 5.3 H) gives a similar set of gene 
categories to the comparison to elav>rCAA (Figure 5.3 F), although there is no 
overlap in the specific genes detected. The lack of gene overlap between the two 
comparisons may not necessarily indicate that different cellular processes are 
disrupted, but merely that the particular genes which exceed the threshold for 
detection are different. Alterations to “signalling” (10.7%), “redox regulation” (8.3%) 
and “RNA binding/metabolism” (7.1%) are most highly represented, again 
suggesting that expression of CUG repeat RNA is able to induce stress responses 
in neuronal cells. There is also a large degree of overlap in the categories of gene 
changes detected in microarray experiment 1 and microarray experiment 2 
confirming that these are likely to be real effects of expressing CUG repeat RNA in 
the neurons of Drosophila. 
While the comparison of categories of genes altered in rCAG and rCUG 
repeat expressing flies identified a number of processes which have been 
previously implicated in expanded repeat pathogenesis, this type of analysis proved 
to be of limited use in ascertaining the primary changes occurring as a result of 
repeat expression in our Drosophila model. There was no clear bias towards 
perturbation of a particular category of genes, but rather an indication of broad 
cellular dysfunction in flies expressing either of these repeat RNAs. Analysis of 
particular genes which were commonly altered in different comparisons was 
therefore performed in order to identify key transcriptional changes elicited by 
hairpin RNA expression in Drosophila.  
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5.6 Analysis of genes significantly altered in both microarray experiment 1 and 2 
 
 In order to identify transcriptional changes which represent key effects elicited by 
rCAG and rCUG repeat expression, genes which were consistently altered in both 
experiment 1 and 2 were more closely investigated. These genes are likely to represent 
specific effects of repeat RNA expression, since they are altered regardless of which 
elav-GAL4 driver and specific transgenic lines are used to express expanded repeat 
RNA. These genes are listed in Tables 5.1-5.4. Only one gene was found to be 
commonly altered when the transcriptional profile of rCAG expressing flies was 
compared to rCAA expressing flies. This gene, CG31781, is a predicted lipase with no 
other associated functional information (Table 5.1). A similar comparison performed for 
rCUG expressing flies compared to rCAA expressing flies identified 9 commonly altered 
genes (Table 5.2). Little functional information is available for these genes, however a 
number of them are involved in stress response mechanisms which is consistent with 





Table 5.1: Common changes for elav>rCAG 
compared to elav>rCAA in experiment 1 and 2.  
 




Gene Title  Gene 
Symbol 
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Table 5.2: Common changes for elav>rCUG 
compared to elav>rCAA in experiment 1 and 2.  
 
Log2(ratio) >0.5 or <-0.5, P<0.05. 
Gene Title  Gene 
Symbol 











  immune response 




  eye pigment 
precursor transport 
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  oxidative stress 
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  hydrogen ion 
transmembrane 
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There are only two genes commonly altered in rCAG repeat expressing flies 
compared to elav>+ between the two experiments (listed in Table 5.3) and three 
genes for rCUG repeat flies (listed in Table 5.4). Of the two genes altered in 
elav>rCAG flies compared to elav>+ in both microarray experiments, one gene, 
mod(mdg4), was previously identified as a modifier in a P-element screen of a SCA8 
Drosophila model where the human SCA8 non-coding RNA was expressed in the 
Drosophila eye (98). Similarly, of the three genes altered in elav>rCUG flies 
compared to elav>+ in both microarray experiments, two genes have been 
previously implicated in expanded repeat pathogenesis. The first, Hu li tai shao (hts), 
is an orthologue of mammalian Adducin 1 (ADD1) (221), a protein which has been 
identified as an HTT interactor by yeast-two-hybrid analysis (121). In Drosophila, Hts 
has been demonstrated to play a role in oogenesis and embryogenesis (221-222) 
however, following identification of ADD1 as an HTT interactor, mutations in hts 
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context of exon1 of the human HTT gene (121). Muscleblind (mbl), the Drosophila 
orthologue of the human MBNL splicing factor, was also identified as commonly 
altered in elav>rCUG flies compared to elav>+. MBNL has been demonstrated to 
play a key role in the pathogenesis of DM1 & 2, where it is thought to be 
sequestered by the presence of CUG or CCUG RNA repeats and therefore cannot 





Table 5.3: Common changes for elav>rCAG 
compared to elav>+ in experiment 1 and 2.  
 
Log2(ratio) >0.5 or <-0.5, P<0.05. 
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Table 5.4: Common changes for elav>rCUG 
compared to elav>+ in experiment 1 and 2.  
 
Log2(ratio) >0.5 or <-0.5, P<0.05. 
Gene Title  Gene 
Symbol 
Ensembl Experiment  1: 
log2(ratio) 














ADD1 Actin  assembly,  ring 
canal formation 




MBNL1 Splicing  factor,  muscle 
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While there are a small number of common changes induced by expression of 
both rCAG and rCUG repeats in the two experiments, in a number of cases there is 
a lack of concordance in the direction of the change (Table 5.3 and 5.4). Since in 
many cases there is more than one transcript detected by a probe-set and, in some 
cases, more than one probe-set for a single gene present on the Affymetrix array, it 
is possible that this represents a difference in the particular splice-forms of the gene 
being detected. It is also possible that there is some threshold effect on these 
pathways, whereby different effects are elicited through the same pathway 
depending on the amount of stress the cell is experiencing. In this study, alterations 
were used as an indication that the particular pathway represented was perturbed by 
repeat expression, irrespective of the direction of the change.  
 
 
5.7 Analysis of genes significantly altered in each microarray experiment 
 
The identification of altered expression of a number of genes previously 
implicated in expanded repeat pathogenesis in rCAG and rCUG repeat expressing 
flies when compared to elav>+ but not elav>rCAA flies may indicate that at least 
some of the detected changes are not specific outcomes of hairpin RNA expression. 
These changes may be due to altered gene expression in elav>+ flies resulting from 
toxicity associated with neuronal expression of GAL4. It is predicted that a 
decreased amount of free GAL4 protein should be present in flies expressing the 
rCAG, rCUG or rCAA repeat constructs due to the presence of an equivalent 
number of UAS sites in each of these genotypes and, therefore, the impact of GAL4 
toxicity should be reduced in these flies. It is also possible that expression of rCAA 
RNA itself may result in a unique alteration to the transcriptional profile of 
Drosophila. Since the elav-GAL4 driver line used to express each of the repeat 
constructs was different between the two microarray experiments, any specific 
effects elicited by rCAA RNA expression may result in differences in the 
transcriptional changes observed in each experiment. For this reason, it was also 
necessary to investigate transcriptional profiles for each of the microarray 
experiments separately.  
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5.7.1 Genes changed in rCAG repeat-expressing flies compared to both 
elav>rCAA and elav>+ 
  
We predict that changes detected in rCAG or rCUG repeat-expressing flies 
compared to both the elav>rCAA and elav>+ control lines will be most likely to represent 
hairpin RNA-dependent pathogenic pathways and not just the result of cellular stress, 
since this comparison takes into account both the documented toxicity of the GAL4 
protein (137) and any possible affect of expressing CAA repeat RNA in cells. 
Investigation of transcriptional changes elicited by neuronal expression of rCAG and 
rCUG repeats should also identify both sequence-independent components of hairpin 
RNA toxicity – that is changes which are seen in both rCAG and rCUG repeat 
expressing flies – and unique sequence-dependent effects of expression of each of 
these repeats.  
 
In experiment 1, eight genes showed a significant change in expression when 
elav>rCAG flies are compared to elav>rCAA and elav>+ (listed in Table 5.5). Of 
these, five have some function ascribed to them: glycogenin is an important 
metabolic enzyme which plays a role in the synthesis of glycogen and mesoderm 
development, muscleblind (Mbl) is the Drosophila orthologue of the human MBNL 
splicing factor, which has been implicated in the pathogenesis of DM1 and DM2 (72, 
81), Pk is involved in determination of cell polarity (223), Zip3 is a zinc transporter 
which may play roles in immune response (224) and Lea is an axon guidance 
receptor which regulates processes in neurogenesis (225). In experiment 2, eight 
genes showed altered expression in rCAG repeat expressing flies compared to both 
the elav>rCAA and elav>+ control lines (Table 5.6). These genes play roles in lipid 
metabolism, myogenesis and neuronal signalling in Drosophila, however there is 
little information available regarding their specific function or the function of their 
mammalian orthologues. While there is no specific overlap in genes altered as a 
result of rCAG repeat expression between the two experiments, there appears to be 
a consistent disruption of processes such as neurogenesis and muscle development 
and therefore these processes are likely to be important components of CAG repeat-









Table 5.5: Genes of particular interest for elav>rCAG identified in microarray experiment 1. 
Genes are significantly altered in elav>rCAG flies compared to both elav
 >rCAA and elav >+. 
Log2(ratio) >0.5 or <-0.5, P<0.05. 
Gene Title  Gene 








orthologue  Function 























MBNL1 RNA  binding 














SLC39A2 zinc  transporter 











ROBO1  axon guidance receptor 
 
Table 5.6: Genes of particular interest for elav>rCAG identified in microarray experiment 2. 
Genes are significantly altered in elav>rCAG flies compared to both elav
 >rCAA and elav>+. 
Log2(ratio)>0.5 or <-0.5, P<0.05. 
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synaptic vesicle amine 
transport 
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5.7.2 Genes changed in rCUG repeat-expressing flies compared to elav>rCAA 
and elav>+ 
  
In experiment 1, 26 genes showed altered expression in elav>rCUG flies 
compared to both elav>rCAA and elav>+ (listed in Table 5.7) and of these, 20 have 
some functional information attributed to them. Amongst these 20 genes, there are a 
number involved in transcriptional regulation and RNA metabolism which are 
downregulated – sv, dve, lola, msl-2, CG8273, MED24, xl6 - while upregulation of 
several metabolic genes is also observed. In contrast, there were no common 
changes detected in elav>rCUG flies compared to elav>rCAA and elav>+ in 
experiment 2, despite a large amount of overlap in categories of detected genes 
between the two experiments (Figure 5.3 F & H).  
 
 
Table 5.7: Genes of particular interest for elav>rCUG 
identified in microarray experiment 1. Genes are 
significantly altered in elav>rCUG flies compared to both 
elav
 >rCAA and elav>+. Log2(ratio)>0.5 or <-0.5, P<0.05. 
 
Log2(ratio) >0.5 or <-0.5, P<0.05. 
Gene Title  Gene 








orthologue  Function 
















  Transcription factor 
activity 
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ZBTB3  Transcription factor 
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cell wall 







































SOCS1  suppressor of cytokine 
signalling 
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Gene Title  Gene 








orthologue  Function 





VPS18 vacuolar  protein  sorting 





C3orf31  Mitochondrial import 
protein 





SON  Double stranded RNA 
binding, DNA binding 













component of mediator 
complex, transcriptional 
co-activator 





SFRS7  splicing factor, 
arginine/serine rich 







kinase, production of UMP 
and CMP 
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inactivates metabolites of 
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5.7.3 Genes changed in both rCAG and rCUG repeat-expressing flies 
compared to elav>rCAA  
 
  Since the hairpin structures predicted for rCAG and rCUG RNAs are 
structurally nearly identical and a number of clinical features of the different 
expanded repeat diseases overlap, we predict that there are likely to be common 
effects of expressing these RNAs in the neurons of Drosophila. Lists were therefore 
also compiled of genes which changed in flies expressing both rCAG and rCUG 
repeats compared to each of the controls. There were no genes altered in both 
rCAG and rCUG repeat-expressing flies compared to both controls.  
 
Of the 38 genes shown in Table 5.8 which are changed in both elav>rCAG 
and elav>rCUG flies compared to elav>rCAA, 23 have some functional information. 
One gene altered in this list is CG5669, an orthologue of the human SP1 
transcription factor which has been implicated in transcriptional regulation in HD 
(226-227). While another gene, CG1343, is more closely related at the sequence 
level to mammalian SP1, regulatory roles for each of the SP1 orthologues in 
Drosophila have not been extensively studied. The mammalian SP1/SP3 family of 
transcription factors have been implicated in regulation of a broad range of 
processes including the mTOR signalling pathway (228), mitochondrial biogenesis 
(229-230), glucose signalling pathways (231), mitosis (232) and glutamate signalling 
(233-235).  Interestingly, Table 5.8 includes changes to genes involved in mTOR 
signalling – CG30044 – and mitochondrial biogenesis – sun, ttm50, CG4306 –  as 
well as the Drosophila orthologue of the wolfram syndrome 1 gene, wfs1, which is 
regulated by SP1 in mammals (236), raising the possibility that dysregulation of 
similar pathways is occurring in flies expressing rCAG and rCUG repeats.   97 
Table 5.8: Common transcriptional changes in 
elav>rCAG and elav>rCUG compared to 
elav>rCAA in experiment 1.  
 
Log2(ratio) >0.5 or <-0.5, P<0.05. 
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In experiment 2, only 8 genes were changed in both elav>rCAG and 
elav>rCUG flies compared to elav>rCAA (Table 5.9) and there is no overlap with the 
list of genes altered in experiment 1 (Table 5.8). Interesting candidates on this list 
include ctp (ddlc1) and insc, which are involved in microtubule-based movement of 
proteins and RNA in the cell. Ctp is the Drosophila orthologue of mammalian dynein 
light chain-like 2 (DYNLL2), a component of the dynein complex which has been 
implicated in processes including axonal transport of mitochondria (237), retrograde 
transport (238) and stress granule formation (239). In Drosophila, Ctp has been shown 
to be involved in dendritic branching and endosome movement (240), axon path-
finding (241) and toxic protein clearance through autophagy and cell death, with 
mutants showing decreased motor activity (242), gross morphological defects and 
apoptosis (243). Ctp has also been previously identified as downregulated in a 
microarray study investigating polyglutamine-specific transcriptional changes common 
to Drosophila and human cell lines (244).  
 
 
Table 5.9: Common transcriptional changes in 
elav>rCAG and elav>rCUG flies compared to 
elav>rCAA in experiment 2.  
 
Log2(ratio) >0.5 or <-0.5, P<0.05. 
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Expression of mutant HTT in Drosophila has been shown to cause visible 
axonal blockages in motor neuron axons, with aggregation of vesicles containing the 
mutant protein observed (13). Similarly, mutant androgen receptor has been 
demonstrated to form aggregates which disrupt transport and cause axonal swelling 
in immortalized motor neuron cells (245). However in a Drosophila model, 
expression of either polyglutamine alone or in the context of the SCA3 gene was not 
able to disrupt axonal traffic in the same manner (119). These observations may 
suggest that transport defects are a context-specific effect related to the function of 
the polyglutamine-containing protein and not a more general property of 
polyglutamine expression. A broader role for both dynein and kinesin motor 
complexes (239) and the microtubule network (246) has also been described in the 
formation and dynamics of stress granule and p-body formation; a role which is 
conserved in Drosophila (247). Both stress granules and p-bodies are involved in 
regulation of translation, editing, splicing, degradation and transport of RNAs in the 
cell and are highly populated by RNA binding proteins. It is therefore possible that 
dynein transport defects can be elicited through either toxic RNA-dependent or toxic 
protein-dependent pathways resulting in some overlapping consequences and that, 
in the polyglutamine diseases, both of these mechanisms may be in action, making 
cells particularly vulnerable. 
 
 
5.7.4 Genes changed in both rCAG and rCUG repeat-expressing flies 
compared to elav>+  
 
Analysis of genes changed in both elav>rCAG and elav>rCUG compared to 
elav>+ was also performed for both experiment 1 and 2. Only 9 genes were altered 
in both elav>rCAG and elav>rCUG compared to elav>+ in experiment 1 (Table 5.10) 
and of these only 4 have a previously characterised function. All 4 of these genes 
have been previously implicated in expanded repeat diseases and 3 were also 
altered for either, but not both, rCAG or rCUG in experiment 2 (Table 5.4 & 5.5). As 
previously described, mutations in hts have been shown to modify a model of 
polyglutamine pathogenesis with 128Q in the context of exon1 of the human HTT 
gene (121), the human orthologue of Mbl, MBNL, has been characterised for a role 
in DM1 & 2 where it is thought to be sequestered by the presence of CUG or CCUG 
RNA repeats and therefore cannot perform its normal splicing functions (72, 76, 220)   101 
and mod(mdg4) has been previously identified as a modifier in a P-element screen 
of a SCA8 Drosophila model where the human SCA8 non-coding RNA was 
expressed in the Drosophila eye (98). The final gene, metabotropic glutamate 
receptor A (mGluRA), is the sole metabotropic glutamate receptor in Drosophila, 
which has been shown to have a mutual negative feedback relationship with 
dFMRP, the Drosophila orthologue of the Fragile X mental retardation protein (248). 
This antagonistic relationship is thought to regulate levels of ionotropic glutamate 
receptors and therefore either dampen synaptic excitability if mGluRA dominates, or 
sharpen it if FMRP dominates (249). 
 
Analysis of genes altered in elav>rCAG and elav>rCUG flies compared to 
elav>+ in experiment 2 (Table 5.11) showed no overlap with the same comparison 
for experiment 1 (Table 5.10). Of the 9 genes identified 5 have functional information 
associated with them, although none of them have been formerly linked to expanded 
repeat disease pathogenesis. Amongst these is hr38, which encodes a Drosophila 
orthologue of Nerve growth factor I-B (NGFI-B) – also known as Nuclear receptor 77 
(NUR77) – which is a nuclear receptor known to play a role in dendritic 
differentiation and synapse formation (250). In humans, it is highly expressed in the 
striatum and prefrontal cortex (251), regions which are most affected in HD. NUR77 
has also been demonstrated to be a regulator of glucose and lipid metabolism in rat 
skeletal muscle (252) and therefore the upregulation of Hr38 expression observed in 
Drosophila expressing CAG and CUG repeat RNAs may be indicative of metabolic 







Table 5.10: Common transcriptional changes in elav>rCAG and elav>rCUG compared 
to elav>+ in experiment 1. Log2(ratio) >0.5 or <-0.5, P<0.05. 
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Table 5.11: Common changes for elav>rCAG and elav>rCUG compared to elav>+ in 
experiment 2. Log2(ratio) >0.5 or <-0.5, P<0.05. 
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5.8 Summary of results from microarray analysis 
 
Microarray analysis was performed on newly eclosed flies expressing rCAG 
and rCUG repeats specifically in the nervous system in order to investigate 
transcriptional changes associated with hairpin RNA expression, which may 
represent some of the earliest pathogenic changes in the expanded repeat diseases. 
A large degree of variation was observed both between independent microarray 
experiments – perhaps as a result of the difference in the driver and repeat lines 
used between the two experiments – and within each experiment, depending on 
whether elav>rCAA or elav>+ was used as a control. However, components of 
pathogenic pathways that have been described in other expanded repeat models 
were identified when either elav>rCAA or elav>+ were used as a control and it is 
therefore unclear whether one control should be deemed preferable to the other.  
 
Analysis of changes occurring in our model identified a number of pathways 
which were dysregulated in response to expression of rCAG and rCUG repeats, 
including transcriptional regulation, redox regulation, axonal transport, RNA 
processing and lipid metabolism. A number of the genes altered in this microarray 
study have been previously identified in other Drosophila expanded repeat disease 
models, including ctp (244), mbl (117), hts (121), mod(mdg4) (98) and mGluRA 
(248-249), suggesting that the expression of hairpin RNA alone is sufficient to 
induce some of the transcriptional dysregulation observed, irrespective of the 
context of the repeat. It is also indicative that at least a proportion of the cellular 
changes in these models are not sequence-dependent, since expression of either 
rCAG or rCUG repeats were both able to induce a number of these changes. Since 
the presence of repeat-containing RNA is common to both the translated and 
untranslated expanded repeat diseases, it seems likely that the changes effected by 
hairpin RNA expression may also play a role in pathogenesis of the polyglutamine 
diseases.  
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Chapter 6: Genetic verification of candidates from microarray analysis 
 
A number of transcriptional changes in Drosophila expressing expanded 
untranslated CAG and CUG repeats in neurons were identified using a microarray 
approach, as described in Chapter 5. From this initial analysis, it is not apparent 
whether these genes represent early pathogenic changes resulting from hairpin 
repeat expression, or are more general downstream effects of cellular stress. This is 
a particularly pertinent distinction since the majority of changes identified in this and 
other expanded repeat disease microarray studies coincide with changes that have 
been described in other neurological diseases. For example, axonal transport defects 
have been described in models of HD (13-14, 119) but also in prion disease (253), 
ALS (254), Parkinson’s disease (255) and Alzheimer’s disease (256-257). These 
sorts of changes are likely to represent common neuronal responses to stress which 
may play a role in expanded repeat disease, but cannot account for differences in 
pathology observed between these and other neurological diseases. 
 
In order to determine which of the changes identified in the microarray study 
can be attributed to expression of hairpin RNA and which are more general 
responses to cellular stress, we performed a genetic screen of candidates from both 
microarray experiment 1 and 2. The candidate genes and alleles tested along with a 
summary of the changes observed in the microarray experiments are shown in 
Figure 6.1. Since expression of up to four transgene insertions of the rCAG, rCUG or 
rCAA repeat constructs in the eye with GMR-GAL4 does not elicit a phenotype, the 
phenotypes observed when polyglutamine encoded by either a CAG or CAA repeat 
or polyleucine encoded by a CUG repeat are expressed in the eye (described in 
section 2.1) were utilised for a primary screen. In this screen, Drosophila expressing 
either polyglutamine or polyleucine specifically in the eye were crossed to candidate 
gene stocks and scored for modification of the eye phenotype. In cases where 
modification of the eye phenotype is observed in Drosophila expressing CAG, CUG 
and CAA repeats, this indicates that the alteration to the phenotype is unlikely to be 
due to a specific interaction with the hairpin repeat RNA – since the CAA RNA is 
unable to form this structure – and these transcriptional changes are therefore more 
likely to represent general outcomes of cellular stress.  A similar methodology has 
been successfully used to identify mbl as a candidate gene which is able to modify 
the phenotype caused by a polyglutamine tract encoded by a pure CAG repeat but 
not a mixed CAG/CAA repeat (117).    106 
We obtained Drosophila stocks from the Vienna Drosophila RNAi Centre 
(VDRC) and Bloomington stock centre to reduce expression of candidate genes by 
either P-element insertion or RNAi (listed in Table 6.1). Flies were generated with a 
recombinant chromosome containing GMR-GAL4 and either a CAG, CUG or CAA 
transgene insertion. These flies were crossed to each of the candidate gene stocks 
to produce flies with expression of either polyglutamine or polyleucine and reduced 
expression of the candidate gene (depicted in Figure 6.1). Where possible, 
independent candidate gene stocks were obtained to verify interactions and rule out 
the effects of background mutations.  
 
 
Figure 6.1: Method to generate Drosophila expressing polyglutamine or polyleucine 
in the eye along with an RNAi construct targeting a candidate gene. A) Flies were 
generated with a chromosome recombinant for GMR-GAL4 and a CAG, CAA or CUG 
repeat tract encoding polyglutamine or polyleucine. Each of these stocks was then crossed 
to the candidate gene stocks (listed in Table 6.1) to produce progeny which express both 
polyglutamine or polyleucine and the RNAi construct specifically in the eye (B). Where P-
element lines were obtained for a candidate gene, the same procedure was followed 
except in this case the progeny have reduced expression of the candidate gene in all 
tissues. A control was included in each set of crosses, consisting of the recombinant line 
carrying GMR-GAL4 and the repeat tract out-crossed to a wild-type line (w
1118). The 
progeny of this cross were used to indicate the severity of the eye phenotype in flies 
without knock-down of the candidate gene.  
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Table 6.1: Overview of genes and alleles tested for genetic interaction with expanded 
repeats. Candidate genes were selected based on the microarray experiments described in 
Chapter 5 (Log2(ratio)>0.5 or <-0.5 and P<0.05). Alleles preceded by “v” were obtained from 
the VDRC stock collection. Alleles of hts were sourced from the Bloomington stock centre. All 
VDRC lines were tested for presence of an eye phenotype when expressed with GMR-GAL4 
and, in all cases, no disruption to the exterior appearance of the eye was seen. Alleles in 
bold are shown in figures. 
 
 
While a modification of the polyglutamine or polyleucine phenotypes would be 
suggestive of a role for the candidate gene in expanded repeat disease 
pathogenesis, the lack of a change does not necessarily rule out a candidate.  In this 
screen, we are utilising the disruption of the ordered structure of the Drosophila eye 
as a marker of cellular dysfunction and death. Since not all of the cells in the eye are 
of neural origin, it is possible that they do not respond in the same manner to 
expanded repeat expression as the cells of the nervous system which were 
investigated by microarray analysis. Furthermore, while the candidate gene lines 
have been tested by quantitative real-time PCR for their ability to knock-down 
expression of their target RNA, there may be cases where the reduction in gene 
expression is insufficient to modify the phenotype. This screen is intended to be a 
primary validation of the experimental methods of the microarray study and not an 
exhaustive investigation of pathogenic pathways in this model.   
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P=0.001 



































        Gene             Alleles 
                             tested       
rCAG  rCUG   108 
6.1 Modification of translated repeat phenotypes by cytoskeletal and trafficking 
components 
 
Defects in axon transport processes have been hypothesised to play a role in 
polyglutamine disease pathogenesis due to the propensity of proteins containing 
polyglutamine tracts to cause axonal blockages. The transport of newly synthesised 
proteins and RNA as well as anterograde signals down the axon to the synapse and 
transport of retrograde signals and waste material in the opposite direction are 
essential to the function of neurons. Axonal transport also plays an important role in 
energy regulation via transport of mitochondria to provide local energy needs (258). 
Mutations in components of the axonal transport machinery, including motor proteins 
kinesin and dynein, have been demonstrated to be sufficient to cause neuronal 
dysfunction and death. Kinesin KIF1A mutations have been shown to cause 
disruptions to synaptic vesicle transport and cell death in mice (259) and the 
neuronal kinesin KIF1B is mutated in Charcot-Marie-Tooth disease type 2A, a 
neuropathy characterised by axonal degeneration resulting in progressive weakness 
and atrophy of muscles. Mutations in dynein heavy chain 1 have similarly been 
demonstrated to result in sensory neuropathy associated with “hind-limb clasping” in 
a mouse model (260). These observations suggest a general link between axonal 
transport dysfunction and neuronal death.  
 
Components of the cytoskeleton and trafficking machinery were found to 
display altered expression in Drosophila expressing either rCAG or rCUG repeats 
pan-neuronally in both microarray experiment 1 and 2 (Chapter 5). Alterations to 
cytoskeletal components have been demonstrated to be amongst the early 
changes observed in HD brains (261) and may be involved in regulation of toxic 
protein aggregation rate, suggesting a broader role in the polyglutamine diseases 
(262). Altered splice-form expression of the microtubule-associated protein Tau, a 
protein involved in stabilisation of axons, has been detected in the brains of DM1 
individuals (263), suggesting that alterations to the structure and function of the 
cytoskeleton may also play a specific role in CNS pathology in this disease. 
Expression of the transcript encoding the cytoskeletal protein Hts was upregulated 
in both rCAG and rCUG expressing flies compared to the elav>+ control in 
microarray experiment 1 and downregulated in rCUG expressing flies compared to 
elav>+ in experiment 2. While there is not concordance in the direction of the   109 
observed change in expression, the consistent alteration to expression of hts 
between the microarray experiments suggests that cytoskeletal organisation is 
affected by the expression of expanded repeat RNA.  
 
Trafficking defects have also been demonstrated in HD including perturbation 
of the retrograde transport of BDNF (264) and impairment of mitochondrial 
movement (265). It is unclear whether these defects are the result of a loss of normal 
HTT function, since HTT is involved in transport processes via its interaction with 
Huntington-associated protein 1 (HAP1), or axonal blockages caused by the 
polyglutamine aggregates themselves (13-14, 119, 264, 266-267). However the 
ability of polyglutamine tracts within a broad range of contexts to cause axonal 
transport defects suggests that these pathways may be commonly perturbed in the 
polyglutamine diseases. In a mouse model of SBMA, expression of mutant AR 
protein was found to result in reduced expression of dynactin 1, correlating with 
accumulation of neurofilaments and synaptophysin at the distal end of motor axons 
and retrograde transport defects resulting in neuronal dysfunction. The neuronal 
toxicity in this model could be mitigated by overexpression of dynactin 1, supporting 
the idea that the transport defects observed did play a major role in pathology (268).  
 
Studies in Drosophila show that expression of either polyglutamine tracts 
alone or in the context of Ataxin-3 are able to induce changes in levels of 
components of the axonal transport machinery – including kinesin light and heavy 
chains, dynein light and heavy chains and the dynactin complex component p150
glued 
– as well as accumulation of organelles consistent with axonal transport dysfunction 
(14). In our Drosophila model, no observable modification of a mild CAA 
polyglutamine phenotype was observed when mutations in kinesin heavy chain, 
kinesin light chain, dynein heavy chain, roadblock, p150
glued or dynamitin were 
introduced (133), however this experiment did not investigate a role for CAG repeat 
RNA in the dysfunction. The results obtained from microarray analysis of Drosophila 
expressing rCAG and rCUG repeat tracts in neurons suggest that expanded repeat 
RNA alone may be capable of disrupting axonal transport pathways.  
 
RNAi lines or mutants for the candidate genes hts, ctp and insc (as listed in 
Table 6.1) were obtained and tested for the ability to modify the CAG and CAA-
encoded polyglutamine and CUG-encoded polyleucine eye phenotypes (Figure 6.1).   110 
Using both CAG and CAA-encoded polyglutamine expressing flies will allow the 
distinction between modifications resulting from an interaction at the RNA level and 
those resulting from an interaction with the polyglutamine peptide itself, since CAA 
repeat RNA is not able to form a hairpin secondary structure in the same manner as 
CAG and CUG repeat RNA. The ability of polyglutamine-containing proteins to 
perturb axon transport and alter levels of cytoskeletal components is well-
documented, however the focus of this experiment is to investigate the contribution of 
the hairpin RNA to transport defects. 
 
It has been previously demonstrated that a Drosophila eye phenotype caused 
by expression of human HTT exon 1 containing 128 glutamines is suppressed by hts 
loss of function alleles 01103 and KG06777 (121). A slight suppression of both the 
CAG and CAA-encoded polyglutamine phenotypes was also observed in our model 
when these repeats were expressed with GMR-GAL4 in flies heterozygous for either 
of these hts alleles (KG06777 shown, Figure 6.2 A&B compared to D&E). This 
suppression consists of a slight reduction in the area of the eye showing loss of 
pigment. The eye appeared slightly darker in flies expressing polyleucine and 
heterozygous for either of the hts alleles compared to eyes of flies expressing 
polyleucine in a wild-type background, which may also indicate a slight suppression 
(Figure 6.2, C compared to F). While there appears be a modification of both the 
CUG and CAG repeat phenotypes when expression of Hts is decreased, this effect is 
unlikely to be mediated through an interaction with hairpin-forming RNA since the 
phenotype associated with expression of a CAA-encoded polyglutamine tract, which 
cannot form a hairpin structure at the RNA level, was also suppressed by both hts 
alleles tested.  
 
The ability of either ctp or insc to interact with polyglutamine has not been 
previously examined. Expression of RNAi constructs targeting either ctp or insc with 
GMR-GAL4 did not cause a visible change to the appearance of the eye (data not 
shown). Co-expression of polyglutamine encoded by either CAG or CAA repeats with 
RNAi constructs targeting ctp resulted in a slight increase in the area of the eye 
showing loss of pigment compared to eyes where only polyglutamine is expressed 
(allele v43115 shown, Figure 6.2 A&B compared to G&H). No significant change was 
observed when an RNAi construct targeting insc was co-expressed with 
polyglutamine (Figure 6.2 A&B compared to J&K). There was also no dramatic   111 
change in the exterior appearance of the eye in flies co-expressing the ctp or insc 
RNAi constructs with polyleucine compared to those expressing polyleucine alone 
(Figure 6.2 C compared to I & L). The enhancement observed when ctp levels were 
reduced in the eyes of polyglutamine-expressing flies is unlikely to be mediated 
through hairpin RNA, since it is observed in both CAG and CAA expressing flies, but 
not in CUG expressing flies.  
 
 
Figure 6.2: Effect of altering 
levels of cytoskeletal and 
trafficking components on 
polyglutamine and polyleucine 
eye phenotypes in Drosophila. In 
all cases repeat and RNAi 
construct expression is driven by 
GMR-GAL4. A&B) Expression of 
polyglutamine encoded by either 
CAG or CAA results in loss of 
pigment in the eye. C) Expression 
of polyleucine results in a mild 
rough eye phenotype. D&E) Flies 
heterozygous for a mutation in hts 
and expressing polyglutamine 
encoded by either a CAG or CAA 
repeat show a reduction in the 
area of loss of pigment compared 
to flies expressing polyglutamine in 
a wild-type background. F) Flies 
expressing polyleucine in a 
heterozygous hts mutant 
background have a darker eye 
colour compared to flies 
expressing polyleucine in a wild-
type background. G,H) Co-
expression of an RNAi construct 
targeting ctp with polyglutamine 
encoded by either CAG or CAA 
results in an slight increase in the 
area and severity of the loss of 
pigment eye phenotype. J&K) Co-
expression of an RNAi construct 
targeting insc with polyglutamine 
encoded by either CAG or CAA 
does not significantly alter the 
exterior appearance of the eye. 
I&L) Co-expression of RNAi 
constructs targeting either ctp or insc with polyleucine does not dramatically modify the 
appearance of the eye compared to polyleucine expression alone. 
 
   112 
The results presented here are not supportive of a role for expanded repeat 
RNA in the axonal transport defects observed in the polyglutamine diseases, since 
phenotypes resulting from expression of polyglutamine encoded by either an RNA 
hairpin-forming CAG repeat or a CAA repeat which is not able to form a secondary 
structure were both modified by reduced expression of hts and ctp. However, the 
ability of reduced expression of cytoskeletal proteins to alter the phenotypes 
associated with expression of polyglutamine in the eye does support a role for axonal 
transport proteins in polyglutamine pathogenesis in our model. The inability of 
reduced expression of kinesin light and heavy chain, dynein light and heavy chain 
and p150
glued to modify a CAA-encoded polyglutamine phenotype (133) may be a 
result of differences between our model and the model in which the alteration of 
expression of these genes was originally observed and does not appear to be 
indicative of a lack of axon transport defects in our model.  
 
 
6.2 Modification of translated repeat phenotypes by mod(mdg4), mGluRA and 
CG5669 
 
  The ability of co-expression of RNAi constructs targeting several other 
microarray candidates to modify the polyglutamine and polyleucine eye phenotypes 
were also examined (listed in Table 6.1). The choice of candidates to test in this 
initial screen was based on their identification in previous studies of expanded 
repeat disease. Of the candidates tested, two have been associated with 
untranslated repeat diseases: mod(mdg4) was identified in a modifier screen using a 
Drosophila model of SCA8 (98) and the metabotropic glutamate receptor (mGluRA) 
has been shown to have a mutually antagonistic relationship with the Drosophila 
FMRP orthologue (249). The remaining candidate, CG5669, encodes an orthologue 
of the SP1/SP3 transcription factor family. SP1 has been implicated in transcriptional 
dysregulation in HD (226-227) and is also downregulated in muscle biopsies from 
DM1 and DM2 patients (83) and therefore may represent a link between 
pathogenesis in the untranslated and translated repeat diseases.  
 
Reducing expression of either mGluRA or CG5669 did not cause a dramatic 
change to the exterior appearance of the eye in flies expressing polyglutamine 
encoded by either a CAG or CAA repeat (Figure 6.3 D,E & J,K compared to A,B).   113 
This result does not support a role for either CG5669 or mGluRA in polyglutamine 
pathogenesis in our Drosophila model, although it is possible that the level of knock-
down elicited by these RNAi constructs is insufficient to cause a modification. A 
slight darkening of the eye was observed when either the CG5669 or mGluRA RNAi 
constructs were co-expressed with polyleucine however, since this is a very mild 
effect in both cases, it could simply be a result of decreased expression of the repeat 
construct resulting from titration of the available GAL4 protein by the UAS sites of 
the RNAi construct. It was therefore concluded that altering expression of mGluRA 
and CG5669 does not have a significant effect on pathogenesis in our Drosophila 
model.  
 
  Expression of an RNAi construct targeting mod(mdg4) showed a strong 
interaction with both polyglutamine encoded by a CAG repeat and polyleucine 
(Figure 6.3 G&I). In the case of CAG-encoded polyglutamine, this enhancement 
resulted in nearly complete lethality of flies expressing both the RNAi construct and 
the CAG construct, while flies expressing either construct alone were viable. The 
observed lethality in these flies may be the result of some expression of these 
constructs in tissues other than the eye, an effect which has been previously 
reported for the GMR-GAL4 driver (109). The few flies expressing both the 
mod(mdg4) RNAi construct and polyglutamine encoded by a CAG repeat which did 
eclose showed significantly greater area of loss of pigment and necrotic patches on 
the eye. Co-expression of the mod(mdg4) RNAi construct with polyleucine also 
resulted in a profound change in the colour of the eye and the appearance of 
necrotic patches. In contrast, expression of the RNAi construct with CAA-encoded 
polyglutamine resulted in only a relatively mild increase in the loss of pigment 
phenotype (Figure 6.3 H) despite the similar starting phenotypes in the chosen CAG 
and CAA polyglutamine lines (Figure 6.3 A&B).  
 
Since mod(mdg4) was previously identified in a P-element screen for modifiers 
of a phenotype caused by expression of the human SCA8 non-coding RNA in the 
Drosophila eye (98), there is already support for an interaction between Mod(mdg4) 
and expanded repeat RNA. In our Drosophila model a much stronger interaction was 
observed with the CUG and CAG expanded repeat constructs than the CAA 
construct, suggesting that the sequence of the repeat may be important for this 
interaction. Mod(mdg4) has numerous biological roles mediated through highly   114 
complex developmental splicing, including regulation of position effect variegation 
and silencing via chromatin remodelling as well as regulation of apoptotic pathways 
(269). Since Mod(mdg4) plays a role in chromatin remodelling, it is also possible that 
the interaction with the expanded repeats may be a sequence-dependent effect 
occurring at the DNA level. One possible mechanism for such an enhancement may 
be mediated via an increase in the expression of the repeat construct resulting from 




Figure 6.3: Modification of 
polyglutamine and polyleucine eye 
phenotypes by altering levels of 
Mod(mdg4), mGluRA and CG5669. In 
all repeat and RNAi construct 
expression was driven by GMR-GAL4. 
A&B) Polyglutamine lines with a similar 
loss of pigment phenotype were 
selected. C) Expression of polyleucine 
results in a mild rough eye phenotype. 
D,E,G,H) Co-expression of an RNAi 
construct targeting CG5669 or mGluRA 
with polyglutamine encoded by either 
CAG or CAA does not significantly alter 
the exterior appearance of the eye. 
F&I) Co-expression of an RNAi 
construct targeting CG5669 or mGluRA 
with polyleucine results in a slight 
darkening of the eye compared to 
expression of polyleucine alone. J) Co-
expression of an RNAi construct 
targeting mod(mdg4) with 
polyglutamine encoded by CAG is 
semi-lethal. The few flies that do eclose 
have a severe loss of pigment eye 
phenotype with necrotic patches. K) 
Co-expression of an RNAi construct 
targeting mod(mdg4) with 
polyglutamine encoded by CAA results 
in a slight decrease in pigmentation 
compared to flies expressing CAA 
polyglutamine alone. L) Co-expression 
of an RNAi construct targeting 
mod(mdg4) with polyleucine causes a 
dramatic change in eye colour and 
appearance of necrotic patches on the 
eye.  115 
6.3 Modification of translated repeat phenotypes by altering levels of mbl and 
mef2 
 
Another gene identified by microarray analysis which has a known role in 
expanded repeat disease pathogenesis is mbl. While a role for the human mbl 
orthologue (MBNL) has been demonstrated in DM1 and DM2, a more general role 
for MBNL in other expanded repeat disorders has only recently been suspected. The 
first indication of this possibility related to the discovery that one of the 
spinocerebellar ataxias, SCA8, displays components of both polyglutamine and CUG 
repeat RNA pathology through bi-directional transcription of ataxin-8 (97). The CUG 
repeat-containing transcripts in this disorder have also been shown to co-localise 
with MBNL1 suggesting that there may be overlap in pathogenesis with myotonic 
dystrophy (270).  MBNL1 has also been shown to have similar affinity for both 
expanded CAG and CUG repeat tracts in vitro (116). The ability of Drosophila mblA 
to interact with CAG repeat transcripts in vivo has also been demonstrated, 
supporting a role for MBNL in polyglutamine disease pathology (117).  
 
Despite evidence of mental impairment in many patients, the role of MBNL1 in 
DM1 has mostly been investigated in relation to muscle phenotypes and there is 
currently only limited evidence of a role for MBNL in neuronal pathology (271). The 
finding that mbl expression is altered in flies expressing rCAG or rCUG repeats pan-
neuronally supports the idea that similar processes to those disrupted in muscle cells 
in myotonic dystrophy may be perturbed in Drosophila neurons in the presence of 
CAG or CUG repeat containing RNA. In order to validate a role for mbl in our model 
of expanded repeat disease, we tested the ability of an RNAi construct targeting mbl 
to modify the phenotypes associated with expression of polyglutamine or polyleucine 
in the eye (Figure 6.4 A-F). Co-expression of this RNAi construct enhanced the 
polyleucine phenotype, resulting in a decrease in the size of the eye and a glazed 
appearance, while only a very mild enhancement of the CAG-encoded polyglutamine 
eye phenotype was seen. No change was observed when mbl expression was 
reduced in flies co-expressing CAA-encoded polyglutamine in the eye, suggesting 
that this interaction is dependent upon the ability of the RNA to form a secondary 
structure. While the observation of a sequence-dependent interaction between 
polyglutamine and Mbl agrees with the findings of a recent study investigating the 
contribution of RNA toxicity to SCA3 pathogenesis (117), in our model altering levels   116 
of Mbl produced only a very mild effect and therefore it is not clear whether this 
pathway represents a major component of polyglutamine pathogenesis in this case.  
 
Closer examination of the microarray data also revealed altered regulation of 
myocyte enhancing factor 2 (mef2) in flies expressing rCUG repeats compared to the 
elav>+ control in microarray experiment 2. Mef2 is a developmentally regulated 
transcription factor involved in neuronal and muscle survival and development (272) 
which has also been demonstrated to regulate mbl expression in Drosophila (273). 
One mammalian MEF2 isoform, MEF2D, has been demonstrated in cultured rat 
neurons to be induced in response to stimulation of distal axons by neurotrophic 
signals. This result suggests that MEF2D is a component of the transcriptional 
response to retrograde signalling and is likely to be important in promoting neuronal 
survival (274). In a mouse model of Fragile X syndrome, MEF2 has been 
demonstrated to be involved in activity-dependent pruning of dendritic spines via an 
interaction with FMRP (275). This sort of role in neuronal plasticity has also been 
demonstrated in the striatal medium spiny neurons which are amongst the most 
vulnerable in HD (276). In mouse cerebellar neurons, MEF2 has also been 
demonstrated to co-localise with the wild-type Ataxin-1 protein. It is predicted that the 
presence of a CAG expansion in the Ataxin-1 protein may result in repression of 
MEF2 activity or sequestration of the protein in nuclear inclusions, resulting in a loss 
of the normal anti-apoptotic function of the protein (277). An interaction between 
MEF2 and the SP1 transcription factor has also been demonstrated (233), 
suggesting a link to the transcriptional dysregulation observed in both DM1 and HD.  
 
Since there is a large amount of evidence to support a role for MEF2 in 
expanded repeat pathogenesis, the effect of reducing Mef2 levels in our Drosophila 
model was tested. Co-expression of an RNAi construct targeting mef2 with 
polyleucine strongly enhanced the eye phenotype, causing the appearance of a 
large number of black spots, discolouration and a reduction in the size of the eye 
(Figure 6.4 I). In contrast, co-expression of this RNAi construct with either CAG or 
CAA-encoded polyglutamine resulted in only a slight enhancement of the eye 
phenotype in both cases (Figure 6.4 G&H). This result appears to support a 
sequence-dependent interaction between mef2 and CUG repeat RNA.   117 
Figure 6.4: Modification of 
polyglutamine and polyleucine eye 
phenotypes in Drosophila by 
altering levels of Mbl and Mef2.  
RNAi and repeat expression are 
driven by GMR-GAL4. A&B) 
Expression of polyglutamine encoded 
by either CAG or CAA results in a loss 
of pigment eye phenotype. C) 
Expression of polyleucine results in a 
very mild rough eye phenotype. D&G) 
Co-expression of an RNAi construct 
targeting either mbl or mef2 with CAG 
encoded polyglutamine slightly 
enhances the loss of pigment eye 
phenotype. E&H) Co-expression of an 
RNAi construct targeting mef2 with 
CAA-encoded polyglutamine slightly 
enhances the loss of pigment eye 
phenotype while co-expression of an 
RNAi construct targeting mbl does not 
significantly alter the appearance of 
the eye. F) Co-expression of an RNAi 
construct targeting mbl with 
polyleucine causes an increase in the 
area of roughness and a decrease in 
the size of the eye. I) Co-expression 
of an RNAi construct targeting mef2 
with polyleucine strongly enhances 
the eye phenotype resulting in a decrease in size and a glazed appearance with necrotic 
patches and loss of pigment. 
 
 
6.4 Investigation of sequence-dependent interactions between expanded repeat 
RNA and Mef2, Mbl and Mod(mdg4) in Drosophila  
 
In order to verify that the interactions observed between expanded repeats 
and mbl, mef2 and mod(mdg4) are occurring at the RNA level, RNAi constructs 
targeting mef2 and mod(mdg4) were co-expressed with four transgene insertions of 
each of the untranslated repeat constructs (rCAG, rCUG and rCAA). Attempts to 
generate flies recombinant for GMR-GAL4 and the mbl RNAi construct were not 
successful, possibly as a result of these insertions being within close proximity on 
the second chromosome, and therefore a deletion allele derived from a P-element 
insertion in mbl designated as allele E27 was tested with these repeat constructs. 
Flies heterozygous for this allele only have a 50% decrease in Mbl expression and 
this allele does not produce as great an enhancement of the polyleucine phenotype 
as expression of the mbl RNAi construct (data not shown). Flies heterozygous for 
the mbl
E27 allele or expressing either the mod(mdg4) or mef2 RNAi constructs or the   118 
rCAG, rCUG or rCAA repeat constructs alone do not show any disruption to the 
exterior appearance of the eye (Figure 6.5 A-D). Therefore only those gene 
expression changes which are rate-limiting to pathogenic pathways involved in RNA 
toxicity will be uncovered in this experiment, since reducing expression of this type 
of candidate would be expected to result in an increase in toxicity of the RNA 
species and therefore may result in the uncovering of a phenotype. 
 
Co-expression of the mef2 RNAi construct with rCUG repeat RNA was found 
to be nearly entirely lethal. The few flies expressing both the mef2 RNAi construct 
and rCUG repeats that did eclose had a strong eye phenotype involving necrosis 
and a severe loss of ommatidial structure and died within one day (Figure 6.5 H). A 
similar effect was also seen when a second independent four transgene insertion 
line of rCUG was tested. The observed lethality is likely to be the result of some level 
of expression of the rCUG repeat RNA and mef2 RNAi construct in tissues other 
than the eye. No change to the appearance of the eye was observed when this RNAi 
construct was co-expressed with either rCAG or rCAA repeats (Figure 6.5 F&G). 
This result, along with the interaction of mef2 with polyleucine, suggests a specific 
interaction between mef2 and CUG repeat RNA which is consistent with the reduced 
levels of mef2 expression observed only in rCUG expressing flies.  
 
Similarly, co-expression of the mod(mdg4) RNAi construct and the rCUG 
repeat construct resulted in an eye phenotype consisting of loss of pigment and 
some roughening of the surface of the eye (Figure 6.5 L). No interaction was seen in 
flies co-expressing either rCAG or rCAA repeats with this RNAi construct (Figure 6.5 
J&K) and therefore there appears to be a specific interaction between mod(mdg4) 
and the CUG repeat. The lack of an interaction between untranslated rCAG repeats 
and mod(mdg4) in this assay is surprising since expression of this RNAi construct 
with polyglutamine encoded by a CAG repeat resulted in a strong enhancement of 
the polyglutamine eye phenotype and lethality, an effect which was not seen in flies 
expressing polyglutamine encoded by a CAA repeat. Analysis of the steady-state 
RNA level in flies expressing rCAG and rCUG from these particular insertion sites 
suggests that a difference in the amount of hairpin repeat RNA present is not likely 
to be responsible for the lack of interaction observed in rCAG repeat expressing flies 
(S. Samaraweera, unpublished data). It is unclear whether this result suggests a real 
difference in the mechanism of pathogenesis of the rCAG and rCUG repeat   119 
sequences, or just the degree of toxicity in this particular assay. Nevertheless, since 
expression of either the mod(mdg4) or mef2 RNAi constructs or rCUG RNA alone do 
not elicit a phenotype, the ability of co-expression of these constructs to dramatically 
disrupt the external appearance of the eye is strongly supportive of a genetic 
interaction between rCUG repeats and mef2 and mod(mdg4). 
 
Figure 6.5: Mod(mdg4) and 
Mef2 show a sequence-
dependent interaction with 
CUG repeat RNA in 
Drosophila. In all cases, 
expression of the RNAi 
construct and four transgene 
insertions of the repeat 
constructs are all driven by 
GMR-GAL4. A-D) 
Expression of four transgene 
insertions of rCAG, rCUG, 
rCAA or the UAS construct 
in the eye does not disrupt 
patterning of the eye. There 
is also no disruption to the 
normal patterning of the eye 
when expression of rCAG or 
rCAA repeats or the UAS 
construct without an insert 
are driven in the eye along 
with either the mef2 RNAi 
construct (E-G) or the 
mod(mdg4) RNAi construct 
(I-K). H) Co-expression of 
rCUG repeats with the mef2 
RNAi construct is nearly 
entirely lethal. The few flies 
that do eclose do not live for 
more than a day and have a 
strong eye phenotype 
consisting of large necrotic 
areas, a decrease in the size 
of the eye and nearly 
complete loss of ommatidial 
organisation. L) Co-
expression of rCUG repeats with the mod(mdg4) RNAi construct causes a strong loss of 
pigment eye phenotype. M-P) Introduction of a null mbl mutation in a heterozygous manner 
does not alter the exterior appearance of eyes of flies co-expressing rCAG, rCUG or rCAG 




E27 into flies expressing rCAG, rCUG or rCAA repeats in the 
eye did not result in any alteration to the exterior appearance of the eye and therefore 
it was not possible to explore the role of expanded repeat RNA in the sequence-
SEMI-LETHAL   120 
dependent interaction which was observed between Mbl and the translated repeats. 
Since this allele also showed a weaker interaction with both polyleucine and CAG-
encoded polyglutamine than the RNAi construct (data not shown), the absence of an 
interaction may be the result of an insufficient reduction in Mbl expression in this case.  
 
 
6.5 Evidence of a role for MBNL1 in expanded repeat disease pathogenesis. 
 
  A significant amount of data regarding the interaction of the human orthologue 
of mbl (MBNL) with expanded repeat RNA in our model had already been 
accumulated prior to performing the microarray study because of the link between 
MBNL and myotonic dystrophy pathology. There are three isoforms of human MBNL 
(MBNL1-3) and, while it is unclear how much overlapping function they have in 
regulation of muscle development and splicing, there is a pool of evidence to suggest 
that MBNL1 at least is involved in the formation of foci in DM1 and DM2 (278-279). To 
verify genetically that MBNL1 is involved in expanded repeat pathogenesis, 
overexpression of a UAS-MBNL1 construct (obtained from (86)) was performed in the 
Drosophila eye using GMR-GAL4. Driving expression of MBNL1 in the eye produces a 
rough eye phenotype at 23ºC, however this phenotype is nearly completely 
suppressed by growing the flies at 18 ºC. In order to investigate the ability of MBNL1 
to interact with our expanded repeat constructs, flies carrying the UAS-MBNL1 
construct were recombined with GMR-GAL4 to produce the GMR>MBNL1 stock (L. 
O’Keefe). 
 
Consistent with what is known about the ability of CUG repeat RNA to interact 
with MBNL, expression of polyleucine encoded by a CUG repeat was able to slightly 
enhance the phenotype seen in GMR>MBNL1 flies, causing an increase in roughness 
and darkening of the eye (Figure 6.6 C&D). This effect does not appear to be additive 
since there is no phenotype in flies expressing polyleucine alone at this temperature 
(Figure 6.6 B). If expression of CUG repeat RNA causes sequestration of MBNL1, it 
would be expected that co-expression of this repeat RNA with MBNL1 would result in 
a decrease in MBNL1-associated pathology in our model. The observed enhancement 
may therefore be a result of the effects of both an alteration to the transcriptional 
profile of the Drosophila mbl gene and the ectopic expression of the human MBNL1 
protein in these flies. It is unclear how the function of the human MBNL isoforms   121 
corresponds to the Drosophila Mbl isoforms and therefore this result is difficult to 
interpret.  
 
Figure 6.6: Co-expression of 
CUG-encoded polyleucine 
enhances the MBNL1 eye 
phenotype. All flies express 
UAS constructs specifically in 
the eye under the control of the 
GMR-GAL4 driver and have 
been grown at 23 ºC. A) 
Expression of MBNL1 alone 
results in a mild roughening of 
the surface of the eye. B) 
Expression of polyleucine in flies grown at 23 ºC does not result in a disruption to the 
structure of the eye. C) Co-expression of polyleucine with MBNL1 causes an increase in the 
area and degree of roughness and a slight darkening of the colour of the eye. 
 
 
In order to further investigate a role for MBNL1 in the polyglutamine diseases, 
the effect of co-expressing MBNL1 with a polyglutamine tract was also investigated.  
Crosses were performed at 18 ºC since no phenotype is observed in flies co-
expressing GFP and MBNL1 at this temperature (Figure 6.7 D). Expression of either a 
CAG-encoded or CAA-encoded polyglutamine tract in the eye at this temperature 
results in a mild rough eye phenotype consisting mainly of loss of pigment (Figure 6.7 
B, C).  Co-expression of MBNL1 in either of these cases enhances this phenotype, 
resulting in a significant increase in the area of the eye affected and the extent of the 
pigment loss (Figure 6.7 E, F). MBNL1 therefore shows a sequence-independent 
interaction with polyglutamine in this model, suggesting that this effect is not mediated 
at the RNA level.  
 
Li et al. (117) previously demonstrated that polyglutamine encoded by a pure 
CAG repeat in the context of a truncated SCA3 transcript is more toxic than 
polyglutamine encoded by mixed CAG/CAA repeats. Furthermore, they reported that 
ectopic expression of mblA was able to modify this CAG repeat phenotype, but not the 
phenotype of the mixed CAG/CAA repeat. They concluded that an interaction at the 
RNA level was at least partly responsible for the enhanced toxicity when mblA was 
overexpressed. This result is consistent with our observation of a sequence-
dependent modification of the phenotype associated with expression of polyglutamine 
encoded by a CAG repeat when Mbl levels are altered, however in our model reducing 
expression of Drosophila Mbl, not overexpression, resulted in an enhancement and   122 
this effect was very mild. Since the overexpression construct used in the study 
performed by Li et al. encodes only one isoform of Mbl and the RNAi construct used in 
this study targets all known Mbl isoforms, the differences observed may demonstrate 
perturbation of specific functions of mbl depending upon which isoforms are 
expressed in each case.  
 
In further contrast to what was seen in the SCA3 study, our model shows 
polyglutamine to be intrinsically highly toxic whether encoded by CAG or CAA repeats, 
suggesting that the context of the repeat tract may play a vital role in determining 
toxicity. It was not possible to ascertain whether ectopically expressed human MBNL1 
was able to specifically interact with CAG repeat RNA in a sequence-dependent 
manner using this model of intrinsic polyglutamine toxicity, since a strong 
enhancement of the polyglutamine eye phenotype was seen when either a pure CAG 
or CAA repeat tract was expressed (Figure 6.7). There are several explanations for 
the lack of sequence-specificity observed when human MBNL1 was overexpressed 
with polyglutamine in our model. Firstly, it is possible that this effect is due to a real 
difference in binding properties of the human and Drosophila proteins at the RNA 
level. This could also somewhat explain the differences in sequence-specificity 
between our model and the SCA3 model, since the context of the repeat tract may 
influence the binding capabilities of the MBNL1 protein. It is also possible that the 
enhancement of the polyglutamine eye phenotypes is simply a dominant effect 
resulting from the effects of ectopic expression of MBNL1.  
 
Figure 6.7: Overexpression of 
MBNL1 enhances both CAA and 
CAG-encoded polyglutamine eye 
phenotypes in Drosophila. All flies 
express UAS constructs specifically in 
the eye under the control of the GMR-
GAL4 driver and have been grown at 
18 ºC. Photographs taken by L. 
O’Keefe.  A) Expression of GFP in the 
eye does not disrupt the structure of 
the eye. B&C) Expression of a poly-
glutamine tract encoded by CAA or 
CAG perfect repeats results in a mild 
eye phenotype consisting of loss of 
pigment and some disorder of 
ommatidial arrays. D) Co-expression of 
MBNL1 with GFP does not disrupt the 
structure of the eye at 18 ºC. E&F) Co-expression of MBNL1 with poly-glutamine encoded 
by either CAG or CAA repeats enhances the eye phenotype causing greater loss of 
pigment and a greater area of disruption.   123 
In order to investigate the contribution of hairpin RNA to the interactions seen 
between MBNL1 and polyglutamine and polyleucine, GMR>MBNL1 flies were also 
crossed to the untranslated repeat stocks (rCAG, rCUG and rCAA respectively) to 
produce flies that express MBNL1 and untranslated repeat RNA. In this experiment, 
flies carrying four insertions of the repeat construct were used to ensure that high 
levels of expression of the repeat were achieved. For each repeat, two independent 
four transgene insertion lines were tested (listed in Appendix B, Table B2). A fly stock 
containing four UAS construct insertions without any transgene present (called UAS) 
was used as a control to ensure that similar levels of free GAL4 and expression of 
MBNL1 are achieved.  
 
Figure 6.8: Expression 
of expanded 
untranslated CAG, CUG 
and CAA repeats in 
Drosophila 
overexpressing MBNL1. 
In all cases flies were 
grown at 23 ºC and 
expression of the repeat 
constructs, the UAS 
control and MBNL1 were 
all driven in the eye by 
GMR>GAL4. All 
photographs were taken 
by S. Samaraweera. 
Repeat line genotypes are 
listed in Table 3.6. 
A,C,E,G,I,K,M) 
Expression of either the 
repeat constructs or the 
UAS control alone do not 
produce any phenotype. 
B) Co-expression of 
MBNL1 with the UAS 
control produces a rough 
eye with necrotic patches 
and reduced size 
compared to UAS alone. 
D,F,H,J,L,N) Co-
expression of MBNL1 with 
2 independent four 
transgene insertion lines 
of each of rCAG, rCUG or 
rCAA repeats did not 
produce a consistent alteration to the phenotype seen in flies co-expressing MBNL1 and 
UAS. Eyes of flies expressing rCAA repeats (L&N) are indistinguishable from those of 
rCAG2(F) and rCUG2(J). Eye phenotypes in flies co-expressing rCAG1 and rCUG1 also 
look markedly different from the other rCAG and rCUG independent lines tested (D&H).    124 
At 23 ºC, GMR-GAL4 driven expression of four insertions of each of UAS, 
rCAG, rCUG or rCAA alone do not produce any disruption to the structure of the eye 
(Figure 6.8 A,C,E,G,I,K,M). Overexpression of MBNL1 in flies carrying four transgene 
insertions of the UAS control results in a reduction in the overall size of the eye and 
roughening of the surface with some necrotic patches which appear as black spots 
(Figure 6.5 B). This phenotype appears to be somewhat suppressed in flies 
expressing one of the rCAG four transgene insertions (rCAG2) or either of the 
independent rCUG four transgene insertions (rCUG1 & rCUG2), however expression 
of either rCAA1 or rCAA2 results in a similar suppression, involving an increase in the 
size of the eye and decrease in the area of roughness and number of necrotic 
patches (Figure 6.8 F, H and J compared to L and N) and therefore this effect does 
not appear to be related to the ability of the expressed RNA species to form a hairpin 
structure. A stronger effect is seen when rCUG1 is expressed than for any other line 
(Figure 6.8 H), with nearly a complete suppression of the roughness and a return to 
wild-type size eye. The expression of rCAG1 appears to slightly enhance the MBNL1 
phenotype, causing a reduction in the size of the eye and an increase in the area of 
roughness (Figure 6.8 B compared to D). These results do not support a sequence-




6.6 Summary of results from genetic screen of microarray candidates 
 
  Interactions were observed between a number of the candidates identified in 
the microarray study and our translated expanded repeat constructs in the 
Drosophila eye (summarised in Table 6.2). In a number of cases, candidate genes 
showed an interaction with both CAG and CAA-encoded polyglutamine, suggesting 
that this effect is not mediated through an interaction with hairpin RNA. RNAi 
constructs for two candidates which did show a sequence-dependent interaction with 
expanded repeats, mef2 and mod(mdg4), were also tested with the untranslated 
rCAG, rCUG and rCAA repeat constructs. A strong interaction was observed with 
CUG repeat RNA but not with CAG or CAA RNA in these cases (Figure 6.5). This 
result supports a role for Mef2 and Mod(mdg4) in CUG-repeat RNA toxicity in the 
expanded repeat diseases. Since altered expression of mef2 was only seen in flies 
expressing rCUG repeats neuronally, this result is consistent with Mef2 playing a   125 
unique role in CUG repeat pathogenesis. However, altered expression of 
mod(mdg4) was observed in both rCAG and rCUG repeat-expressing flies and 
therefore it is unclear whether the absence of an interaction between rCAG and 
mod(mdg4) in the eye indicates that this is a more important component of CUG 
repeat pathogenesis, or that different pathways are perturbed in flies expressing 
CAG repeats in the eye compared to the nervous system. The observation that 
reducing expression of Mod(mdg4) in flies co-expressing translated CAG repeats 
encoding polyglutamine resulted in nearly complete lethality suggests that there is 
likely to be a strong interaction between mod(mdg4) and CAG repeats in tissues 
other than the eye. Since this effect was not seen in flies co-expressing the 
mod(mdg4) RNAi construct and polyglutamine encoded by a CAA repeat which 
cannot form a hairpin RNA, this interaction may be mediated via an interaction with 
the hairpin-forming CAG repeat RNA. Since Mod(mdg4) has been demonstrated to 
play a role in position effect variegation and transcriptional silencing (269), it is also 
possible that this interaction is mediated through an interaction with CAG and CUG 
repeat tracts at the DNA level.  
 
A mild interaction was also observed between Drosophila mbl and 
polyglutamine encoded by a CAG repeat and polyleucine encoded by a CUG repeat, 
but not polyglutamine encoded by a CAA repeat (Figure 6.4). This result supports a 
role for Mbl in both CAG and CUG repeat toxicity in our model and suggests that the 
secondary structure of the RNA is important for this interaction. However, since no 
interaction was observed when rCAG or rCUG repeats were expressed in a 
heterozygous mbl null background, the biological importance of this interaction in 
RNA toxicity could not be further investigated. The ability of human MBNL1 to 
interact with repeat RNAs in a sequence-dependent manner was not supported in 
our Drosophila model. While an enhancement of the phenotype associated with 
overexpression of human MBNL was seen when CUG-encoded polyleucine was co-
expressed (Figure 6.6), a sequence-independent enhancement of both CAG and 
CAA-encoded polyglutamine phenotypes was also seen (Figure 6.7) which may 
suggest that human MBNL1 has a dominant toxic effect in our model. Co-expression 
of MBNL1 with rCAG, rCUG and rCAA repeat constructs did not give a consistent 
effect between independent transgenic lines (Figure 6.8) and therefore any role of 
the repeat RNA in the interactions observed between polyglutamine and polyleucine 
with MBNL1 in this model remains unclear.    126 
 
The two CUG repeat sequence-dependent interactions uncovered in this 
analysis are likely to represent real components of RNA toxicity in this Drosophila 
model, since these candidates were identified as showing altered transcription in 
flies expressing untranslated repeat RNA neuronally and were also genetically 
verified in flies expressing both translated and untranslated CUG repeats in the eye. 
The results of this primary screen therefore suggest that further analysis of the 
microarray data may identify more components of toxicity in both CUG and CAG 
repeat-expressing flies and that the use of this kind of approach is likely to yield 
















Table 6.2 Summary of results from genetic screen of microarray candidates. Alleles are 
all RNAi or P-element insertions which reduce expression of the candidate gene, except for 
MBNL1 which is an overexpression construct. Alleles tested are listed in Table 7.1. Dashes 
indicate that interactions were not tested in this study. S=suppression of eye phenotype, 
E=enhancement of eye phenotype, NS=no significant change to appearance of eye, + 
indicates a mild interaction, ++indicates a medium strength interaction, +++ indicates a 










rCAG rCAA rCUG 
hts  S+ S+ S+ - - - 
ctp  NS NS NS - - - 
insc  E+ E+ NS - - - 
CG5669  NS NS S+ - - - 
mod(mdg4)  E+++  
(lethal) 
E+ E++  NS  NS  E+ 
mGluRA  NS NS NS - - - 
mef2  NS NS E++  NS  NS  E+++ 
(lethal) 
mbl  E+ NS E++  NS  NS  NS 
MBNL1  E++ E++ E++ NS  NS  NS   127 
Chapter 7: Spinocerebellar ataxia 10: a unique untranslated repeat disease? 
 
  Spinocerebellar ataxia type 10 (SCA10) is a rare cerebellar ataxia caused by 
the expansion of a pentameric ATTCT repeat within exon 9 of the ataxin-10 gene 
(280). This mutation is believed to have arisen in Latin American populations and 
SCA10 largely affects individuals of Brazilian and Mexican origin (281). Like other 
SCAs, SCA10 presents as cerebellar dysfunction resulting in ataxia with other 
features including cognitive impairment, dementia and seizures in a proportion of 
patients (282). Genetic anticipation with a bias towards expansion on paternal 
transmission and a correlation between repeat size and age-at-onset have also been 
observed in some families (283). Cases of repeat-size mosaicism within tissues and 
repeat-size variability between tissues are common, suggesting that these repeats 
are also highly somatically unstable (283).  
 
  Despite resulting in a fairly pure cerebellar ataxia, there are several unique 
features of the SCA10 mutation. Firstly, the disease-causing expansions in ataxin-10 
are extremely large: generally more than 800 repeats and frequently many 
thousands of repeats are detected in affected individuals (280). The repeat itself is 
also unusual, firstly because it is very AT rich but also because it is the only SCA-
causing repeat tract present within the intron of a gene. These features have a 
number of implications for disease pathogenesis. Examination of the behaviour of 
the SCA10 repeat at the DNA level has revealed that it is a DNA unwinding element 
(284-285) and that the ATTCT strand, but not the anti-sense TAAGA strand, is able 
to form a secondary structure under physiological conditions (100). This propensity 
of the repeat tract to unwind is believed to be part of the repeat expansion 
mechanism responsible for the large size of the SCA10 repeat expansions (285).   
 
The outcomes of the ATTCT repeat expansion in ataxin-10 are largely 
unknown, however the discovery that the repeat itself is a DNA unwinding element 
caused speculation that the expression of ataxin-10 and surrounding genes might be 
altered by the expansion. Similar to CAG repeats, the expanded ATTCT repeat has 
been associated with strong binding of nucleosomes which is further enhanced by 
the presence of interruptions to the repeat sequence, supporting the idea that the 
repeat may alter gene regulation (286). The Ataxin-10 protein has been 
demonstrated to be essential for the survival of primary cerebellar neurons in culture 
(6, 287), however it has been reported that the mutant ataxin-10 allele is both   128 
transcribed and processed normally in patient-derived cells, suggesting that loss of 
function alone is not responsible for the pathogenesis of SCA10 (288).  Furthermore, 
while mice null for ataxin-10 are embryonic lethal, heterozygotes do not recapitulate 
any SCA10 symptoms, supporting the idea that a simple gene-dosage effect is 
unlikely to be responsible for pathogenesis (288).  
 
Since the SCA10 repeat resides within an untranslated region of the ataxin-10 
gene and the disease exhibits dominant inheritance, it has been proposed that this 
mutation may be pathogenic because it results in the production of a dominant toxic 
RNA (100). While rCAG/rCUG repeats have been demonstrated to form a simple 
hairpin structure with a mis-match every third base, the only structure consistent with 
NMR spectroscopy data for rAUUCU repeats under physiological conditions is an 
anti-parallel hairpin including a C-C mismatch every 5 bases and an equal ratio of A-
U/U-U matches (100). In the context of the SCA10 repeat, the presence of U-U mis-
matches is predicted to stabilise the hairpin secondary structure (100). Splicing of 
the SCA10 transcript may result in the release of the extremely large hairpin-forming 
AUUCU RNA in the cell which may have the potential to bind RNA binding proteins 




7.1 Modelling SCA10 in Drosophila 
  
The observation that expanded AUUCU repeat RNA is also able to form a 
hairpin structure supports our hypothesis that RNA secondary structure may be 
involved in pathogenesis of the expanded repeat diseases. In order to investigate 
the contribution of rAUUCU repeat-containing RNA to pathology in SCA10, a 
Drosophila model was generated. To do this, the intron 9 region from ataxin-10 
containing the repeat tract and 141 bp of surrounding sequence was amplified from 
HeLa cell DNA and the ATTCT repeat expanded from a starting size of 13 repeats 
using a PCR method. Both GFP-tagged and untagged constructs were generated as 
depicted in Figure 7.1. These constructs contain an expanded ATTCT repeat either 
in the 3’UTR of a short peptide, as described for rCAG, rCUG and rCAA constructs, 
or in the 5’UTR of the GFP transcript. Repeat tracts of 65 repeats for the 3’UTR 
insertion and 67 repeats for the GFP tagged construct were obtained and completely   129 
sequenced. A clone for the GFP-tagged construct was also obtained which gave a 
PCR product of the expected size for a repeat tract of around 100 repeats. On 
sequencing at least 100 repeats were detected, however it was not possible to 
completely sequence across the repeat tract, presumably because of the AT-rich 
nature of the sequence. In the case of the repeat tracts which were completely 
sequenced, the injected constructs also contained interruptions to the repeat tract as 
listed in Table 7.1. The AT-rich nature of the sequence and the instability observed 
during cloning once the repeat number exceeded this range may have prevented the 
generation of repeat tracts within the range seen in SCA10 individuals.  
 
 
Figure 7.1: Constructs generated to 
model SCA10 pathogenesis in 
Drosophila. A) A construct was 
generated with 65 ATTCT repeats 
inserted into the 3’UTR of a short 
peptide. B) Constructs were also 
generated with the ATTCT repeat tract 
inserted upstream of a GFP tag, such 
that the repeat is effectively in the 5’UTR. Repeat tracts of 67 and at least 100 repeats were 




Construct Repeat  sequence  Number of lines 
generated 
rAUUCU65  (ATTCT)20 ACTCT (ATTCT)23 ATTCC (ATTCT)15 
ATTTT (ATTCT)7 
7 
rAUUCU67-GFP  (ATTCT)20 ACTCT (ATTCT)25 ATTCC (ATTCT)15 
ATTTT (ATTCT)7 
9 
rAUUCU100+-GFP -  8 
 
Table 7.1: rAUUCU repeat constructs injected into Drosophila. Constructs are 
represented in Figure 8.1A for rAUUCU65 and Figure 8.1B for rAUUCU67-GFP and 
rAUUCU100+-GFP. Interruptions were introduced into repeat tracts during expansion. In all 
cases, multiple independent lines were generated by random P-element mediated 
integration.  
 
Although the repeat copy number of the longest un-tagged rAUUCU repeat 
construct generated is less than those generated for rCAG/rCUG repeats, which 
contain 93 and 114 repeats respectively, the actual length of the repeat tract is 
approximately 300 bp in all cases and therefore the hairpin formed by this RNA 
would be predicted to be approximately the same size as those formed by the   130 
rCAG/rCUG repeats. Furthermore, while the secondary structures formed by 
AUUCU repeats are not as stable as those formed by similar lengths of repeats 
associated with other expanded repeat diseases, rAUUCU RNA containing as few 
as 9 repeats has been demonstrated to form a hairpin structure under physiological 
conditions in vitro (100) and therefore a repeat tract of this size should form a stable 
secondary structure capable of eliciting dominant toxic effects. Expression of up to 
four transgene insertions of either rAUUCU65 or the largest GFP-tagged construct, 
rAUUCU100+-GFP, either in the eye using the GMR-GAL4 driver (Figure 7.2) or in the 
nervous system using the elav-GAL4 driver did not result in a phenotype. 
 
 
Figure 7.2: Expression of 
four transgene insertions 
of an expanded ATTCT 
repeat does not alter the 
exterior appearance of the 
Drosophila eye. Expression 
of constructs is driven by 
GMR-GAL4. A&C) Driving 
expression of four transgene 
insertions of GFP or the UAS 
construct without an insert 
(UAS) results in eyes of wild-type appearance. B&D) Expression of four transgene insertions 
of either rAUUCU65 or the largest GFP-tagged construct (rAUUCU100+-GFP) does not cause a 




7.2 Investigation of cellular localisation of expanded rAUUCU repeats  
 
  One of the mechanisms by which RNA is suggested to act as a pathogenic 
agent in the expanded repeat diseases is through formation of RNA foci which may 
result in the sequestration of RNA binding proteins. Localisation of expanded CUG 
repeat-containing RNAs to foci has been demonstrated in a number of studies using 
either patient tissues or animal models of DM1 (72, 81, 86, 289-290), DM2 (81), HDL-
2 (107) and SCA8 (270). The splicing factor MBNL has been demonstrated to be 
present in foci with CUG repeat-containing RNA both in human tissue and in 
Drosophila models (72, 86, 147, 278), supporting the idea that foci formation is 
involved in pathogenesis and can explain splicing defects observed in DM1 and DM2. 
More recently, CAG repeat-containing RNA has also been demonstrated to be able to 
form RNA foci in Drosophila (71) and it has therefore been suggested that the ability to   131 
aggregate in this manner is a more general property of the expanded repeat-
containing RNAs. It is not clear whether the formation of foci necessarily correlates 
with pathogenesis however, since altered splicing was observed in the presence of 
CUG repeats irrespective of whether foci were evident and was not observed in the 
presence of CAG repeats even when foci were evident (71).  
 
Since the expanded rAUUCU RNA present in SCA10 has also been 
demonstrated to form a stable secondary structure (100), we examined the ability of 
this RNA to localise to foci in Drosophila cells. We expressed four transgene insertions 
of untranslated GFP-tagged CUG, CAA and AUUCU repeats ubiquitously using the 
da-GAL4 driver and cut 10 m sections from 3
rd instar Drosophila larvae. In each 
case, we detected the repeat-containing RNA using a Cy3 labelled oligonucleotide 
probe against the GFP tag – since this allowed us to detect all three repeats under the 
same hybridisation conditions – and co-stained the samples with DAPI to mark the 
nuclei of cells. We frequently observed nuclei with four hybridised spots in cells 
expressing each of the different repeat sequences (Figure 7.3 B, C, E filled arrow 
heads) which we predict are unlikely to be RNA foci, but rather are sites of 
transcription correlating to the four transgene insertion sites. This is supported by the 
observation that larvae expressing GFP without a repeat sequence also show 
hybridised spots in many cells, with the number of hybridised spots observed 
corresponding to the number of transgene insertions being expressed (K. Lawlor, 
unpublished data).  
 
In sections from larvae expressing rCUG-GFP (Figure 7.3 B) and rAUUCU-
GFP (Figure 7.3 D-F) but not rCAA-GFP (Figure 7.3 C), we also observed a subset of 
nuclei which contain a large number of hybridised spots. We predict that these cells 
are likely to be muscle cells because of their morphology. It therefore appears that 
rAUUCU repeat-containing RNA is able to aggregate in a similar manner to rCUG 
repeat RNA in Drosophila and, since aggregation was not observed in cells 
expressing rCAA repeat-containing RNA, that this propensity to aggregate may be 
related to the ability of the RNA to form a stable secondary structure. While these foci 
were only observed in a subset of cells, this may be more indicative of the limitations 
of the detection method and does not necessarily reflect a lack of foci formation in 
other cells such as neurons. It is unclear how these foci in non-neuronal cells relate to 
pathogenesis in neuronal cells in SCA10, however this result points towards common   132 
behaviour of expanded repeat-containing RNA in cells and supports the hypothesis 




Figure 7.3: rAUUCU repeat-containing transcripts form aggregates in a sub-set of 
Drosophila cells. In each case, 3
rd instar larvae expressing four transgene insertions of 
GFP-tagged repeats driven by da-GAL4 were frozen and 10 m cryostat sections were 
performed. All sections cut by K. Lawlor. In all cases, a Cy3-labelled oligonucleotide probe 
specific for the GFP-tag was hybridised. A-F show Cy3 signal, A’-F’ are merged images 
showing DAPI staining overlaid on the Cy3 signal. A, A’) The da-GAL4 stock was out-
crossed to a wild-type stock (w
1118)
 to generate da-GAL4>+ larvae. No specific probe 
hybridisation was detected in this case, even when the image was over-exposed. B, B’) A 
number of CUG-repeat expressing nuclei were observed containing a large number of 
hybridised spots (un-filled arrowhead). Many cells were also observed showing only four 
hybridisation spots (filled arrowhead). C, C’) Expression of CAA repeat RNA tagged with 
GFP did not result in the appearance of RNA aggregates. Some cells were observed with 
up to four hybridisation spots (filled arrowhead), again probably corresponding to the 
location of transcription from the four transgene insertions. D, D’-F, F’) Expression of 
AUUCU repeat RNA resulted in many cells showing four hybridisation spots (filled 
arrowhead). A subset of cells was observed containing multiple hybridisation spots (un-
filled arrows). These spots were not as defined as those observed for the CUG repeat (B) 
but were distinctly different in appearance to those observed when CAA repeat RNA was 
expressed (C).  
 
 
7.3 Identification of transcriptional changes in neuronal cells resulting from 
expression of SCA10 repeats 
 
Whilst rAUUCU RNA has previously been demonstrated to have the ability to 
form a complex hairpin secondary structure in vitro (100) and appears to aggregate 
in a similar manner to CUG repeat RNA in at least a sub-set of cells in our Drosophila   133 
model, the cellular outcomes of expression of the expanded SCA10 repeat have 
never been investigated. If there is a common pathogenic mechanism involving RNA 
toxicity for the expanded repeat diseases, expression of expanded rAUUCU repeat 
RNA would be expected to elicit similar transcriptional changes as those observed for 
rCAG and rCUG expanded repeat RNAs. Microarray analysis was therefore 
performed on flies expressing the rAUUCU65 construct to investigate cellular changes 
resulting from the expression of the SCA10 expanded repeat in Drosophila neurons. 
This experiment was of dual purpose: firstly to test whether expression of rAUUCU 
RNA is sufficient to induce cellular changes which could explain SCA10 disease 
pathology and, secondly, to investigate the similarities and differences between these 
changes and those induced by expression of rCAG and rCUG repeat RNAs. As for 
the analysis of Drosophila expressing expanded rCAG and rCUG repeats, RNA for 
the rAUUCU analysis was extracted from newly eclosed flies in order to identify early 
events in disease progression which may provide insight into causative changes. 
 
Microarray analysis was performed on Drosophila expressing four transgene 
insertions of the untagged rAUUCU65 construct under the control of the elavII-GAL4 
driver. This experiment is therefore the equivalent of microarray experiment 2 for 
rCUG, rCAG and rCAA repeats (as described in Chapter 5.2) and therefore all 
comparisons discussed in this section refer to the data presented for experiment 2. A 
much larger number of genes were identified as changed in flies expressing 
rAUUCU65 compared to the microarray analysis of elav>rCAG and elav>rCUG in 
microarray experiment 2, where only genes commonly altered in two independent 
four insertion lines were further analysed. An independent four transgene insertion 
line for rAUUCU65 was not able to be generated during this study due to an apparent 
bias for insertion of this transgene on chromosome 3. 391 genes were identified 
which showed altered expression in flies expressing rAUUCU RNA compared to both 
elav>+ and elav>rCAA flies (listed in Appendix C, Table C1). This list should not 
contain transcripts which are altered as a result of either GAL4 toxicity or effects of 
rCAA RNA expression and therefore should provide a more robust data set for 
further analysis.   
 
Analysis of functional information for the genes in this list resulted in 
categorisation of the altered genes into a large number of ontologies, with the most 
highly represented categories being “redox regulation” (9.5%), “transcriptional   134 
regulation” (7.2%), “immune response” (8.5%) and “protein modification/ metabolism” 
(5.9%) (Figure 7.4). The majority of genes with known function detected in this 
analysis fell into the same categories as those identified in the analyses of 
elav>rCAG and elav>rCUG flies in microarray experiment 2 (shown in Figure 5.3), 
suggesting that expression of rAUUCU RNA alone is sufficient to induce similar 
cellular changes as expression of rCAG and rCUG repeat RNAs. Since both rCAG 
and rCUG expanded repeat RNAs have been demonstrated to have dominant toxic 
effects (117, 270), this result supports the hypothesis that RNA pathology may also 
play a role in cellular dysfunction in SCA10.  
 
 
7.4 Investigation of common transcriptional changes in flies expressing 
rAUUCU, rCAG and rCUG repeats 
 
  To investigate common effects of hairpin RNA expression, lists of transcripts 
which were altered in flies expressing rAUUCU RNA compared to either elav>rCAA 
or elav>+ flies were generated (log2(ratio)>0.5 or <-0.5). From these lists, genes 
were then selected which were also altered in the same comparison for either 
elav>rCAG or elav>rCUG flies (select transcripts are listed in Figure 7.5 and all 
transcripts are listed in Tables 7.3-7.4 and Appendix C, Table C2-C5). A large 
proportion of genes short listed for elav>rCAG and elav>rCUG compared to either 
elav>rCAA or elav>+ in microarray experiment 2 were also altered in flies expressing 
rAUUCU RNA (Table 7.2): the highest concordance between identified genes was 
71.4% observed between elav>rCUG compared to elav>+ and the same comparison 
for elav>rAUUCU flies and the lowest concordance was 40.7% observed between 
elav>rCAG compared to elav>rCAA and the same comparison for elav>rAUUCU 
flies. Furthermore, of the 9 transcripts commonly altered in flies expressing rCAG and 
rCUG RNA compared to each of elav>rCAA and elav>+, 6 genes were also altered in 
flies expressing rAUUCU RNA compared to elav>rCAA and 7 genes for the 
comparison to elav>+. These genes are listed in Table 7.3 and Table 7.4 
respectively. This result supports our hypothesis that there are common cellular 
changes induced by the expression of hairpin-forming expanded repeat RNAs, 



















Figure 7.4: Gene ontology analysis of 
transcripts altered in Drosophila 
expressing rAUUCU RNA compared to both 
elav>+ and elav>rCAA. In all cases, 
expression of expanded repeat constructs was 
driven by elavII-GAL4. Transcripts were 
selected for log2(ratio) >0.5 or <-0.5 when 
compared to either elav>+ or elav>rCAA flies.  
A) Number of transcripts detected in each 
comparison, filtered so that a “present” call is 
achieved for all lines tested.  Genes with 
transcripts detected in both comparisons are 
listed in Appendix C, Table C1. B) Number of 
genes in each category and the percentage of 
the total number of genes which they 
represent. Categories are as listed in figure 
legend. Genes in the “unknown” category have 
no known function. Gene ontology was 
determined either from known phenotypic data 
or homology with other genes of known 
function. Genes in the “other” category have a 
known or suspected function that does not fit 
into one of the listed categories. 
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Table 7.2: Percent of transcripts commonly 
altered in Drosophila expressing rCAG or 
rCUG repeats and rAUUCU repeats pan-
neuronally. In all cases, expression of 
expanded repeat constructs was driven by 
elavII-GAL4. Transcripts altered in elav>rCAG 
and elav>rCUG flies compared to either elav>+ 
or elav>rCAA were selected for log2(ratio) >0.5 
or <-0.5 (which corresponds to a fold change of 
approximately ±1.4) with P<0.05. The percent of 
these transcripts which are also altered when 
the same comparison is performed for flies 
expressing rAUUCU repeats are listed.  
 
Comparison  Transcripts 
altered 











































Figure 7.5: Comparison of transcripts altered in Drosophila expressing rCAG, rCUG 
and rAUUCU repeats pan-neuronally. In all cases, expression of expanded repeat 
constructs was driven by elavII-GAL4. Transcripts were selected for Log2(ratio) >0.5 or <-0.5 
for each comparison, which represents a fold increase or decrease of 1.4. T-tests were 
performed for genotypes where more than one line was available for analysis and genes 
filtered for P<0.05. A) Number of transcripts altered in elav>rCAG, elav>rCUG and 
elav>rAUUCU flies compared to elav>rCAA.  B) Number of transcripts altered in elav>rCAG, 
elav>rCUG and elav>rAUUCU flies compared to elav>+. C&D) Select genes are listed for 
each comparison. Genes in bold were validated for a role in CAG and CUG repeat 
pathogenesis by genetic means in Chapter 5. Genes identified in each comparison are listed 
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7.4.1 Common transcriptional changes in Drosophila expressing rCAG, rCUG 
and rAUUCU expanded repeats compared to elav>rCAA 
  
A comparison of transcriptional changes in Drosophila expressing rAUUCU 
repeats and rCAG or rCUG repeats compared to elav>rCAA flies resulted in lists of 18 
and 75 common transcripts respectively (Listed in Appendix C, Table C2 and C3). 
Amongst the 18 changes detected which were common to elav>rCAG and 
elav>rAUUCU flies compared to elav>rCAA (summarised in Figure 7.5), the RNA-
binding protein Staufen was found to be downregulated in both genotypes. Staufen has 
been previously identified as a modifier in a screen of a Drosophila SCA8 model (98). 
This model consists of the non-coding CUG repeat-containing SCA8 transcript under 
the control of the UAS-GAL4 system. The observation that expression of Staufen is 
altered in flies expressing rCAG and rAUUCU hairpin RNAs implicates this RNA 
binding protein more broadly in expanded repeat pathogenesis.  
 
In Drosophila, there is a single Staufen protein which has been associated with 
RNA transport processes and is important in localisation of transcripts during 
polarisation of the oocyte (291) and determination of neuroblast asymmetry (292). 
Staufen mutants – along with mutants for several genes encoding RNAs which are 
normally localised by Staufen – show long-term memory defects, suggesting that 
localised translation of RNAs is important for memory formation in Drosophila (293). 
There are two Staufen orthologues in mammals, each encoded by a separate gene. 
While they have similar functions, there is evidence to suggest that they are associated 
with transport of a unique set of mRNAs. Staufen1 also appears to be fairly ubiquitous, 
while Staufen2 is specifically expressed in neurons where it is thought to be important 
in the localisation of RNA to dendrites (193). Staufen2 also plays a role in nuclear RNA 
export via an interaction with Exportin 5 (294) as well as the nucleoporin Nup62 (193), 
a protein which was present in the single commonly downregulated spot observed in 
the proteomics analysis of both elav>rCAG and elav>rCUG flies compared to 
elav>rCAA flies (described in Chapter 4).  
 
A similar analysis of elav>rCUG and elav>rAUUCU compared to elav>rCAA 
revealed 75 transcripts commonly altered (summarised in Figure 7.4 and listed in 
Appendix C, Table C3). These transcripts include the muscle transcription factor mef2 
which was previously demonstrated in this study to be able to modify a CUG-encoded   138 
polyleucine eye phenotype (Chapter 6). Mammalian MEF2 transcription factors have 
been primarily characterised for a role in transcriptional regulation during muscle 
development (295) and neuronal survival (296). Recent studies suggest that MEF2 
also functions with FMRP in eliminating excitatory synapses in a mouse model (275). 
The role of FMRP in regulation of synaptic activity is thought to be regulated via 
alteration of dendritic spine number which is elicited through regulation of transport and 
translation of a particular sub-set of mRNAs (297). The functional interaction between 
MEF2 and FMRP implicates MEF2 in RNA localisation and therefore provides a 
mechanistic relationship via which the expression of hairpin-forming RNAs, which may 
alter RNA transport dynamics in the cell, might alter MEF2 function.  
 
The cytoskeletal adaptor protein insc, was upregulated in elav>rCAG, 
elav>rCUG and elav>rAUUCU flies compared to elav>rCAA (Table 7.3) further 
supporting the idea that cellular transport is generally disrupted by hairpin repeat 
expression. Interestingly, a requirement for Insc in Staufen-mediated RNA localisation 
during neuroblast asymmetrical division has been reported in Drosophila (292), 
supporting a link between alterations to the cytoskeleton and RNA transport processes. 
The observation that components of RNA transport pathways are altered in flies 
expressing rCAG, rCUG and rAUUCU expanded repeat RNA suggests that this effect 
is sequence-independent and may represent a common pathogenic mechanism 
amongst the expanded repeat diseases.  
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Table 7.3: Changes common to elav>rAUUCU, 
elav>rCAG and elav>rCUG flies compared to 
elav>rCAA.  
 
Log2(ratio) >0.5 or <-0.5, selected for P<0.05 for 
elav>rCAG and elav>rCUG comparisons. 
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7.4.2 Common transcriptional changes in Drosophila expressing rCAG, 
rCUG and rAUUCU expanded repeats compared to elav>+ 
 
A comparison of transcriptional changes in Drosophila expressing rAUUCU 
repeats and rCAG or rCUG repeats compared to elav>+ flies resulted in lists of 19 
and 48 common transcripts respectively (Listed in Appendix C, Table C4 and C5). 
Several of these transcripts were previously tested in this study for interactions with 
translated CUG repeats encoding polyleucine or translated CAG and CAA repeats 
encoding polyglutamine (Chapter 6). One of these, mod(mdg4), was previously 
identified in a P-element screen for modifiers of a phenotype caused by expression 
of the human SCA8 non-coding RNA in the Drosophila eye and also showed altered 
expression in both rCAG and rCUG repeat expressing flies in microarray experiment 
1. Reducing mod(mdg4) expression in flies co-expressing CAG-encoded 
polyglutamine or CUG-encoded polyleucine resulted in lethality or a strong 
enhancement in the associated eye phenotypes. Whilst there was also an 
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polyglutamine tract with an RNAi construct targeting mod(mdg4), this interaction did 
not appear to be as strong (Figure 6.3). The finding that mod(mdg4) transcript levels 
are also altered in rAUUCU repeat-expressing flies may suggest a broader role for 
this protein in expanded repeat disease pathogenesis. Since Mod(mdg4) has been 
shown to play a role in chromatin remodelling and gene silencing, this result may 
indicate that structural properties of these repeat tracts at the DNA level also play a 
role in pathogenesis.  
 
Comparing elav>rCUG and elav>rAUUCU to elav>+ also revealed a number 
of interesting transcripts including the cytoskeletal protein and orthologue of ADD1, 
hts, and splicing factor mbl. Both Hts and Mbl have been previously implicated in 
Drosophila expanded repeat disease models (98, 117, 121). In our model, reducing 
expression of hts resulted in suppression of phenotypes associated with expression 
of polyglutamine encoded by either a CAG or CAA repeat or polyleucine encoded by 
a CUG repeat. This result does not demonstrate a sequence-specific interaction 
between Hts and expanded repeats at the RNA level, however it is possible that any 
difference in effect that Hts may have at the RNA level was masked by the 
interaction with polyglutamine. The observation that hts expression is also altered in 
Drosophila expressing rAUUCU repeat RNA supports a role for Hts in RNA toxicity. 
Altering levels of mbl was found to modify eye phenotypes associated with 
expression of translated CUG or CAG repeats in a sequence-dependent manner, 
although overexpression of human MBNL1 in Drosophila did not show the same 
sequence dependence. The splicing factor Bruno – an orthologue of CUG-BP1 
which is the MBNL1 antagonist implicated in DM1 (86) – was also downregulated in 
microarray analysis of rAUUCU repeat expressing flies. These results may indicate a 
broader role for the MBNL/CUG-BP1 pathway in RNA pathogenesis in the expanded 
repeat diseases.  
 
Seven transcripts were altered in all of elav>rCAG, elav>rCUG and 
elav>rAUUCU compared to elav>+ (Table 7.4), 4 of which have functional 
information associated with them. Amongst these is hr38, a nuclear receptor and 
orthologue of mammalian NGFI-B/NUR77 which has been linked to induction of 
apoptosis via translocation to the nucleus (298) as well as inhibition of dendritic 
differentiation and synapse formation (250). NUR77 is highly expressed in the 
striatum and prefrontal cortex (251), regions of the brain which are highly susceptible   141 
to degeneration in Huntington’s disease, and has been demonstrated to be regulated 
by the transcription factors MEF2 and CREB (299), both of which have been 
implicated in expanded repeat disease (273, 277, 300-302). The CREB binding 
protein orthologue nej, the GSK3- orthologue sgg and mef2 also show altered 
expression in flies expressing rAUUCU RNA compared to both elav>+ and 
elav>rCAA controls (Appendix C, Table C1). GSK3- has been demonstrated to 
regulate activity of a large number of transcription factors including CREB (303) and 
MEF2 (296) and has been linked with numerous human diseases including Fragile X 
syndrome (304), Alzheimer’s disease (305), diabetes (306) and a number of cancers 
(307). The identification of altered transcription of the Gsk3- orthologue (sgg) in flies 
expressing expanded untranslated repeat tracts may further implicate it in the 
expanded repeat diseases and therefore a role for GSK3- signalling in RNA toxicity 





Table 7.4: Changes common to elav>rAUUCU, 
elav>rCUG and elav>rCAG flies compared to elav>+.  
 
Log2(ratio) >0.5 or <-0.5, selected for P<0.05 for 
elav>rCAG and elav>rCUG comparisons. 
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7.5 Investigation of a role for the Akt/GSK3-  signalling pathway in expanded 
repeat disease pathogenesis 
 
Glycogen synthase kinase 3 beta (GSK3-) was originally identified for its role 
in regulation of glycogen metabolism, but has more recently been characterised as a 
central regulator of a number of distinct signalling pathways including the Wnt, 
insulin and EGF signalling pathways (308). One mechanism by which GSK3- 
activity can be regulated is through inhibitory phosphorylation by the protein serine-
threonine kinase Akt. This phosphorylation event promotes cell survival and has 
been demonstrated to be dysregulated in Alzheimer’s disease (309). Regulation of 
signalling of the Akt/GSK3- pathway is a complex system which is responsive to 
several different signals including calcium influx and various neurotrophic signals 
(summarised in Figure 7.6). 
 
7.5.1 Evidence for alterations to Akt/GSK3-  signalling in the expanded 
repeat diseases  
 
There are several lines of evidence which implicate alterations in Akt activity 
in expanded repeat disease pathogenesis, including the ability of phosphorylation by 
Akt to regulate activity of several expanded repeat-containing proteins: Akt is able to 
phosphorylate Ataxin-1 (126), the androgen receptor (310) and HTT (287) and 
hence regulate their interactions with other proteins. Upregulation of Akt activity in a 
mouse model of SBMA has also been demonstrated to alleviate pathology by 
reducing aggregation of the mutant androgen receptor, an effect which can also be 
induced through overexpression of IGF-1 (311).  
 
In Drosophila, akt has been identified as a common modifier of phenotypes 
induced by expression of expanded polyglutamine-containing HTT and Ataxin-1 (312). 
Interestingly, altering Akt levels appears to have opposite outcomes in these two 
models, with stabilisation of the expanded polyglutamine-containing Ataxin-1 protein 
increasing toxicity in the SCA1 model and enhanced proteasomal function mitigating 
toxicity in the HD model. In another study investigating polyglutamine-specific changes 
in Drosophila and cell lines, Nelson et al. (2005) identified the target of rapamycin 
(TOR) pathway, which is regulated by Akt activity, as one component that was 
consistently deregulated (244). Hernandez-Hernandez et al. (2006) also report   143 
disruption of Akt/GSK3- signalling in PC12 cells expressing expanded CUG repeats 
which they suggest is mediated through NGF signalling (313). These observations 
suggest that Akt/GSK3- signalling may be disrupted by several mechanisms in 
expanded repeat disease: firstly, by the aggregation of expanded polyglutamine tracts, 
but also by alterations to the physical shape of the polyglutamine tract-containing 
proteins themselves, some of which are targets of Akt. Finally, the expression of 
hairpin-forming RNA species such as CUG repeats may also perturb signalling. This 
pathway may therefore represent a key effector of neurodegeneration in the expanded 
repeat diseases.  
Figure 7.6: Alteration to activity of the Akt/GSK3- signalling pathway can explain a 
number of the changes observed in microarray analysis of flies expressing rCAG, 
rCUG and rAUUCU repeats in the nervous system. Coloured shapes indicate genes 
which showed altered transcript levels in microarray analysis in flies expressing at least one 
of the untranslated repeat constructs. A number of links between Akt activity and expanded 
repeat-containing proteins themselves have also been demonstrated. Akt phosphorylates 
HTT and Ataxin-1 (represented as a star), altering their interactions with other proteins (126, 
287, 314). Phosphorylation of ataxin-3 by GSK3- (star) has also been recently 
demonstrated to regulate nuclear entry and therefore may play a role in SCA3 (315). 
Expression of expanded CUG repeats has also been demonstrated to alter activation of the 
Akt/Gsk3- pathway (313). Activation of Akt can be regulated by a number of different 
signals, including glutamate (316) or neurotrophic (317-318) signals and Ca
2+ signalling 
(319). Activated Akt is in turn involved in downregulation of GSK3- activity which is 
involved in regulation of a number of transcription factors, including MEF2 (296) and CREB 
(303). Both CREB and MEF2 have been demonstrated to play a role in regulation of 
expression of the nuclear receptor NUR77, an orthologue of Drosophila Hr38, in a calcium- 
dependent manner (299). Activation of NUR77 can also be regulated directly by Akt (320). 
The Akt/GSK3- signalling pathway is therefore able to have broad downstream 
transcriptional effects.   144 
Altered transcription of components of the Akt/GSK3- regulatory pathway 
was consistently observed in rCAG, rCUG and rAUUCU repeat-expressing flies by 
microarray analysis, suggesting that this is a key component of cellular dysfunction in 
our Drosophila model of untranslated repeat disease pathogenesis. Transcripts 
which showed altered regulation in the microarray experiments are shown in colour in 
Figure 7.6. Importantly, one of the downstream effectors of this pathway, hr38, was 
consistently upregulated, irrespective of the sequence of the repeat being expressed 
and in comparisons to both the elav>rCAA and elav>+ control lines. Downregulation 
of the Drosophila GSK3- orthologue sgg, as well as the downstream targets mef2, 
mbl and the CREB binding protein orthologue nej was also observed in some cases. 
While the ability of CUG repeat RNA to disrupt Akt/GSK3- signalling has been 
described, this is the first evidence that expression of other hairpin-forming RNA 
species can also influence activity of this pathway.  
 
The initial stimulus resulting in the disruption of Akt/GSK3- signalling in our 
model is unclear, however there is precedent for similar effects in Fragile X syndrome 
where increased levels of stimulation of the mGluR5 receptor have been 
demonstrated to increase GSK3- activity (321). A disruption to mGluR5 signalling 
has also been described in a pre-symptomatic model of HD (322), and in other HD 
models alterations to N-Methyl-D-Aspartate Receptor (NMDAR) (323), brain-derived 
neurotrophic factor (BDNF) (264, 324) and nerve growth factor (NGF) (325) 
signalling, all of which are associated with activation of the Akt/GSK3- pathway, 
have also been observed. Our observations indicate that expression of expanded 
repeat RNA alone is sufficient to cause transcriptional changes to the Akt/GSK3- 
pathway, and therefore that the hairpin RNAs expressed in the disease situation 
might also interact with components of this pathway to disrupt normal signalling.  
 
The mutation-containing gene in Fragile X syndrome, FMRP, is itself an RNA 
binding protein involved in translational regulation and transport of numerous RNAs 
through formation of mRNA/protein complexes. A decrease in FMRP levels perturbs 
neuronal function via dysregulation or mis-localisation of a subset of mRNAs (297). 
This kind of dendritic localisation and translation of specific mRNAs is a repeated 
theme in neuronal signalling: BDNF signalling has also been demonstrated to be 
important for regulation of GSK3- activity and neuron survival (326) and BDNF is 
itself transported and locally translated within neurons (reviewed in (327)).Therefore   145 
expression of hairpin-forming RNAs may be detrimental to neuronal function because 
it causes mis-localisation of other RNA species, possibly through sequestration of 
RNA binding proteins involved in transport and processing, and therefore disrupts 
signalling pathways. Since both the RNA binding proteins themselves and the RNA 
species which they regulate are likely to be specific to certain neuronal sub-types, 
this also offers some explanation of the observation that some cells are more 
vulnerable to degeneration than others. 
 
 
7.5.2 Effect of altering expression of Akt and GSK3-  in our Drosophila 
model of expanded repeat disease pathogenesis 
 
  The Drosophila orthologue of GSK3-, Shaggy (Sgg), has been shown to be 
concentrated at motor-neuron terminals in larvae, where it is involved in the 
regulation of dynamics of the cytoskeleton. Mutations in sgg are associated with 
neuromuscular junction over-growth phenotypes (328). A role for Sgg in 
maintenance of olfactory neurons has also been demonstrated, with loss of activity 
associated with adult degeneration despite normal development (329). 
Phosphorylation of Sgg by the Drosophila Akt kinase (Akt1) is involved in regulation 
of Sgg activity, suggesting that these pathways are largely conserved in Drosophila 
(330).  
 
In order to investigate a role for the Akt/GSK3- pathway in RNA toxicity, the 
effect of altering expression of sgg and akt1 in flies expressing translated expanded 
repeats was initially tested. It is predicted that modification of phenotypes associated 
with expression of polyglutamine encoded by a CAG repeat and polyleucine 
encoded by a CUG repeat, which are both able to form hairpin secondary structures 
at the RNA level, but not polyglutamine encoded by a CAA repeat, which cannot 
form a secondary structure, may be indicative of a specific role for this pathway in 
RNA-mediated toxicity. RNAi lines targeting akt1 and sgg and an overexpression 
construct for sgg were obtained and expressed in the eye with GMR-GAL4. 
Reducing expression of sgg did not result in a disruption to the external appearance 
of the eye (Figure 7.7 D). Co-expression of an RNAi construct targeting sgg with 
polyglutamine encoded by either a CAG or CAA repeat tract did not significantly alter 
the appearance of the eye, although a slight improvement in the ordered 
arrangement of the ommatidial arrays could be seen (Figure 7.7 E&F compared to   146 
A&B). However, reducing expression of sgg in flies expressing polyleucine resulted 
in a reduction in the severity of the eye phenotype, consisting of a complete 
suppression of the rough eye phenotype and a darkening of the colour of the eye 
(Figure 7.7 C compared to G). 
 
Since overexpression of Sgg alone resulted in a severe disruption to the eye 
consisting of a decrease in size, marked lightening of colour and disorganisation of 
the patterning of the ommatidial arrays (Figure 7.7 H), it was more difficult to 
interpret the results of co-expression of the translated repeats in this case. In flies 
ectopically expressing Sgg, co-expression of polyglutamine encoded by either CAG 
or CAA repeats resulted in a significant change to the eye phenotype consisting of a 
significant enlargement of the size of the eye with the appearance of necrotic 
patches and an enhancement of the loss of pigment phenotype (Figure 7.7 I&J 
compared to A&B). It is not clear whether this change in phenotype indicates a 
genetic interaction, or the additive outcome of the polyglutamine and Sgg 
overexpression phenotypes. Co-expression of polyleucine and ectopic Sgg resulted 
in complete lethality which supports the conclusion that there is a stronger effect of 
altering Sgg expression levels in polyleucine-expressing flies than polyglutamine 
flies. 
 
While expression of an RNAi construct targeting akt1 did not disrupt the 
Drosophila eye (Figure 7.7 L), reducing akt1 expression resulted in an increase in 
the loss of pigment in the eyes of both CAG and CAA-encoded polyglutamine 
expressing flies (Figure 7.7 M&N compared to A&B). Co-expression of polyleucine 
with the RNAi construct targeting akt1 also resulted in a loss of pigment phenotype, 
with a complete suppression of the roughness seen when polyleucine is expressed 
alone in the eye (Figure 7.7 O compared to C). It is not clear whether this constitutes 
an increase in the severity of the eye phenotype or an alteration to the pathogenic 
pathway, however it does suggest a role for Akt1 in polyleucine pathogenesis. The 
effects of altering expression of akt1 and sgg in this assay are consistent with what 
is known about the mechanism of regulation of signalling through GSK3- since a 
decrease in Akt1 expression is expected to result in alleviation of Sgg activity 
inhibition and therefore should give a similar effect to overexpression of Sgg. 
However, since both CAA and CAG-encoded polyglutamine expressing flies showed 
similar alterations to the appearance of the eye when Akt1 expression was   147 
decreased or Sgg was ectopically expressed, it is unclear whether hairpin-forming 
expanded repeat RNA plays a role in these interactions or if the effect is mediated 
through an interaction with the polyglutamine peptide. 
 
Figure 7.7: Investigation 
of a role for the 
Akt/GSK3- signalling 
pathway in pathogenesis 
in polyleucine and 
polyglutamine-
expressing Drosophila. 
In all cases, expression of 
constructs is driven by 
GMR-GAL4. A&B) 
Expression of 
polyglutamine encoded by 
either a CAG or CAA 
repeat results in an 
indistinguishable loss of 
pigment eye phenotype. C) 
Expression of polyleucine 
encoded by a CUG repeat 
results in disorganisation of 
patterning of the 
ommatidia. D) Expression 
of an RNAi construct 
targeting transcripts of the 
Drosophila orthologue of 
gsk3- (sgg) does not 
significantly alter the 
appearance of the eye. 
E&F) Reducing expression 
of Sgg in flies expressing 
polyglutamine encoded by 
either CAG or CAA repeats 
does not significantly alter 
the appearance of the eye. 
G) Reducing expression of 
Sgg in flies expressing 
polyleucine completely suppresses the rough eye phenotype and results in darkening of the 
eye. H) Ectopic expression of Sgg in the eye results in a severe rough eye phenotype with a 
dramatic reduction in the size of the eye and the amount of pigmentation. I&J) Co-expression 
of polyglutamine encoded by either a CAG or CAA repeat with ectopically expressed Sgg 
results in an increase in the size of the eye compared to ectopic expression of Sgg alone. 
There appears to be a reduction in the amount of pigment in the eye and in most cases there 
are necrotic patches and nearly complete loss of the ommatidial array structure. K) Ectopic 
expression of Sgg in flies expressing polyleucine is completely lethal. L) Expression of an 
RNAi construct targeting akt1 does not significantly alter the appearance of the eye. M&N) 
Reducing expression of Akt1 in flies expressing polyglutamine encoded by either a CAG or 
CAA repeat results in an increase in the loss of pigment phenotype. O) Reducing levels of 
Akt1 in flies expressing polyleucine suppresses the ommatidial disorganisation seen in flies 
expressing polyleucine alone, but causes a loss of pigment phenotype.    148 
In order to further examine the ability of expanded repeat RNA to disrupt 
signalling through GSK3-, the ability of co-expression of rCAG, rCUG, rAUUCU and 
rCAA repeats to alter the phenotype associated with overexpression of Sgg in the 
Drosophila eye was tested. This phenotype consists of a strong disruption to 
patterning of the eye, a decrease in overall size and a loss of colour (Figure 7.8 
F,F’). Co-expression of four transgene insertions of the UAS construct with no insert 
in flies overexpressing Sgg resulted in a suppression of all components of this 
phenotype, probably as a result of titration of GAL4 by the UAS sites and therefore 
lower expression of ectopic Sgg (Figure 7.8 G,G’). While co-expression of four 
transgene insertions of the rCAA construct did not reduce the loss of colour 
phenotype, a slight increase in the size of the eye and a significant suppression of 
the rough appearance of the surface of the eye were seen (Figure 7.8 I,I’). Again, 
these are likely to be effects of titration of GAL4 in the cells of the eye.  
 
Flies co-expressing rCAG and rAUUCU repeat RNAs with the Sgg 
overexpression construct had rougher eyes than flies co-expressing either the UAS 
construct of rCAA repeat RNA (Figure 7.8 H,H’ & K,K’), which may indicate that 
expression of RNA which is able to form a hairpin structure genetically interacts with 
sgg in Drosophila. This effect was stronger in rCAG repeat expressing flies, possibly 
as a result of the greater stability of the secondary structure formed by this repeat 
sequence compared to rAUUCU repeats. In support of a hairpin-dependent 
interaction between sgg and expanded repeat RNA, co-expression of rCUG repeat 
RNA with the Sgg overexpression construct resulted in complete lethality. This result 
is also consistent with the lethality observed when Sgg was overexpressed in 
polyleucine expressing flies, which may indicate that the interaction observed with 
polyleucine is also mediated by expanded repeat RNA and not the polyleucine 
peptide. Expression of hairpin-forming RNA species therefore seems sufficient to 
perturb signalling through GSK3- in our Drosophila model, although this effect is 
significantly stronger in flies expressing CUG repeats. GSK3- signalling may 
therefore represent a common pathogenic pathway in the expanded repeat 
diseases.   149 
 
 
Figure 7.8: Investigation of a role for the Akt/GSK3- signalling pathway in RNA-
mediated pathogenesis in Drosophila. In all cases, expression of repeats and the UAS-
Sgg construct are driven by GMR-GAL4. Set 1 and 2 refer to progeny from independent 
crosses. A-E) Expression of four transgene insertions of the UAS construct with no insert 
(UAS) or containing the rCAG, rCAA, rCUG or rAUUCU repeats does not alter the external 
appearance of the eye. F, F’) Overexpression of Sgg in the eye results in a strong disruption 
to patterning, a decrease in overall size and a loss of colour. G, G’) Co-expression of four 
transgene insertions of the UAS construct with the Sgg overexpression construct 
dramatically decreases the loss of colour and improves patterning in the eye. I, I’) Co-
expression of four transgene insertions of the rCAA construct with the Sgg overexpression 
construct improves the patterning of the eye and increases the overall size of the eye but 
does not alter the colour compared to expression of Sgg alone. H, H’ & K, K’) Co-
expression of the rCAG or rAUUCU repeat constructs with the Sgg overexpression construct 
results in eyes which are consistently rougher than those of flies co-expressing either rCAA 
or the UAS construct with Sgg. J, J’) Co-expression of rCUG with the Sgg overexpression 




7.6 Validation of an interaction between rAUUCU RNA and mod(mdg4), mbl and 
mef2 in Drosophila 
 
  A number of other candidate genes which showed altered expression in 
flies expressing rCAG and rCUG repeats pan-neuronally were also altered in 
rAUUCU repeat expressing flies. In order to further investigate the role of these   150 
candidate genes in SCA10 pathogenesis, the ability of altering expression of mbl, 
mef2 and mod(mdg4) to induce a phenotype in flies expressing the rAUUCU repeat 
RNA was also tested. Since no phenotype was elicited by expression of rAUUCU 
repeat RNA alone, only expression changes which increase the toxicity of this repeat 
RNA can be identified in this case and therefore candidates were chosen on the 
basis that they were previously demonstrated to enhance toxicity in translated CUG 
and CAG repeat-expressing flies. For two of the candidates, mef2 and mod(mdg4), 
reducing expression was also demonstrated to enhance toxicity of untranslated CUG 
repeats, further supporting a role for these genes in RNA toxicity. In rat cerebellar 
neurons, MEF2D activity has been shown to be regulated by GSK3- signalling 
(296) while in Drosophila, regulation of mbl by Mef2 has been demonstrated (273). 
These observations suggest a mechanism by which expression of mef2 and mbl 
might be altered in response to expression of expanded repeat RNA.  
 
  Expression of RNAi constructs targeting mef2 and mod(mdg4) has 
previously been demonstrated to have no effect on the appearance of the 
Drosophila eye (Figure 6.5 E&I). Co-expression of these RNAi constructs with four 
transgene insertions of the rAUUCU65 construct driven by GMR-GAL4 did not result 
in a disruption in the external patterning of the eye (Figure 7.9 B&C). Similarly, 
expression of four transgene insertions of the rAUUCU65 construct in the eye of flies 
heterozygous for the mbl
E27 loss of function allele did not result in any change in the 
appearance of the eye. This result, along with the inability of alterations in these 
candidate genes to elicit a phenotype in flies expressing rCAG repeat RNA, may 
indicate that there are real differences in the degree or mechanism of toxicity of 
rCUG repeat RNA in this model. However, since expression of rAUUCU repeats was 
able to induce similar transcriptional changes to those induced in rCUG repeat-
expressing flies, a difference in the degree of toxicity and not the actual mechanism 
seems to be a more likely explanation. It is unclear whether this difference is a 
feature of greater tolerance for some repeat sequences in Drosophila or a more 
general property of the repeat sequences themselves, which may therefore be 
relevant to disease pathology.  151 






RNA. In all cases, 
rAUUCU repeat RNA 
and RNAi construct 
expression was driven 
by GMR-GAL4. A) Expression of four transgene insertions of the rAUUCU65 construct does 
not cause any disruption to the exterior appearance of the eye. B-C) Co-expression of RNAi 
constructs targeting mef2 or mod(mdg4) with four transgene insertions of the rAUUCU65 
construct does not cause any disruption to the exterior patterning of the eye. D) Expression 
of four transgene insertions of the rAUUCU65 construct in flies heterozygous for mbl
E27 also 





7.7 Further investigation of a role for MBNL1 in expanded repeat pathogenesis  
 
  Since MBNL has been demonstrated to co-localise with both expanded 
CAG and CUG repeat-containing transcripts in a number of disease models, a 
central role for this splicing factor in RNA pathogenesis has been suggested. While 
altering expression of the Drosophila orthologue of MBNL, Mbl, was not able to elicit 
a phenotype in flies expressing the expanded rAUUCU repeat construct, it is 
possible that there are differences in the binding capacity of the Drosophila and 
human proteins and therefore the ability of rAUUCU repeat RNA to interact with 
MBNL1 in this model was also investigated. The effect of expression of both the 
rAUUCU65 and rAUUCU100+-GFP constructs in the eye on the phenotype observed 
when human MBNL1 is expressed alone was tested.  
 
  Flies co-expressing MBNL1 with four transgene insertions of GFP alone 
(GFP) or four transgene insertions of the UAS construct alone (UAS) were used as 
controls for these crosses. Co-expression of the UAS control takes into account the 
contribution of GAL4 toxicity to the MBNL1 eye phenotype, since the presence of 
four transgene insertions of the UAS construct should reduce the amount of free 
GAL4 in the cells of the eye in the same manner as the four transgene insertions of 
the repeat constructs (Figure 7.10 B). Similarly, co-expression of four transgene 
insertions of the GFP construct takes into account the contribution of GAL4 toxicity 
but also the effect of GFP expression on the eye phenotype and therefore is the 
appropriate control for flies expressing the GFP tagged rAUUCU100+-GFP construct.    152 
Flies co-expressing either UAS or GFP with MBNL1 showed an increase in the size 
of the eye compared to those expressing MBNL1 alone (Figure 7.10 A compared to 
B and D), however eyes of GFP-expressing flies appeared less rough and had 
lighter colour than eyes of UAS-expressing flies (Figure 7.10 C) which suggests that 
there is some difference in the effect of expression of these constructs.  
 
Figure 7.10: Interaction of rAUUCU repeats with MBNL1 in the Drosophila eye. All 
constructs are driven in the eye by GMR-GAL4 and flies were grown at 23 ºC. A) 
Expression of MBNL1 in the eye results in a rough eye phenotype with necrotic patches. 
B) Expression of MBNL1 and the UAS control results in an increase in the size of the eye 
compared to expression of MBNL1 alone. C) Co-expression of rAUUCU65 with MBNL1 
results in a slight decrease in the size of the eye compared to co-expression with the UAS 
control. However, since the eye appears lighter in colour and has fewer necrotic patches, 
it is unclear whether this demonstrates an enhancement. D)  Expression of MBNL1 and 
GFP alone results in a mild rough appearance of the eye with no necrotic patches evident. 
E) Co-expression of rAUUCU100+-GFP with MBNL1 results in a slight enhancement 
compared to the eye phenotypes seen when MBNL1 is co-expressed with GFP alone. 
Eyes appear smaller and slightly darker in colour, with more necrotic patches evident. 
  
 
  Expression of the un-tagged rAUUCU65 construct resulted in a slight 
decrease in the size of the eye compared to flies co-expressing MBNL1 and UAS, 
however the eye also appeared to have a smaller area of roughness and necrosis 
and therefore it is unclear whether this indicates an interaction between MBNL1 and 
rAUUCU RNA (Figure 7.10 B compared to D). A mild enhancement, consisting of an 
increase in the appearance of necrotic patches and a decrease in the size of the 
eye, was observed when the effect of co-expression of rAUUCU100+-GFP RNA with 
MBNL1 was compared to co-expression of MBNL1 with GFP alone (Figure 7.10 C 
compared to E) suggesting that rAUUCU-GFP RNA may interact with MBNL1, 
however this was not a strong effect. These results demonstrate inconsistency in the 
ability of rAUUCU repeat-containing RNA to interact with MBNL1 which appears to 
depend upon the context of the repeat tract. This effect could be the result of 
differences in the stability or localisation of each of the repeat-containing transcripts.    153 
7.8 Summary of Drosophila model for SCA10 
 
This is the first study to model toxicity of the rAUUCU repeat RNA associated 
with SCA10. Using expression of this repeat tract in Drosophila, the ability of 
rAUUCU repeat-containing RNA to form foci reminiscent of those observed in models 
of DM1 in vivo was demonstrated in a subset of Drosophila cells. This result supports 
the idea that the rAUUCU repeat RNA may have a dominant toxic effect in the cell 
and may induce pathology through a similar mechanism to other expanded repeat 
RNAs.  
 
Analysis of the transcriptional changes resulting from expression of rAUUCU 
repeats in Drosophila neurons further supported the hypothesis that this expanded 
repeat RNA alone may be sufficient to induce cellular changes which could result in 
neurodegeneration over an extended period of time. The degree of concordance in 
genes altered by expression of rAUUCU RNA with those previously detected as 
altered in rCAG and rCUG repeat-expressing flies, as well as the identification of a 
number of genes already associated with repeat pathology in different models, 
strongly supports our hypothesis that expression of expanded repeat RNA alone is 
sufficient to induce cellular changes consistent with pathology in a sequence-
independent manner. This finding is consistent with a model where expression of 
hairpin-forming RNA may sequester RNA binding proteins and thus cause mis-
localisation and subsequent dysregulation of RNA species, although this is likely to 
be only one component of disease pathology.  
 
Analysis of the common changes identified in flies expressing rCUG, rCAG 
and rAUUCU repeat RNA identified hr38 which is a down-stream effector of the 
Akt/GSK3- signalling pathway. This observation suggests that this pathway is likely 
to be important in disease pathology and therefore that components of this pathway 
may be useful therapeutic targets. An interaction was observed between the 
Drosophila GSK3- orthologue, sgg, and rCAG, rCUG and rAUUCU RNAs 
suggesting that the ability of the RNA to form a secondary structure, but not the 
sequence of the repeat itself, is important for an interaction. This result supports a 
role for signalling through the Akt/GSK3- pathway in pathogenesis of both translated 
and untranslated repeat diseases.    154   155 
Chapter 8: Discussion 
 
8.1 Summary of results 
 
  The principle aim of this study was to investigate the cellular pathways 
involved in toxicity of expanded repeat RNA. Recent evidence (117) suggests a 
common role for RNA-mediated toxicity in both the translated and untranslated 
repeat diseases and therefore understanding the mechanism by which the expansion 
of repeat tracts can be pathogenic at the RNA level is vital to the development of 
effective therapies for these diseases. Initial experiments in this study tested the 
intrinsic pathogenicity of a CUG repeat tract, which is the repeat involved in DM1, 
SCA8 and HDL-2, and a CAG repeat tract, which is the repeat associated with all of 
the polyglutamine diseases as well as the untranslated repeat disease, SCA12.  
 
The focus of this initial investigation was the elucidation of common pathways 
of pathogenesis in untranslated rCUG and rCAG repeat expressing flies, since these 
repeat RNAs form strikingly similar secondary structures and therefore may perturb 
cellular function in a similar manner. Expression of an expanded CAA repeat RNA 
was used as a control, as it is unable to form this type of structure. Early alterations 
to cellular homeostasis were identified in newly eclosed Drosophila expressing each 
of these repeat sequences pan-neuronally by both microarray and proteomic 
analysis. Applying this method should allow the identification of the primary outcomes 
of neuronal hairpin RNA expression, which may be the cause of neural dysfunction 
and death in the disease situation. A role for candidates identified in this manner was 
then genetically verified by altering expression in the eye of flies expressing hairpin-
forming expanded repeat RNA.  
 
Since expression of untranslated CAG and CUG RNA repeats does not cause 
a neuronal phenotype or a disruption to the organisation of the eye in this Drosophila 
model, initial screening of these candidates tested their ability to modify phenotypes 
caused by expression of translated repeat sequences. This type of approach has 
been previously used to uncover components of RNA pathogenesis in a Drosophila 
model of SCA3 pathogenesis (117). Both translated CAG and CAA repeats encode 
polyglutamine and expression of either repeat in the Drosophila eye as part of an 
open reading frame causes a severe disruption to patterning of the eye. In the case   156 
of the lines used in this study, this disruption mainly consists of a loss of pigment eye 
phenotype. Expression of translated CUG repeat RNA, which encodes a polyleucine 
tract, causes a distinct phenotype mainly consisting of a roughening of the surface of 
the eye. Several candidates identified by microarray or proteomic analyses of flies 
expressing untranslated hairpin (rCAG and rCUG) repeats also showed some 
genetic interaction in translated CAG and CUG repeat-expressing flies, supporting a 
functional role in expanded repeat pathogenesis in this model. Amongst these 
candidates were genes and proteins involved in functions including nuclear transport, 
chromatin modification, splicing and transcriptional regulation. A select group of 
these candidates was then tested for the ability to induce a phenotype in flies 
expressing expanded untranslated repeats in the Drosophila eye. Expression of 
RNAi constructs targeting two of these candidates, mod(mdg4) and mef2, or 
expression of untranslated rCUG RNA alone does not elicit a phenotype in the 
Drosophila eye. However, co-expression of untranslated rCUG RNA and either of 
these RNAi constructs in the eye induces a significant disruption to the eye, 
suggesting that mod(mdg4) and mef2 represent rate-limiting steps in RNA 
pathogenesis in this Drosophila model.  
 
Subsequent generation of a Drosophila model of SCA10 pathogenesis 
allowed investigation of the cellular outcomes of expression of an expanded repeat 
tract with distinctly different sequence composition; in this case a pentanucleotide 
AUUCU repeat. Microarray analysis was also performed on the Drosophila SCA10 
model to determine whether similar cellular perturbation is induced by expression of 
other hairpin-forming disease-associated sequences. A large amount of concordance 
with the transcriptional changes observed when untranslated rCAG and rCUG RNAs 
were expressed was seen in flies expressing the untranslated rAUUCU RNA, 
consistent with a common RNA hairpin-mediated pathogenic mechanism in this 
Drosophila model. Performing comparisons with the different repeat sequences also 
highlighted common transcriptional changes in a number of down-stream effectors of 
the Akt/GSK-3 signalling pathway in flies expressing rCAG, rCUG or rAUUCU 
repeat RNAs. An interaction between the Drosophila orthologue of GSK-3 (Sgg) 
and untranslated rCAG, rCUG and rAUUCU repeats was observed in the Drosophila 
eye, further supporting a role for this pathway in pathogenesis. Using this Drosophila 
SCA10 model, the ability of this pentanucleotide repeat sequence to form RNA foci in 
a similar manner to those reported for CAG and CUG repeat RNAs was also   157 
demonstrated. It was therefore concluded that formation of RNA foci, which may be 
regions of high concentration of RNA binding proteins, may also be one outcome of 
repeat expansion in the SCA10 transcript. The pathogenic potential of RNA foci in 
expanded repeat disease requires further investigation. 
 
One mechanism by which expanded repeat RNA has been proposed to be 
toxic is through the sequestration of RNA binding proteins which can result in a loss 
or reduction of the normal activity of the protein. In DM1, the splicing factor MBNL 
has been implicated as playing a major role in pathogenesis through a reduction in 
splicing activity resulting from sequestration by CUG repeat RNA. A role for altered 
activity of the RNA editing protein Adar was investigated in Drosophila expressing 
CAG repeat transcripts, since a reduction in editing of the normal targets of this 
enzyme is known to have dramatic neurological effects. No role for the Drosophila 
editing enzyme Adar in either polyglutamine pathogenesis or pathogenesis of 
untranslated CAG repeat RNA was observed in this model, however this does not 
rule out a role for the human enzyme in disease pathogenesis.  
 
 
8.2 Implications for expanded repeat disease pathogenesis 
 
The results presented in this study have demonstrated the ability of 
expression of hairpin RNA alone to perturb cellular homeostasis and, in conjunction 
with other components, to act as a cellular toxin. Given the degree of concordance in 
the pathways disrupted by expression of different repeat sequences, this study also 
suggests a sequence-independent element to pathogenesis in this Drosophila model 
of expanded repeat disease. Nevertheless, since expression of untranslated 
expanded repeat tracts in Drosophila is not sufficient to induce degeneration within 
the life-time of the fly – while expression of polyglutamine results in severe early 
degeneration irrespective of whether it is encoded by a hairpin-forming CAG repeat 
or a non-hairpin-forming CAA repeat – the extent to which RNA-mediated toxicity 
contributes to phenotypes in polyglutamine-expressing Drosophila remains unclear. 
Evidence from other Drosophila models supports a requirement for high levels of 
hairpin repeat RNA expression to induce degeneration (117), while expression of 
polyglutamine peptide is consistently highly toxic from early in development (61,   158 
109). It is unclear whether this high tolerance for expression of hairpin-forming RNAs 
is a unique feature of Drosophila. 
 
Since the expanded repeat diseases generally involve late onset 
degeneration, the high level of toxicity induced by expression of polyglutamine in this 
model does not appear consistent with the slow progression seen in the 
polyglutamine diseases. It has been demonstrated that introduction of amino acids 
outside of the polyglutamine tract can mitigate toxicity in a Drosophila model (109), 
suggesting that context plays a major role in determining toxicity in the polyglutamine 
diseases. Furthermore, evidence from other Drosophila models of untranslated 
repeat disease pathogenesis supports a similar role for regions outside of the 
expanded repeat tract in determining toxicity of expanded repeat RNA (86, 98). It is 
therefore possible that the polyglutamine diseases demonstrate a greater 
contribution of RNA-mediated pathogenesis and a lesser contribution of 
polyglutamine pathogenesis than what is seen in this Drosophila model. In the case 
of the untranslated expanded repeat diseases where there is no toxic peptide 
expressed, RNA-mediated pathogenesis is presumably sufficient to induce all of the 
cellular changes leading to neurodegeneration. It is likely that the sorts of changes 
observed in this model represent components of pathogenesis in these diseases, but 
that there are also specific effects of expression of the repeat-containing transcript in 
each disease which are dependent on the context of the repeat tract. Nevertheless, 
several candidates which showed strong interactions with the context-independent 
repeats used in this study, including Mod(mdg4) and Mbl, have been previously 
identified in other Drosophila models which used repeats within the disease context 
(98, 117), suggesting that sequence-independent toxicity does play a role.  
 
 
8.3 Limitations of the Drosophila model 
 
In this study, microarray and proteomic analyses were performed to identify 
early transcriptional and protein changes which should represent hallmarks of RNA-
mediated pathogenesis in Drosophila. While each of these techniques is useful in 
identifying global cellular changes resulting from a particular treatment, they are not 
comprehensive identification methods. Microarray analysis is limited not only by the 
number of transcripts represented on the chip, but also by the detection threshold set 
for analysis which, for the purposes of this study, was deliberately set at a very   159 
stringent level in order to produce a robust data set. Proteomic analyses are largely 
limited by the abundance of proteins and their ability to be properly resolved on the 
gel and therefore generally only a small proportion of the total number of proteins 
from any organism are able to be detected and identified. The candidates 
investigated in this study are therefore likely to represent only a small number of all of 
the genes and proteins altered by expression of expanded repeat RNA. Furthermore, 
in this preliminary investigation of pathogenic pathways, candidates were chosen 
preferentially on the basis that they were commonly altered in flies expressing more 
than one of the repeat sequences and therefore this study does not attempt to 
investigate sequence-dependent effects of expression of each of the repeat 
sequences.  
 
In using the Drosophila eye to model expanded repeat pathogenesis, it is also 
important to remember that expression of the toxic species is being induced in cells 
of both neuronal and non-neuronal origin. Therefore, the results obtained by 
screening candidates in this manner should be considered only as preliminary 
evidence for an interaction (or lack of interaction) with expanded repeats. 
Nevertheless, this sort of strategy is routinely used in Drosophila studies and has 
previously been successfully applied to identification of modifiers of 
neurodegenerative phenotypes. It should be noted, however, that since the 
candidates tested using the Drosophila eye in this study were identified in flies 
expressing expanded repeat RNA specifically in the neurons, it is quite possible that 
some of them are either more or less toxic in non-neuronal cells in the Drosophila 
eye than they may be in neurons. A Drosophila study examining the ability of 
modifiers of polyglutamine-induced eye phenotypes to similarly alter polyglutamine 
toxicity in post-mitotic neurons demonstrated that in a large number of cases 
examination of interactions in the eye and the brain does give consistent results. 
Nevertheless, there were three cases identified in this study where candidates which 
were able to enhance the polyglutamine eye phenotype had no effect on 
polyglutamine toxicity in the brain (331). For this reason, candidates identified in this 
study should be further investigated for their specific effect in neurons. Given that 
expression of these rCAG, rCUG or rAUUCU repeats does not appear to induce 
degeneration within the life-time of the fly when expressed pan-neuronally, one way 
in which this could be done is to investigate the ability of expression of these repeat   160 
sequences to modify phenotypes associated with altered expression of the candidate 
genes in the nervous system. 
 
 
8.4 Further Experiments 
 
The results presented in this study are a preliminary examination of cellular 
processes which are disrupted in Drosophila expressing different expanded repeat 
sequences. Analyses performed in this study have successfully identified a number 
of candidates which show a genetic interaction with expanded repeats and therefore 
there are likely to be more functional interactors amongst the remaining data 
obtained by microarray and proteomic analysis. While there are indications that some 
common pathways are disrupted by expression of different hairpin-forming repeat 
sequences, candidates which should be further investigated are those which are 
altered uniquely in response to expression of particular repeat sequences, since 
these are likely to represent specific pathways involved in different expanded repeat 
diseases. Given that the candidates tested so far consistently showed stronger 
genetic interactions with untranslated CUG repeat RNA, it seems likely that there are 
also other pathogenic mechanisms at play in CAG and AUUCU RNA pathogenesis. It 
will also be important to confirm that these candidates, or the pathways in which they 
are involved, are altered during pathogenesis in the human diseases. 
 
  Following from the results described in this thesis, a model investigating the 
context-dependence of CAG repeat toxicity is being generated. This model will test 
the ability of an expanded CAG repeat tract within the context of the human ataxin-12 
5’UTR, the only known example of an untranslated expanded CAG repeat involved in 
human disease, to induce neurodegeneration. The ability of candidates identified in 
the model of intrinsic rCAG repeat RNA toxicity described in this study to interact with 
this repeat tract will provide information regarding the degree of context-
independence involved in pathogenesis in SCA12. Investigation of unique 
perturbations resulting from expression of the SCA12 non-coding RNA will also 
provide insight into disease-specific pathogenic pathways.  
 
Since the commencement of this study, there have also been reports of 
situations where bi-directional transcription in the region containing the expanded   161 
repeat tract can result in the expression of perfectly double-stranded RNA species in 
SCA8 and FXTAS (97, 332). This finding has led to suggestions that hairpin RNA 
may only be one component of pathogenesis and that the formation of perfectly 
double-stranded RNAs may also cause cellular dysfunction. The ability of this sort of 
RNA species to induce neuronal dysfunction is also being tested using this 
Drosophila system and will provide information on the contribution of this pathogenic 
agent in the human disease. The results obtained in this and other studies suggest 
that hairpin-forming repeat RNAs have the potential to play a role in pathogenesis of 
the expanded repeat diseases. Further use of Drosophila to investigate the 
contribution of different sorts of RNA species in both the polyglutamine and 
untranslated repeat diseases – that is hairpin RNAs versus perfectly double-stranded 
RNAs – as well as the role of the expanded polyglutamine peptide in the 
polyglutamine diseases will provide information on the degree to which each one of 
these agents is responsible for the degeneration seen in the disease situation. An 
understanding of the molecular components and pathways of pathogenesis will 








elav>+  c155 
elav>rCAG  “C+D” 
elav>rCUG  “A+B” 
elav>rCAA  “A+B” 
 
Table A1: Genotypes of flies analysed by 2D DIGE analysis. All repeat-expressing flies 
carry 2 insertions of the respective expanded repeat construct driven by the elav
c155–GAL4 
driver. The control elav>+ line is the elav
c155–GAL4 driver line out-crossed to the wild-type 
w
1118 line. Letters are arbitrarily used to denote independent insertions of each repeat 
transgene and in each case, insertions on the same chromosome have been recombined to 







T-test  Average 
ratio  T-test  Average 
ratio 
215 0.041  -1.25  0.036  -1.29 
363 0.009  -1.38  0.032  -1.3 
368 0.034  1.28  0.004  1.27 
373 0.034  1.22  0.001  1.24 
449 0.047  1.47  0.022  1.53 
550 0.036  1.39  0.046  1.31 
712 0.035  1.34  0.037  1.34 
713 0.026  1.46  0.028  1.42 
940 0.015  1.27  0.013  1.32 
1183 0.003  1.44  0.004  1.48 
1439 0.016  1.21  0.041  1.22 
1444 0.016  1.63  0.007  1.65 
1467 0.002  1.4 0.001  1.44 
1520 0.029  1.57  0.010  1.47 
1526 0.025  1.40  0.039  1.35 
1593 0.039  -1.40  0.006  -1.46 
1622 0.015  -1.57  2.2E-5  -1.54 
1778 0.007  -1.51  0.006  -1.51 
1911 0.049  1.47  0.023  1.46 
1974 0.024  -1.77  0.029  -1.86 
1983 0.013  -1.38  0.015  -1.37 
1989 0.011  1.45  0.013  1.32 
2040 0.022  -1.55  0.008  -1.45 
2049 0.022  -1.63  0.004  -1.58 
2300 0.025  1.62  0.043  1.46 
 
Table A2: Spots altered in elav>rCAA and elav>rCAG flies compared to elav>+. The 
average ratio is the average change in spot intensity compared to elav>+ across the four 
gels for each genotype. Spots were selected for P<0.05.  164 
 
 
Table A3: Spots altered in elav>rCAA and elav>rCUG flies compared to elav>+. The 
average ratio is the average change in spot intensity compared to elav>+ across the four 









elav>rCAA elav>rCAG elav>rCUG 
Spot Number 
T-test  Average 
ratio  T-test  Average 
ratio  T-test  Average 
ratio 
595 9.6E-4  1.51  4.6E-4  1.53  0.012  1.35 
704  0.012 -1.54 0.002 -1.59 0.018 -1.36 
1472  0.015 -1.52 0.002 -1.49 0.008 -1.37 
2361  0.008 -4.09 0.013 -3.55 0.016 2.43 
 
Table A4: Spots altered in elav>rCAA, elav>rCAG and elav>rCUG compared to elav>+.  
The average ratio is the average change in spot intensity compared to elav>+ across the four 











w1118-1 w1118-2 w1118-3 MB01457-1 MB01457-2 MB01457-3
 
 
Figure A5: Transcript levels of DPx-2540-1 normalised to rp49. Quantitative real time 
PCR was performed on biological triplicates of w
1118 and the MB01457 insertion line. 




T-test  Average 
ratio  T-test  Average 
ratio 
914 0.042  -1.24  0.020  -1.32 
1497 0.006  -1.71  0.003  -1.43 
1962 1.5E-5  1.27  0.003  1.35 
1966 0.018  -1.35  0.017  -1.27 
w
1118  MB01457




T-test  Average 
ratio 
1101 0.001  -1.51 
1136 0.010  -1.79 
1738 0.047  -1.53 
 
Table A6: Spots altered in elav>rCAG flies compared to elav>rCAA. Average ratio is the 
average change in spot intensity compared to elav>rCAA across the four gels for each 
genotype. Spots were selected for P<0.05, average ratio >1.5 or <-1.5. Bold text indicates 








elav>rCUG  Spot 
Number  T-test  Average 
ratio 
185 0.021  -1.54 
366 0.037  -1.68 
393 0.038  -2.85 
402 0.035  -1.72 
668 0.009  -1.6 
970 0.044  -1.53 
1101 3.50E-04  -1.51 
1403 0.002  -1.84 
1520 0.031  1.78 
1531 0.002  1.72 
1566 0.016  -1.53 
1573 0.036  -2.12 
1895 5.40E-05  -1.67 
1896 0.003  1.52 
1983 8.00E-05  -1.74 
1998 0.001  -1.55 
2026 4.40E-06  1.72 
2027 4.40E-06  -1.66 
2169 1.40E-05  2.21 
2361 3.20E-04  9.93 
2455 0.023  -1.79 
2495 0.025  -1.59 
2542 0.012  -1.66 
2552 0.035  1.83 
2621 0.035  1.95 
2665 0.014  1.68 
2681 0.038  -1.58 
 
Table A7: Spots altered in elav>rCUG flies compared to elav>rCAA. Average ratio is the 
average change in spot intensity compared to elav>rCAA across the four gels for each 
genotype. Spots were selected for P<0.05, average ratio >1.5 or <-1.5. Bold text indicates 






Genotype Line  Insertions  Insertion 
Chromosome 
elav>rCAG  Line 1  “A+E”  2 
 Line  2  “C+D”  2 
 Line  3  “G+I”  3 
elav>rCUG  Line 1  “A+B”  2 
 Line  2  “C+D”  2 
 Line  3  “E+F”  3 
elav>rCAA  Line 1  “A+B”  2 
 Line  2  “C+I”  2 
 Line  3  “E+F”  3 
elav>+  -  -  - 
 
Table B1: Genotypes of two insertion repeat lines analysed in microarray experiment 
1. All repeat-expressing flies contain 2 insertions of the respective expanded repeat construct 
driven by the elav–GAL4 driver. The control “elav>+” line is the elav–GAL4 driver line out-
crossed to the wild-type w
1118 line. Letters are arbitrarily used to denote independent 
insertions of each repeat transgene and in each case 2 insertions on the same chromosome 







Construct Line Insertions  Insertion 
Chromosomes 
rCAG  Line 1  “A+E+G+I”  2,3 
  Line 2  “J+K+D+H”  1,2 
rCUG  Line 1  “C+D+E+F”  2,3 
  Line 2  “H+I+J+G”  2,3 
rCAA  Line 1  “C+I+E+F”  2,3 
  Line 2  “A+B+G+H”  2,3 
 
Table B2: Genotypes of four insertion repeat lines analysed in microarray experiment 
2 and MBNL interactions. Letters are arbitrarily used to denote independent insertions of 
each repeat transgene and in each case 2 insertions on the same chromosome have been 
recombined to make 2 insertion lines. Four insertion lines consist of two insertions on each 
chromosome listed. In the microarray experiment, expression of these constructs was driven 
by the elav-GAL4 driver inserted on the second chromosome.   167 
Table B3: Genes altered in elav
 >rCAG flies compared to elav>
 rCAA in microarray 
experiment 1. Selected for Log2(ratio) >0.5 or <-0.5, P<0.05. 
 















ATP5E mitochondrial ATP synthase 
epsilon chain 




 Immune response 




 Serine-type endopeptidase 














ZNF650 Ubiquitin protein ligase 




CAP1 adenylate cyclase associated 






CG31613 -0.88 -0.65 HIST2H3 H3 histone 













HIST1H1 H1 histone 
molting 
defective













HIST2H3 H3 histone 




USP9X Ubiquitin-specific protease 









PCDH15 protocadherin 15 precursor, 
smoothened signaling 
pathway, cell-cell adhesion 












CRSP6 co-factor for Sp1, 
transcription co-activator 




BCAR3 Tyrosine kinase, estrogen 
independent cell division, cell 
cycle regulation 




CCDC102A Tropomyosin, component of 
myosin complex 














GYG1 Glycogenin, mesoderm 
development 




    168 















NFXL1 Nuclear transcription factor 






















TOMM40 mitochondrial import receptor 




PLSCR1 Phospholipid scramblase, 
synaptic transmission 




GPATC1 RNA processing 




 Cuticle protein 









MBNL1 RNA binding 
prickle-spiny 
legs




PRICKLE2 neurite outgrowth 


































SLC39A2 zinc transporter 














DDI1 DNA damage repair 




 Cuticle protein 












 Sensory perception of 
chemical stimulus 




    169 















SFRS16 Splicing factor, 
arginine/serine-rich 16 



















GPS2 Component of NCoR-HDAC3 
complex 




REV1 DNA-template dependent 
dCMP transferase, DNA 
lesion bypass 




 Cell adhesion 









ROBO1 axon guidance receptor 
wolfram 
syndrome 1




WFS1 modulates free calcium in 
ER, regulated by Sp1 
serendipity 
beta














ZMIZ1 transcriptional coactivator 




SP1 Transcription factor 




PDZK8 Intracellular signaling 
cascade, DAG binding 
























CXXC1 regulation of histone 
modification and cytosine 
methylation 





















TIMM50 Translocase of inner 
mitochondrial membrane 




COQ6 Co-enzyme Q, component of 
respiratory chain   170 















WDR36 rRNA processing, Human 
orthologue has association 
with adult-onset primary 
open-angle glaucoma 
(POAG) 




 Lipid metabolism 




CSTF1 polyadenylation and 3' 









SOCS1 suppressor of cytokine 
signaling, JAK-STAT cascade 









RAB27A vesicle trafficking 




CWF19L2 cell cycle control 




 RNA binding 




 Transmembrane transporter 




ABHD13 hydrolase activity 




ODF3 Outer dense fibre component, 
cytoskeleton 




 Electron carrier 




PAPLN Glycoprotein, ECM 
component 




FCER2 Lymphocyte Ig receptor 




TTPA Vitamin E metabolism, 








GNRHR Gonadotropin releasing 
hormone receptor, lipid 
metabolism and homeostasis 














NFAT5 Transcription factor, 
regulation of osmolarity, 
possible association with 
SCA4 





 Electron carrier 




 Regulation of apoptosis, 
regulation of chromatin 
assembly 









    171 

















 Innate immune response 









SOX11 neuron survival and 
outgrowth 

















 Imaginal disc development 




 Hemocyte migration, VEGF-
like activity 









GGCT glutathione homeostasis, 
release of cytochrome c from 
mitochondria 




EST2 carboxylesterase 2, lipid 
metabolism 













































 Immune response   172 
Table B4: Genes changed in elav>rCUG flies compared to elav>rCAA in experiment 1. 
Log2 >0.5 or <-0.5, p<0.05. 
 















 Immune  response 




ATP5E mitochondrial  ATP  synthase 
epsilon chain 




  Eye pigment precursor 
transport 



















SLC18A2 vesicular  monoamine 
transporter 




hAtNOS1 mitochondrial  GTP  binding 




PCDH15  protocadherin 15 precursor 




RYK  Receptor-like tyrosine kinase, 
required for neurite outgrowth 









PAX5  B cell specific transcription 
factor/ midbrain dopaminergic 
neuron specification 




IGSF9  Required for coordinated 
motor control, 
Immunoglobulin super family 
member 9 









LONP1 mitochondrial  ATP-dependent 
protease, removal of oxidised 
aconitase 




PLSCR1 Phospholipid  scramblase, 
synaptic transmission 












CTNL1 cell-cell  recognition 
defective pro-
ventriculus 




 Transcription  factor  activity 














SFRS16 Splicing  factor, 
arginine/serine-rich 16   173 






































ECE2 Endothelin  converting 
enzyme, role in clearing 
Abeta in the brain 






K[+] channel 1 




KCNK4  2 pore K+ channel 






























HIST2H3 H3  histone 




FAM44A  Structural component of cell 
wall 





















HIST1H1 H1  histone 




AASDH 2-aminoadipic  6-
semialdehyde 
dehydrogenase, fatty acid 
metabolism 




KCNK6 Potassium  channel 
















RYR2 Cardiac  muscle  calcium 
regulation 





maintenance of transcription 




RSHL2  ciliary motion, microtubule 
associated protein   174 


















CARM1 co-activator  interacting 
arginine methyltransferase, 
interacts with HuR (elav-L), 
histone methyltransferase 




  Component of cuticle  




LMX1A  Differentiation of midbrain 
dopaminergic neurons, 
transcription factor activity 
wolfram 
syndrome 1 




WFS1  modulates free calcium in 
ER, regulated by Sp1 









TIMM50 Translocase  of  inner 
mitochondrial membrane 












MSL3L1 histone  acetylation 




AFG3L2 mitochondrial  ATPase, 
highest expression in skeletal 
muscle and heart 




 Dendrite  morphogenesis 























GBF1  Guanine nucleotide exchange 
factor 




SH3D19  Enhances TNF-mediated cell 
death 









EIF3A Translation  initiation  factor 
male specifc 
lethal 




MSL2L1 H4  histone  acetylation 




SP1 Transcription  factor 









GPATC1 RNA  processing 









OCA2  regulation of pH of 
melanocytes   175 



















SOCS1 suppressor  of  cytokine 
signaling, JAK-STAT cascade 




CIDEA  cell death activator, caspase 
activated nuclease 














ZMIZ1 transcriptional  coactivator 




ABHD13 hydrolase  activity 









RUNDC1  modulates p53 activity 




VPS18  vacuolar protein sorting, eye 
pigment metabolism 




  Mitochondrial import protein 




SON  Double stranded RNA 
binding, DNA binding 




 Cuticle  component 









MAPKAP1 Stress-activated  protein 
kinase, component of TOR 
complexes, regulation of 
apoptosis 


















GUCY1A2  cGMP synthesis, A2 isoform 
is important in 
neurotransmission 




BLNK Protein  binding 




BCAN Ig  receptor 




CCDC102A Component  of  myosin 
complex 




ROBO1  axon guidance receptor 




PRPF8 Component  of  spliceosomes, 
highest expression in skeletal 
muscle and heart, candidate 
for retinitis pigmentosa 
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INTS2  Subunit of integrator 
complex, 3' RNA processing 
of small nuclear RNAs 














MKX Homeobox  protein, 
transcription factor activity 




CTPS  Synthesis of CTP from UTP 




SMOX  Polyamine oxidase, eye 
development 




SPIRE1 actin  organisation,  highest 
expression in cerebellum 


















PPI Peptidyl-prolyl  cis-trans 
isomerase 














FBXL16  Ubiquitination and protein 
catabolism 




KCTD15 voltage  gated  potassium 
channel 














TTLL12  Tubulin tyrosine ligase, 


















MED24  component of mediator 
complex, transcriptional co-
activator 












PRKD1 serine  threonine  kinase 











VHL microtubule  binding  and 
stabilising   177 




















SFRS7 splicing  factor,  arginine/serine 
rich 




BOK Apoptosis  inhibitor 




HIP14 Huntington  interacting 
protein, intracellular 
trafficking 









SRL Calcium  storage  and 
regulation in skeletal and 
cardiac muscle, cell adhesion 




RHBDF1  serine protease, cleaves spitz 









SFRS18 splicing  factor,  arginine/serine 
rich 




HMGCR HMG-CoA  reductase, 
cholesterol synthesis 




 Negative  regulation  of 
neuroblast differentiation 














BTBD7 cell  proliferation 




UGT1A3 UDP-glucuronosyl  and  UDP-
glucosyl transferase 











Transportation of neurotoxins 
and neurotransmitters 




NR2E3 Retinal  nuclear  receptor, 
ligand dependent 
transcription factor 













UBE2 Ubiquitin  protein  ligase, 
regulation of cell death 























ERGIC2    178 























DATF1 Apoptotic  pathways 




FBXO32 Ubiquitin  protein  ligase, 









 Sensory  perception  of 
chemical stimulus 




ECHS1  Fatty acid oxidation, 
mitochondrial protein 











CYP4B1 Electron  carrier  activity 




SERPINI1  regulation of axonal growth 
and neural plasticity, serine 
protease inhibitor 




DSCR3 Down  Syndrome  critical 
region 3, vacuolar transport 




NAGA lysosomal  glycohydrolase 































PRDX6  Redox regulation of cell 




UGT2B7  Conjugation and elimination 
of toxic compounds 




MOGAT2 Triacylglycerol  synthesis 









UCK2 pyrimidine  ribonucleoside 
kinase, production of UMP 
and CMP 






















DBI Lipid  metabolism  and 
modulation of signalling at 
GABA-A neuron synapses 




AQP Aquaporin  protein  family   179 















HSD17B8 Regulation  of  concentration 
of biologically active 
estrogens and androgens 









SPINK Trypsin  inhibitor 




PGLYRP1 peptidoglycan  recognition 
protein 












CYP3A5 Electron  carrier 




 Pheromone  biosynthesis 

















CYP24A1 Electron  carrier 











TALDO1  Reduction of reactive oxygen 
intermediates 




ISOC1 Isochorismatase  hydrolase 




DCXR Dicarbonyl  L-xylulose 
reductase 














CYP24A1  Mitochondrial enzyme that 
inactivates metabolites of 
vitamin D 




MAN2B1 hydrolyses  alpha-D-
mannose, defects result in 
lysosomal mannosidosis 




MRRF Mitochondrial,  release  of 
ribosomes from mRNA at 
stop codon 
























SCAMP1  vesicular transport to cell 
surface 




XYLB Energy  metabolism   180 















RGN Calcium  homeostasis 

































CECR1 Adenosine  deaminase, 
growth factor 




















































MTR Methionine  synthase 




















CREG1 Transcriptional  repressor 
activity 














DCI  beta oxidation of fatty acids in 
the mitochondria 









    181 



































PEX6 cytoplasmic  ATPase, 
peroxisomal import protein 


























ODC1 polyamine  biosynthesis 




 Peptidyl  dipeptidase 





























 Immune  response 












  Regulation of imaginal disc 
development 




TTPA  Vitamin E metabolism, 
deficiency leads to cerebellar 
degeneration 









GALK2 Galactokinase,  galactose 
metabolism 














QRICH2    182 

































SORD Sorbitol  dehydrogenase 




CRYL1 fatty  acid  metabolism, 
oxidoreductase activity 




RGN Calcium  homeostasis 




DHRS10  Short chain dehydrogenase 
reductase 









GGCT glutathione  homeostasis, 
release of cytochrome c from 
mitochondria 

























   183 
Table B5: Genes altered in elav>rCAG flies compared to elav>+ in microarray 
experiment 1. Selected for Log2(ratio) >0.5 or <-0.5, P<0.05. 
  















SBK1 Kinase,  mesoderm 
development 



















  Transcription factor, dendrite 
morphogenesis and muscle 
development 














SLC39A2 zinc  transporter 




GYG1 glycogen  synthesis 




RNF11  induced by mutation to MEN 
proteins 









TRIM24 transcriptional  co-repressor 









PGLYRP1 peptidoglycan  recognition 































PRICKLE2 neurite  outgrowth 




KLHL5 actin  binding 
molting 
defective 




 ecdysone  synthesis 









    184 















ZNF499 neural  and  photoreceptor 









  Release of Ca+ from ER, 
olfaction 




 Carnitine  transport 









RAB27A vesicle  transport 









ROBO1  axon guidance receptor 









 Protective  against  DNA 
damage induced apoptosis 









IRX iroquois  homeobox  family 
member, regulation of 
rhodopsins, MAPK regulated 













CSAD taurine  synthesis,  excitatory 
pathways 









MEN1 Inhibits  JunD  activity, 
transcriptional regulation 











 neuropeptide  signalling 
lethal (1) 
G0196 














HuR RNA  binding 









ADD1 Cytoskeletal  protein, 
substrate for protein kinase A 
& C 




  Possible role in axon 
guidance 




ARIH1 Ubiquitin  conjugating  enzyme   185 




























GRM3 Glutamate  receptor, 
neuromuscular junction 
development 









BNC2 mRNA  processing,  regulated 
by SP1, brain development 




  Regulation of apoptosis, 
regulation of chromatin 
assembly 




SLC39A9 Zinc  transporter 




  G-protein coupled receptor 




MEX3A  RNA binding, colocalises with 
DCP1A and AGO1 in P 
bodies 









MBNL1 RNA  splicing 


















    186 
Table B6: Genes altered in elav>rCUG flies compared to elav>+ in microarray 
experiment 1. Selected for Log2(ratio) >0.5 or <-0.5, P<0.05. 
 










Function   


















    




PAX5  B cell specific transcription 
factor/ midbrain dopaminergic 
neuron specification 




    




    




 Cysteine-type  endopeptidase   




RNF150 Transcriptional  regulation, 









 Transcription  factor  activity   












  Regulation of meiotic cell 
cycle 
 




MSI2  RNA binding, post-
transcriptional gene 
regulation 




    




CCDC85  Putative component of RNAi 
pathways 
 




 Adenosine  kinase  activity   




SON  Double stranded RNA 
binding, DNA binding 




FAM44A  Structural component of cell 
wall 
 





















MSL2L1 H4  histone  acetylation   
will die 
slowly 




WDR5    




SLC25A32  folate shuttle, cytoplasm to 
mitochondria   187 










Function   




AASDH 2-aminoadipic  6-
semialdehyde 
dehydrogenase, fatty acid 
metabolism 




EYA1 Transcriptional  regulation   




DAGLA Associated  with  SCA20, 
contributes to purkinje cell 
synapse formation 




























SOCS1 suppressor  of  cytokine 
signaling, JAK-STAT cascade 
 




    




VPS18 vesicle  trafficking 




    























OAF Nervous  system  development   












GRM3 Glutamate  receptor 




  Regulation of apoptosis, 
regulation of chromatin 
assembly 
 




    











CYP24A1 Electron  carrier   




    




SKI TGFB1  signaling  pathway 




 Electron  carrier     188 










Function   




 Immune  response   
lethal (3) 
neo38 




 Nucleic  acid  binding   











    












 Glutathione  transferase   




ADAM9  binds mitotic arrest deficient 2 
beta protein 




UCK2 pyrimidine  nucleoside 
triphosphate production 




XYLB    




    




ATHL1    




PRDX4 activation  of  NF-kappaB 




GALM galactose  metabolism 




ADD1 Cytoskeletal  protein, 
substrate for protein kinase A 
& C 




    




    




c10orf4  FRA10AC spanning gene 




    




MBNL1 RNA  splicing   




FAHD1    




CHRAC1 Chromatin  accessibility 
protein 




FAAH  hydrolysis of primary and 
secondary amides 




DSCAM  Down syndrome cell 
adhesion molecule, axon 
guidance 




      189 


















 Neuropeptide  signaling   




VWF  antihemophilic factor carrier 
and a platelet-vessel wall 
mediator 




 Immune  response   




    




      190 
Table B7: Genes altered in elav>rCAG flies compared to elav>rCAA in microarray 
experiment 2. Selected for Log2(ratio) >0.5 or <-0.5, P<0.05. 
 







































STAU2 double-stranded  RNA 
binding, RNA localisation 
involved in cell fate 
determination 












 Insulin  signalling 




THOC6  mRNA export from nucleus 














  oxidative stress response 




KATNB1 microtubule  binding/severing 












LAMA1  actin cytoskeleton, cell 
adhesion 




 patterning  of  gut 





















ELAC2 pre-tRNA  processing 









LIPC triacylglcerol  lipase 




AMPD2 AMP  deaminase 




EVI1 regulation  of  dendrite 
morphogenesis, promotes 
single dendrite 
morphogenesis   191 
































 Sensory  perception  of 
chemical stimulus 









SLC18A2 Neurotransmitter  secretion, 
synaptic vesicle amine 
transport 




LSM7 pre-mRNA  processing 




  septate junction formation, 
role in polarisation of cells 












MMP14  Role in ECM regulation, cell 
adhesion 




LIPF-002 triacylglcerol  lipase 




REXO1 Transcriptional  elongation, 
RNA exonuclease activity 




TTC26 cilium  assembly 





FZD8  Wnt receptor signalling, axon 
extension, found on 
postsynaptic motor neurons, 
requires Grip to be 
endocytosed and elicit 
transcriptional changes. 









CUTL1 transcriptional  regulation, 
regulation of dendrite 
morphogenesis 




















movement, required for 
proper axon guidance of 
sensory neurons. 














NOL10  Putative nucleolar protein   192 















SEPT11  Filament forming cytoskeletal 
GTPase, role in vesicle 
transport cytokinesis 




HECW2 Ubiquitin  protein  ligase 




  Fat body protein, lipase? 









 lipase  activity 




























 neuropeptide  receptor  activity 
Ret 
oncogene 




RET homophilic  cell  adhesion 




INSC cytoskeletal  adaptor,  protein 
and RNA localisation, 
localisation is dynein 
dependent 









 actin  cytoskeleton/cell 
adhesion, may form a 
signalling complex with Grip, 
important in myogenesis 
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Table B8: Genes altered in elav>rCUG flies compared to elav>rCAA in experiment 2. 
Selected for Log2(ratio) >0.5 or <-0.5, P<0.05. 
 

































 synaptic  transmission 




CYP3A7 electron  carrier 




 mesoderm  development 
(Zasp66) - cytoskeletal 
remodelling 






ation group C 




MEF2C  transcription factor, muscle 
development 




CYP3A5 electron  carrier 














 gamma-tubulin  binding, 
cell-cycle regulation 




 phospholipase  activity,  lipid 
metabolism 









 glial-derived  neurotrophic 
factor 




TTLL1  Tubulin tyrosine ligase, 
essential post-translational 
modification for normal 
brain and muscle 
development 














 associated  with 
mitochondria in flagella 
during spermatogenesis 














 RNA  binding  protein   194 






















CHRNA4 Acetylcholine  receptor 
subunit, neurotransmitter 
signalling, insulin signalling 
pathway 




NDUFB3 NADH  dehydrogenase, 
electron transport chain, 
RNA import into nucleus 




ZZZ3 histone  acetylation 



















DNAJC4 molecular  chaperone 









BTBD14B positive  regulation  of 
transcription, interacts with 
mod(mdg4) 































POLE DNA-dependent  DNA 
polymerase 




SKP1A ubiqutin-dependent  protein 
catabolism, cell cycle? 





















phospholipase C, mutants 
are slow to terminate 
phototransduction 




GSTO1 glutathione  dehydrogenase 
activity, eye pigment 
biosynthesis 




GINS3 DNA  helicase  activity 
transcription 
unit 




 electron  carrier 




GTF3C2  putative transcription factor   195 















 eye  pigment  precursor 
transport activity 




SNF1LK2 protein  kinase 






orthologue of MPS IIIB 
gene 




GNPNAT1 glucosamine  6-phosphate 
N acetyltransferase 
activity, energy metabolism 




 peptidase  activity 




  cell adhesion and 
microtubule organisation 









 cuticle  protein 









CES2 carboxyl  esterase 




LAMB1 sub-unit  of  laminin, 
promoter of neurite 
outgrowth 











 immune  response 




 glutathione  transferase 




 acyl  transferase 









  role in cardiogenesis? 





















INSC cytoskeletal  adaptor, 
protein and RNA 
localisation, localisation is 
dynein dependent 










movement, required for 
proper axon guidance of 
sensory neurons. 




AMT Aminomethyl-transferase   196 




















AASS lysine  ketoglutarate 
reductase, regulation of 
histone modification 











SPARCL1 mesoderm  development 











ACO1 iron  homeostasis 









MAP2K3  MAPK activity, involved in 
oocyte polarity 
















GARS glycyl-tRNA  synthetase 











LIG3 DNA  repair 





















  possible immune function 




SLC5A12 sodium:solute  symporter 




  cell cycle control, interacts 
with Dicer1 and spen 




LIPA/LIPF lipid  metabolism 




CIAO1  orthologue of S. cerevisiae 
cytosolic iron-sulfur protein 
assembly 









  ATP coupled transporter, 
phagocytosis 




VAMP1 neurotransmitter  secretion 
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ACAA2  lipid metabolism, fatty acid 
beta oxidation, 
mitochondrial 




ACADM  lipid metabolism, fatty acid 
beta oxidation, 
mitochondrial 














 chitin  metabolism 









CLN3 human  gene  deficiencies 
show neuronal 
degeneration 




























involved in long-term 
memory formation 




 hemolymph  clotting 




NMUR2 neuropeptide  receptor 



















 insulin  receptor 
fragment K  alpha-
Est10 




CES2 carboxyl  esterase 

























FMO6/FMO5  oxidative stress response, 
possible neurological role 





transporter   198 



































SERPINB4 serine  protease  inhibitor 




 sodium:solute  symporter 









PC Gluconeogenesis,  pyruvate 
carboxylase 




 iron  transport 














 electron  carrier 









 Nimrod  B4 




 dopachrome  conversion, 
melanazation 




  upregulated in response to 
viral infection, responsive 
to RNAi pathway 
components 
fragment D  alpha-
Est5 






growth factor 5 




 Development  of  imaginal 
discs 




  microtubule based G-
protein coupled signal 
transduction 




  oxidative stress response 























GLBL1  autophagic cell death   199 
























  degradation of juvenile 
hormone 








































 hydrogen  ion 
transmembrane transporter 












CYP3A4 electron  carrier 




  cellular iron ion 
homeostasis 




 sterol  transporter 









 peptidase  inhibitor 














  G-protein coupled receptor 
signalling pathway, 
extended lifespan 
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  TweedleE, possible cuticle 
protein 









 structural  component  of 
cuticle 




GNMT methionine  metabolism 




 defense  response 
Cytochrome 
P450-4e3 




 electron  carrier 









PNLIP triacylglycerol  lipase 




 stress  response 




 stress  response   201 
Table B9: Genes altered in elav>rCAG flies compared to elav>+ in microarray 












Orthologue  Function 





  Spermatogenesis, 
protein kinase regulator 





























 Vitamin  E  binding 






Regulation of chromatin 
assembly/disassembly, 









  Sensory perception of 
chemical stimulus 





  Glutathione transferase 
activity 













activity, component of 
axonemal dynein 
complex 






Jun kinase activity, roles 
in establishment  of 
planar polarity 


















Axon guidance, muscle 
attachment, Wnt 
signalling pathway 









































XAB2  Regulation of alternative 
splicing, phagocytosis 
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Gene Title 
Gene 








Orthologue  Function 





BAP1 Ubiquitin  thiolesterase 





SLC45A1  Glucose trans-
membrane transport 

















GTF2H4  Regulation of 
transcription, DNA repair 





CHAC2 Cation  transporter 





 Electron  carrier 























AQP1 Water  transporter 





 mRNA  binding 













activity, germ cell 
development 

















SLC5A12  Sodium:iodide 
transporter 

















activity, growth factor 
activity 







adhesion, may form a 
signalling complex with 
Grip, important in 
myogenesis 





SPINK2  Serine-type 
endopeptidase inhibitor 





  Innate immune response 














vesicle amine transport 





SMOX    203 
Gene Title 
Gene 








Orthologue  Function 




















 Immune  response 











 Chitin  binding 





 Lipase  activity 











  Insulin-like growth factor 
binding protein complex 























NR4A1  Ligand-dependent 
nuclear receptor activity 


























 lipid  metabolism 






Eye pigment precursor 
transport, metabolic 
process   204 
Table B10: Genes altered in elav>rCUG flies compared to elav>+ in microarray 
experiment 2. Selected for Log2(ratio) >0.5 or <-0.5, P<0.05. 
 
Gene Title  Gene 








Orthologue  Function 
Stellate 





  Spermato-genesis, protein 
kinase regulator 





  Neuropeptide receptor 
activity 






Fibrinogen complex, bristle 
morphogenesis, nervous 
system development, signal 
transduction 





SSU72 mRNA  processing 





MARS Glutathione  transferase 











TARDBP  Neuromuscular junction 
development, RNA binding 





























CYP24A1 Electron  carrier  activity 





 Dendrite  morphogenesis 





 Immune  response 











TTN  Mesoderm development, 
myoblast fusion 

























Fibrinogen complex, bristle 
morphogenesis, nervous 
system development, signal 
transduction 
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AQP12A  Water transporter, 
mitochondrial 


















Dorsal closure, nervous 
system development 

















DNM1  Synaptic vesicle endocytosis, 
microtubule motor activity 





 Oxidoreductase  activity 





ST14 Serine-type  endopeptidase 

















FZD1  Wnt receptor, establishment 
of cell polarity, cell adhesion 






















  Nuclear export, embryonic 
patterning 












HBLD2  Iron-sulfur cluster assembly, 
mitochondrial 











MBNL1  Splicing factor, muscle and 
nervous system development 











TRAFIP1  TRAF3 associated, cilium 
assembly 

















FRMD6  Regulation of cell proliferation 
and differentiation 











SPON2    206 


























MAP3K7  JNK cascade, apoptosis, 
immune response 




















 GTPase  activity 











  Serine-type endopeptidase 
inhibitor 














TGS1 RNA  methylation 





  TGF signalling, patterning 
and organ development 






























CRYAB  Response to heat 











SARM1  Innate immune response 





CUGBP1  Regulation of alternative 
splicing and translation 





RTEL1  Nucleotide excision repair 





SMG5  Gene silencing by miRNA, 
nonsense-mediated decay 





SYT12 Neurotrans-mitter  secretion 













  Sensory perception of 
chemical stimulus 





SEMA5A Axon  guidance 











    207 



















 Component  of  cuticle 



























receptor activity, transcription 
activity 























  Regulation of apoptosis 















 Potassium  channel 

















  Glucoronosyl-transferase 
activity 





SOD1 Superoxide  dismutase  activity 






















 Mitotic  spindle  arrangement 





























SLC39A6 Metal  ion  transporter 





ACY1  Hydrolysis of acetylated 
amino acids 





GLIS2 Transcriptional  regulation   208 



















YKT6  Vesicle-mediated transport, 









  Sensory perception of 
chemical stimulus 














 Protein  kinase 

















RALA  GTPase, actin cytoskeleton 




Table C1: Genes altered in elav>rAUUCU compared to both elav>+ and elav>rCAA. 
Selected for Log2(ratio) >0.5 or <-0.5. 
 
Gene Title  Gene 








Orthologue  Function 
CG3898  CG3898 CG3898 -1.27 -1.78    
CG32553  CG32553 CG32553 -0.87 -1.73    
CG6416  CG6416 CG6416 -1.62 -1.66   Mesoderm  development 
Stretchin  Strn-Mlck CG18255 -0.96 -1.64   
Myosin light chain kinase, 
component of 
cytoskeleton 
0.9kb transcript   CG2650   CG2650  -0.80 -1.62    
arthrin  Act88F CG5178  -1.13 -1.57   Cytoskeleton  organisation 
CG18646  CG18646 CG42629 -1.03 -1.55    Regulation of GTPase 
activity 




CG15335  CG15335 CG15335 -1.57 -1.43    
DCorin  Corin CG2105  -1.26 -1.39  CORIN  Serine-type 
endopeptidase 
79B Actin  Act79B CG7478  -0.89 -1.36  ACTA2 Cytoskeleton  organisation 
CG40484  CG40484 CG40484 -0.82 -1.36    
CG40485  CG40485 CG40485 -0.92 -1.35   Oxidoreductase  activity 
CG17378  CG17378 CG17378 -0.79 -1.35    
CG13131  CG13131 CG13131 -1.21 -1.29    
CG12455  CG12455 CG12455 -0.82 -1.23   Calcium  channel  activity 
CG31174  CG31174 CG31174 -1.60 -1.23    
Male-specific 
RNA 84Dc 
Mst84Dc CG17945  -0.79 -1.22   Electron  carrier  activity 
CG9194  CG9194 CG9194 -0.75 -1.2    Potassium ion transporter 
CG12716  CG12716 CG12716 -1.29 -1.2    
CG32652  CG32652 CG32652 -0.51 -1.19    
CG31708  CG31708 CG31708 -0.68 -1.18      210 












CG10260  CG10260 CG10260 -0.88 -1.17  PIK4CA  1-phosphatidylinositol 4-
kinase activity, signalling 
CG14133  CG14133 CG14133 -0.65 -1.14    
CG31730  CG31730 CG31730 -0.97 -1.13  ARD1A  N-acetyl transferase 
activity 
CG40323  CG40323 CG40323 -0.88 -1.12    
whacked  wkd CG5344  -0.65 -1.11  TBC1D10A  Regulation of RAB 
GTPase activity 
CG40139  CG40139 CG40139 -0.73 -1.09    
CG11637  CG11637 CG11637 -0.63 -1.09   Cell  adhesion 
CYP4-related  Cyp4ad1 CG2110  -1.20 -1.09   Electron  carrier  activity 
CG18747  CG18747   -1.02 -1.08    
larval-opioid-
receptor 
FR CG2114  -0.87 -1.08   Neuropeptide  receptor 
CG13060  CG13060 CG13060 -0.79 -1.08    
Complement-




-0.71 -1.04  MEF2C 
Mesoderm and heart 
development, 
transcriptional regulation 
CG7544  CG7544 CG7544 -0.78 -1.04  METT10D Methyl-transferase  activity 
CG33147  Hs3st-A CG33147  -0.62 -1.03  HS3ST5 
Heparan sulphate-
glucosamine 3-
sulfotransferase 1 activity 
CG7341  CG7341 CG7341 -0.60 -1.02    
CG18348  Cpr67Fb CG18348  -0.97 -1.01    Structural component of 
cuticle 
CG12524  CG34356 CG34356 -0.82 -1.00   DNA  methylation 
CG9264  CG9264 CG9264 -0.88 -0.97    Trans-membrane amino 
acid transporter 
CG14669  CG14669 CG14669 -0.99 -0.97    





dtr CG31623  -0.75 -0.93   Synaptic  transmission 
CG17290  CG17290 CG17290 -1.60 -0.93    
Cyp313b1  Cyp313b1 CG9716  -0.74 -0.92   Electron  carrier 
Hemese  He CG31770  -1.32 -0.92    Innate immune response    211 












CG13762  CG13762 CG13762 -1.34 -0.91   Calcium  ion  transport 
CG31878  CG31878 CG42367 -0.88 -0.91    
calcium binding 





CycJ CG10308  -0.98 -0.9  CCNJ  Cyclin-dependent protein 
kinase regulator  
khotalo  kto CG8491  -0.61 -0.89  MED12L 
Transcriptional regulation, 
positive regulator of wnt 
signalling pathway 
Odorant 
receptor 59b  Or59b CG3569  -0.69 -0.87   Olfactory  receptor  activity 
hu-li tai shao  hts CG9325 -1.12  -0.87  ADD1  Actin assembly, ring canal 
formation 







-0.89 -0.86  POU4F3  Dendrite morphogenesis, 
transcription factor activity  
CREB binding 
protein  nej CG15319  -0.66 -0.84  EP300  Transcriptional co-
activator 
CG15214  CG34391 CG34391 -0.97 -0.84    
roughened eye  rn CG42277  -1.00 -0.83   Transcriptional  regulation 
CG13235  CG13235 CG13235 -0.64 -0.83    
SP71  SP71 CG17131  -0.90 -0.82    
Shaker  Sh CG12348  -0.63 -0.81  KCNA2  Voltage-gated potassium 
channel 
grapes  grp CG17161  -0.59 -0.81  CHEK1 Cell-cycle  check-point 
oskar  osk CG10901  -0.83 -0.81    P-granule assembly, pole 
cell formation 
CG9009  CG9009 CG9009 -0.76 -0.8    Long-chain-fatty-acid-CoA 
ligase activity 
CG31988  CG31988 CG31988 -0.64 -0.79   Zinc  ion  binding 
Rbp1-like  Rbp1-like CG1987  -0.64 -0.79  SFRS3 Nuclear  mRNA  splicing 
CG5048  CG5048 CG5048 -0.62 -0.78    
TpnC4  TpnC4 CG12408  -0.92 -0.78   Calcium  ion  binding 
dpr8  dpr8 CG32600  -0.52 -0.77      212 












CG32425  CG32425 CG32425 -0.54 -0.77    
CG14151  CG14151 CG14151 -1.05 -0.77    
dumbfounded  kirre CG3653  -0.66 -0.76    Myoblast fusion, muscle 
tissue development 
CG16758  CG16758 CG16758 -0.62 -0.75   Nucleoside  metabolism 
seven-up  svp CG11502  -0.59 -0.75  NR2F1 Synaptic  transmission 
fau  fau CG6544  -0.53 -0.74    
CG34135  CG34135 CG34135 -0.81 -0.73    
Shaker  Sh CG12348  -0.51 -0.72  KCNA2  Voltage-gated potassium 
channel 
turtle  tutl CG15427  -0.67 -0.72  IGSF9  Regulation of dendrite 
morphogenesis 
CG13545  CG13545 CG13545 -0.59 -0.71    
Fancd2  Fancd2 CG17269  -1.21 -0.71  FANCD2  Protein kinase activity 
crossover 
suppressor on 
2 of Manheim 
c(2)M CG4249  -0.99 -0.7    Resolution of cross-over 
intermediates in meiosis 
Adenylate  
cyclase 3 
Ac3 CG1506  -0.59 -0.7  ADCY3  cAMP synthesis, 
signalling cascade 
CG17446  CG17446 CG17446 -0.56 -0.69  CXXC1 DNA  binding 
CG14655  CG14655 CG14655 -0.62 -0.69    
CG40092  CG40092 CG40092 -0.53 -0.69    
CG31283  CG31283 CG31283 -0.59 -0.68    
CG40450  CG40450 CG40450 -0.59 -0.67    




sgg CG2621  -0.51 -0.66  GSK3B 
Protein serine threonine 
kinase activity, synaptic 
growth at neuromuscular 
junction  
methuselah-like 
13  mthl13 CG30018  -0.69 -0.66    
CG4328  CG4328 CG4328 -0.73 -0.66  LMX1B  Dendrite morphogenesis, 
transcription factor activity 
RNA-binding 
protein 1 
Rbp1 CG17136  -0.70 -0.66  SFRS3  Nuclear RNA splicing   213 












CG9200  Atac1 CG9200  -0.58 -0.65  ZZZ3  Regulation of histone 
acetylation 
His1:CG31617   His1:CG31
617   CG31617  -0.69 -0.65  HIST1H1B  Chromatin assembly or 
disassembly 
5' gene  Gpdh CG9042  -0.90 -0.65  GPD1  Glycerol phosphate 
dehydrogenase 
CG8501  CG8501 CG8501 -0.84 -0.65    
CG18304  CG18304 CG18304 -0.52 -0.65   Component  of  ribosome 






CanA-14F CG9819  -1.21 -0.64  PPP3CA  Amino acid de-
phosphorylation 
CG11374  CG11374 CG11374 -0.62 -0.64   Sugar  binding 
CG30271  CG30271 CG30271 -0.52 -0.64    
CG40449  WDY CG40449  -0.55 -0.64    
Serotonin 
receptor  5-HT7 CG12073  -0.55 -0.64  ADRA2B 
Serotonin receptor 
signalling, activation of 
adenylate cyclase 
CG32532  CG32532 CG32532 -0.50 -0.64    Transcription factor 
activity 
Interferon-like 
protein  ect CG6611  -0.65 -0.63    
CG11188  CG11188 CG11188 -0.73 -0.63  AATF  Regulation of apoptosis, 
transcription factor activity 
CG32026  CG32026 CG32026 -0.58 -0.63    Isocitrate dehydrogenase 
activity 
vasa  vas CG3506  -0.99 -0.63  DDX4  Regulation of RNA 
localisation and translation 
CG33279  CG33279 CG42458 -0.54 -0.63   mRNA  binding 
CG30054  CG30054 CG30054 -0.55 -0.62    G-protein coupled 
signalling 










absent  lola CG12052  -0.65 -0.62  ZBTB3  Axon guidance, 
transcriptional regulation   214 













ation group D 




CG13834  CG34375 CG34375 -0.51 -0.61    Ubiquitin-dependent 
catabolism 
CG31513  CG31513 CG31513 -0.66 -0.61    




Dhc93AB CG3723  -0.74 -0.6  DNAH9  Microtubule-based 
movement 
CG15308  CG15308 CG15308 -0.52 -0.6    
CG17163  CG17163 CG17163 -0.54 -0.6    
CG13012  CG13012 CG13012 -0.51 -0.59    
5' gene  Gpdh CG9042  -0.76 -0.59  GPD1  Glycerol phosphate 
dehydrogenase 
female lethal d  fl(2)d CG6315  -0.59 -0.59  WTAP  RNA splicing, sex 
determination 
CG2260  CG2260 CG2260 -0.85 -0.59    
CG40137  CG40137 CG40137 -0.54 -0.58    
CG6185  CG6185 CG6185 -0.72 -0.57    Glutamate-gated ion 
channel activity  
CG11617  CG11617 CG11617 -0.56 -0.56   Transcriptional  regulation 
CG6012  CG6012 CG6012 -0.52 -0.56   Oxidoreductase  activity 
CG10086  CG10086 CG10086 -0.64 -0.55    
CG14662  CG14662 CG14662 -0.55 -0.55    
CG30054  CG30054 CG30054 -0.56 -0.54    G-protein coupled 
receptor activity 
Rpb4  Rpb4 CG33520  -0.70 -0.53  TADA2L 
Regulation of histone 
acetylation, transcriptional 
activator adaptor protein 
CG14131  CG14131 CG14131 -0.67 -0.53    
Lipase 1  Lip1 CG7279  -0.70 -0.53   Lipid  metabolism 
CG13038  CG13038 CG13038 -0.69 -0.53    
fru-satori  fru CG14037  -0.85 -0.53    CNS development, 
transcription factor activity 
CG18606  CG10476 CG10476 -0.68 -0.52      215 












Modifier67.2  mod(mdg4) CG3249  -0.75 -0.52  AKAP1 
Regulation of chromatin 
assembly/disassembly, 
regulation of apoptosis 
CG8511  Cpr49Ag CG8511  -0.54 -0.52   Component  of  cuticle 
CG13484  CG13484   -0.62 -0.52    




mre11 CG16928  -0.85 -0.52  MRE11A  Nucleotide excision repair 
CG16800  CG16800 CG16800 -0.89 -0.52    
VEGF-related 
factor 2  Pvf2 CG13780  0.52 -0.51  Hemocyte  migration 
CG34114  CG34114 CG34114 -0.55 -0.51    




star1 CG7285  -0.57 -0.51  SSTR5  G-protein coupled 
receptor protein signalling 
CG10265  CG10265 CG10265 -0.64 -0.51    
scrambled  sced CG3273  -0.51 -0.51   
Actin filament re-






CG42388  0.53 0.51    
ninjurin A  NijA CG6449  0.63 0.51  NINJ1  Axon guidance, cell 
adhesion 
bves  bves CG32513  0.72 0.52  BVES Cell  adhesion 








Mmp1 CG4859  0.95 0.52  MMP14  Metallo-endopeptidase, 
cell adhesion 
NtR  NtR CG6698  0.50 0.53    Ligand-gated ion channel 





IM10 CG18279  0.86 0.53    Toll-signalling pathway, 
immune response 
CG17264  CG17264 CG17264 0.64 0.53      216 












CG11899  CG11899   CG11899  0.59 0.53  PSAT1 Pyridoxine  biosynthesis 
CG3091  CG3091 CG3091 0.57 0.53   Transporter  activity 
fragment K  alpha-Est10 CG1131  0.56 0.54   Carboxyl-esterase 





smp-30 CG7390  0.83 0.54   Lipid  metabolism 




Obp56a CG11797  0.52 0.55    Sensory perception of 
chemical stimulus 





Cyp6a22 CG10240  0.65 0.55  CYP3A5 Electron  carrier  activity 
CG6294  CG6294 CG6294 0.59 0.56   metallopeptidase 
Ugt86Da  Ugt86Da CG18578  0.54 0.56  UGT2B10 Lipid  transporter  activity 
net  net CG11450  0.67 0.56  ATOH8  Transcription factor 
activity 




hgo CG4779  0.74 0.56  HGD  L-phenylalanine/tyrosine 
catabolism 
CG32695  CG32695 CG32695 0.60 0.56    
CG9312  CG9312 CG9312 0.74 0.57    
CG14117  CG14117 CG14117 0.70 0.57    
Glutathione S 





Fdh CG6598  0.50 0.57  ADH5  Alcohol metabolism, 
oxidation 
Spaetzle  spz CG6134  0.61 0.57    Immune response, motor 
axon guidance 
CG2938  CG2938 CG2938 0.50 0.58    
CG17350  CG17350 CG17350 0.53 0.58      217 












CG17928  CG17928 CG17928 0.57 0.58    Fatty acid biosynthetic 
process, oxidation  
Cyp6a23  Cyp6a23 CG10242  0.61 0.58   Electron  carrier  activity 
predicted gene 
W  
CG31217   CG31217   0.52 0.59    Innate immune response 
CG18107  CG18107 CG18107 -1.02 0.59    
CG18473  CG18473 CG18473 0.51 0.6  PTER 
Aryldialkylphosphatase 









CG6113  CG6113 CG6113 0.77 0.6  LIPA Triglyceride  lipase   
CG18249  CG18249 CG18249 0.59 0.6    
Serine Protease 
2  Ser7 CG2045  0.68 0.6    Serine-type 
endopeptidase 
CG18547  CG18547 CG18547 0.68 0.61   Oxidoreductase  activity 
CG9377  CG9377 CG9377 -0.63 0.61    Serine-type 
endopeptidase 
CG12262  CG12262 CG12262 0.60 0.61  ACADM Fatty  acid  beta-oxidation 
CG13833  CG13833 CG13833 0.70 0.61   Oxidoreductase  activity 
Cytochrome 
P450-9c1 
Cyp9c1 CG3616  0.84 0.61  CYP3A4 Electron  carrier  activity 





CG10621 CG10621 0.61 0.62  MTR  Selenocysteine 
methyltransferase activity 
CG3663  CG3663 CG3663 0.65 0.62    
CG31436  CG31436 CG31436 0.68 0.62    
CG18302  CG18302 CG18302 0.72 0.62  LIPA Lipid  metabolism 
brahma 
associated 
protein 60 kDa 
Bap60 CG4303  0.59 0.62  SMARCD1 
Dendrite and muscle 
development, transcription 
factor activity 
fly plexin a  Cyp9b2 CG4486  0.61 0.62  CYP3A4 Electron  carrier  activity 
Cyp6a13  Cyp6a13 CG2397  0.62 0.63  CYP3A4 Electron  carrier  activity 
GIP-like  Gip CG2227  0.52 0.64  HYI  Hydroxy-pyruvate 
isomerase   218 












CG5222  CG5222 CG5222 0.68 0.64  RC74  mRNA cleavage and 
polyadenylation 
CG14692  CG14692 CG14692 0.60 0.64    cAMP-dependent protein 
kinase regulation 
CG10575  CG10575 CG10575 0.94 0.64  COASY  Co-enzyme A 
biosynthesis  
CG9631  CG9631 CG9631 0.50 0.64    Serine-type 
endopeptidase 
CG5707  CG5707 CG5707 0.64 0.64    




CG5697  CG5697 CG5697 0.93 0.64    
Glutathione S 
transferase E4  GstE4 CG17525  1.04 0.64   Glutathione  transferase 
CG16926  CG16926 CG16926 0.79 0.64    
Ugt86Di  Ugt86Di CG6658 0.79 0.64  UGT2B4 glucoronosyltransferase 
CG10026  CG10026 CG10026 0.64 0.65    Vitamin E binding, 
transporter 
Nedd2-like 
caspase  Nc CG8091  0.97 0.65  CASP7 
Induction of apoptosis, 
CNS and eye 
development 
CG6421  CG6421 CG6421 0.55 0.65    Lysozyme activity, 
antibacterial 
CG13912  CG13912 CG13912 0.60 0.66    
CG13283  CG13283 CG13283 0.89 0.66   metalloendopeptidase 




Reg-2 CG3200  0.79 0.66  HDH3  Phosphoglycolate 
phosphatase 
CG31769  CG31769 CG31769 0.90 0.66    




gce CG6211  0.59 0.67  ARNT  Transcription factor 
activity 





Jhedup CG8424  0.63 0.67   Carboxylesterase  activity   219 












CG30503  CG30503   0.61 0.67  PLA2G3 Phospholipase  activity 
Transcription 
unit B   CG14630   CG14630  0.63 0.68   Oxidation  regulation 
regucalcin  regucalcin CG1803  0.51 0.68  RGN  





GNBP3 CG5008  0.52 0.68   Immune  response 
CG7339  CG7339 CG7339 0.58 0.68  POLR3H Transcriptional  regulation 
lethal (2) 
k10201  l(2)k10201 CG13951  0.70 0.69    












Pbprp4 CG1176  0.58 0.69    Sensory perception of 
chemical stimulus 
CG31414  CG31414 CG31414 0.55 0.69    
cathepsin B   CG10992   CG10992  0.66 0.69  CTSB 








yip2 CG4600  0.54 0.69  ACAA2 Fatty  acid  beta-oxidation 
CG6426  CG6426 CG6426 0.58 0.69    Lysozyme activity, 
immune response 




IM23 CG15066  1.11 0.69    Toll signalling pathway, 
immune response 




sPLA2 CG11124  0.53 0.7  PLA2G3 Phospholipase  activity 
CG13845  CG34376 CG34376 0.57 0.7      220 












CG15414  CG15414 CG15414 0.63 0.7    
CR30029  CR30029 CR30029 0.64 0.7    
CG1889  CG1889 CG1889 0.64 0.7    
no-on-transient 
A 
nonA CG4211  0.84 0.71  SFPQ Nuclear  mRNA  splicing 
Cytochrome b5-
related  Cyt-b5-r CG13279  0.60 0.71  FADS1  Fatty acid biosynthesis, 
oxidation regulation 
CG2004  CG2004 CG2004 0.82 0.71    
MSP protein  CG33523 CG33523 0.65 0.71    
CG2444  CG2444 CG2444 0.72 0.72    
CG1397  CG1397 CG1397 0.84 0.72   Cuticle  synthesis 
CG10352  CG10352 CG10352 0.80 0.72    









CG3303  CG31292  0.72 0.73    Serine-type 
endopeptidase 
CG9519  CG9519 CG9519 0.65 0.73  CHDH  Choline dehydrogenase 
activity 
Drosomycin B  dro5 CG10812  0.79 0.74   Defense  response 
Pugilist  pug CG4067  0.64 0.74   Folic  acid  synthesis 
CG14935  CG14935 CG14935 0.85 0.75  SLC3A1  Alpha glucosidase, 
carbohydrate metabolism 
CYP6-like  Cyp6g1 CG8453  0.98 0.75  CYP3A7 Electron  carrier  activity 
CG14872  CG14872   0.68 0.75  CG14872  
drosomycin-F  dro4 CG32282  1.02 0.75   Defense  response 




ninaD CG31783  1.12 0.75    Cell adhesion, rhodopsin 
biosynthesis 
Maternal 
transcript 89Bb  Mat89Bb CG6814  0.68 0.76    
CG9396  CG9396 CG9396 0.66 0.76    
CG9455  CG9455 CG9455 0.86 0.76    Serine-type 
endopeptidase   221 












CG5288  CG5288   CG5288  0.58 0.76  GALK2  Galactokinase, 
carbohydrate metabolism 
CG4576  CG4576 CG4576 0.63 0.77   Amino  acyl-transferase 
CG11550  CG11550 CG11550 0.57 0.77    




Acer CG10593  0.65 0.78    Heart development, 
peptidyl-dipeptidase 
CG16713  CG16713 CG16713 0.67 0.79    Serine-type 
endopeptidase inhibitor 
CG31643  CG31643 CG31643 0.56 0.79  FASTKD1  Regulation of apoptosis, 
ATP binding 
CG1791  CG1791 CG1791 0.54 0.79  TNR Signal  transduction 
CG12713  CG12713 CG12713 0.70 0.79    
serpin 1  Spn1 CG9456  0.81 0.79  SERPINB4  Serine-type 
endopeptidase inhibitor 
Cyp28d1  Cyp28d1 CG10833  0.59 0.79  CYP3A4 Electron  carrier  activity 




Myoglianin  myoglianin CG1838  0.62 0.79  GDF8 Growth  factor  activity 
CG2118  CG2118 CG2118 0.84 0.8  MCCC1 Leucine  metabolism 
CG12269  CG12269 CG12269 0.52 0.82   Sterol  carrier 
CG15281  CG15281 CG15281 0.52 0.82    
CG3603  CG3603 CG3603 0.54 0.82  HSD17B8 Oxidoreductase  activity 
Mth-like 2  mthl2 CG17795  0.97 0.82   
G-protein coupled 
receptor signalling, 
response to stress 
CG9689  CG9689 CG9689 0.93 0.82    
virus-induced 1  vir-1 CG31764  0.66 0.83    Defense response to virus 
CG4716  CG4716   CG4716   0.56 0.83    Methylenetetrahydrafolate 
dehydrogenase activity 
Cyp309a2  Cyp309a2 CG18559  0.63 0.83   Electron  carrier  activity 
CG11395  CG11395 CG11395 0.73 0.85    
lush  lush CG8807  0.52 0.87    Sensory perception of 
chemical stimulus   222 












CG3301  CG3301 CG3301 0.68 0.87  MGC4172 Oxidoreductase  activity 
CG7219  CG7219 CG7219 0.60 0.87    Serine-type 
endopeptidase inhibitor 
CG4721  CG4721 CG4721 0.89 0.88   metalloendopeptidase 
beta-
galactosidase  Ect3 CG3132  0.88 0.88  GLB1L Autophagic  cell  death 
PGRP-SD  PGRP-SD CG7496  0.71 0.89    
Cytochrome 
P450-4e1  Cyp4e1 CG2062  0.65 0.89    




IM1 CG18108  0.99 0.89    
CG15293  CG15293 CG15293 0.66 0.9    
CG14629  CG14629   CG14629   0.53 0.9    
CG32613  CG32613 CG32613 0.66 0.9    Immune response, 
polysaccharide binding 
CG5791  CG5791 CG5791 0.81 0.91    
CG1468  CG1468 CG1468 0.63 0.91    




IM4 CG15231  0.72 0.92   Immune  response 
CG14400  CG14400 CG14400 0.75 0.92    
CG15067  CG15067 CG15067 0.89 0.92    
sex-specific 




takeout  to CG11853  0.66 0.94    Circadian rhythm and 
feeding behaviour 
CG4408  CG4408 CG4408 0.73 0.94    Metallocarboxypeptidase 
activity 
Lipid storage 
droplet-1  Lsd-1 CG10374  0.72 0.94   Lipid  storage 




Obp59a CG13517  0.71 0.95    Sensory perception of 
chemical stimulus   223 












CG17324  CG17324 CG17324 0.79 0.95  UGT1A3  UDP-glycosyltransferase 
activity 
CG11842  CG11842 CG11842 0.86 0.95    Serine-type 
endopeptidase 
CG17325  CG17325 CG17325 0.95 0.96    
CG34020  CG34020 CG34020 1.08 0.96    
hemolectin  Hml CG7002  0.57 0.97  VWF Hemostasis,  cell  adhesion 
antdh  antdh CG1386  0.50 0.97  MGC4172 Carbonyl  reductase 
CG14567  CG14567 CG14567 0.54 0.98    
CG7299  CG7299 CG7299 0.90 0.98    
CG5126  CG5126 CG5126 0.51 0.99    
CG6206  CG6206 CG6206 0.69 0.99  MAN2B1  Alpha-mannosidase 
activity 
Ance-4  Ance-4 CG8196  0.84 1   Peptidyl  dipeptidase 




smp-30 CG7390  0.72 1.02    
cuticle cluster 2  Ccp84Ag CG2342  0.56 1.02   Component  of  cuticle 
CG15065  CG15065 CG15065 1.16 1.02    
Turandot X  TotX CG31193  1.26 1.02   Stress  response 
CG10357  CG10357 CG10357 1.09 1.03    Lipid metabolism, 
triglyceride lipase 
CG1667  CG1667 CG1667 1.16 1.03    
bangles and 
beads 




TepII CG7052  0.83 1.04  CD109  Antibacterial humoral 
response 
CG14528  CG14528 CG14528 0.91 1.04   Metalloendopeptidase 
Iris  Iris CG4715  0.88 1.05    
CG12656  CG12656 CG12656 0.77 1.05    
CG17189  CG17189 CG17189 0.79 1.06    
CG31839  CG31839 CG31839 0.79 1.06  FLJ14712 Mesoderm  development   224 












CG4335  CG4335 CG4335 1.29 1.06  TMLHE Oxidation  reduction 
CG17777  CG17777 CG17777 0.96 1.06    
CG4250  CG4250 CG4250 0.67 1.07    
Cecropin  CecB CG1878  0.79 1.07    Antibacterial humoral 
response 
CG3588  CG3588 CG3588 0.78 1.07    




fit CG17820  0.53 1.09    
CG13086  CG13086 CG13086 0.89 1.09    
CG8147  CG8147 CG8147 0.55 1.09   Alkaline  phosphatase 
CG14872  CG14872 CG14872 0.97 1.09    
CG15282  CG15282 CG15282 0.87 1.09    
CG11314  CG11314 CG11314 0.59 1.1   Mesoderm  development 
CG4950  CG4950 CG4950 0.69 1.1    
semmelweis  PGRP-SA CG11709  0.63 1.11  PGLYRP3 Immune  response 
CG9511  CG9511 CG42370  0.80 1.13    
CG5428  CG5428 CG5428 1.28 1.13   sulfotransferase 




CG2540  CG2540 CG2540 1.00 1.18    
Ance-2  Ance-2 CG16869  1.24 1.2   Peptidyl  dipeptidase 
PGRP-SB1  PGRP-SB1 CG9681  0.57 1.2   Immune  response 
CG7526  CG7526 CG7526 0.57 1.21   Calcium  ion  binding 
CG6188  CG6188 CG6188 1.34 1.23  GNMT Methionine  metabolism 
CG15068  CG15068 CG15068 1.38 1.25    
Turandot C  TotC CG31508  3.19 1.27   Stress  response 
CG4716  CG4716   CG4716   0.99 1.29    
CG16836  CG16836 CG16836 1.04 1.3    
CG14495  CG14495 CG14495 0.86 1.3      225 














Odc1 CG8721  0.65 1.32  ODC1 Polyamine  biosynthesis 





CG32641  CG32641  1.44 1.34   Protein  folding 
turn on sex-
specificity 
Obp99b CG7592 1.15 1.39   
Autophagic cell death, 
sensory perception of 
chemical stimulus 
CG13335  CG13335   CG13335   1.01 1.4    
CG5966  CG5966 CG5966 1.49 1.44  PNLIP Triglyceride  lipase 
Cytochrome 
P450-4e3  Cyp4e3 CG4105  1.35 1.45   Electron  carrier  activity 
lethal (1) G0237  l(1)G0237   -1.06 1.55    
Turandot  TotA CG31509  2.66 1.55   Response  to  stress 
CG13704  CG13704 CG13704 1.08 1.56    
CG3699  CG3699 CG3699 0.52 1.62   Oxidation  reduction 
Vago  Vago CG2081  0.96 1.64    




attacin  AttA CG10146  1.16 1.76    Antibacterial humoral 
response 
CG13422  CG13422 CG13422 1.26 1.79   Defense  response 
Amylase  Amy-d /// 
Amy-p 
CG17876  1.49 1.85  AMY2A Carbohydrate  metabolism 
metchnikowin  Mtk CG8175  1.52 2    Antibacterial humoral 
response 
Cytochrome 
P450 A1  Cyp4g1 CG3972  2.02 2.05    Lipid metabolic process, 
oxidation reduction 
attacin  AttC CG4740  1.38 2.05    Antibacterial humoral 
response 
Turandot M  TotM CG14027  3.77 3.07   Response  to  stress 
white   w CG2759  1.30 3.59  ABCG2  Eye pigment biosynthesis 
 
   226 
Table C2: Genes altered in elav>rAUUCU and elav>rCAG flies compared to elav>rCAA. 
Selected for Log2(ratio) >0.5 or <-0.5 for elav>rAUUCU and elav>rCAG compared to 
elav>rCAA, P<0.05 for elav>rCAG. 
 











Staufen  stau CG5753  -0.66 
P=0.029 
-1.10  STAU2 double-stranded  RNA 
binding, RNA localisation 
involved in cell fate 
determination 
CG32736  CG32736 CG32736  -0.51 
P=0.025 




Ilp5 CG33273  -0.59 
P=0.001 




omd CG9591  -0.66 
P=0.001 
-0.64  INTS5  
gliotactin  Gli CG3903  0.60 
P=0.040 
0.54    septate junction formation, 
role in polarisation of cells 
CG9400  CG9400 CG9400  0.84 
P=0.042 
0.55    
CG9079  Cpr47Ea CG9079  0.51 
P=0.021 
0.56    
CG34104  CG34104 CG34104  0.58 
P=2.87E-5 




Ggamma30A CG3694  0.83 
P=0.016 
0.57  GNG13 phototransduction 
cut  ct CG11387  0.65 
P=0.025 
0.57  CUTL1 transcriptional  regulation, 
regulation of dendrite 
morphogenesis 
Inscuteable  insc CG11312  0.89 
P=0.025 
0.60  INSC cytoskeletal  adaptor,  protein 
and RNA localisation, 
localisation is dynein 
dependent 
CG13065  CG13065 CG13065  0.64 
P=0.046 
0.61  LSM7 pre-mRNA  processing 
CG10632  CG10632 CG10632  0.67 
P=0.041 
0.61    
CG13277  CG13277 CG13277  0.60 
P=0.045 
0.70    
CG32850  CG32850 CG32850  0.80 
P=0.017 
0.75  RNF11    227 











CG7744  CG7744 CG7744  0.87 
P=0.017 




Obp56f CG30450  0.58 
P=5.94E-5 
0.82   Sensory  perception  of 
chemical stimulus 
CG1397  CG1397 CG1397  0.59 
P=0.028 
0.84    
CG12998  CG12998 CG12998  0.92 
P=0.036 
0.88    
CG14528  CG14528 CG14528  0.72 
P=0.048 




Mmp1 CG4859  0.62 
P=0.041 
0.95  MMP14  Role in ECM regulation, cell 
adhesion 
CG4525  CG4525 CG4525  0.63 
P=0.044 
0.99  TTC26 cilium  assembly 
CG12877  CG12877 CG12877  0.62 
P=0.030 
1.03  REXO1 Transcriptional  elongation, 
RNA exonuclease activity 
CG3099  CG3099 CG3099  0.79 
P=0.024 
1.03  HECW2 Ubiquitin  protein  ligase   228 
Table C3: Genes altered in elav>rAUUCU and elav>rCUG flies compared to elav>rCAA. 
Selected for Log2(ratio) >0.5 or <-0.5 for elav>rAUUCU and elav>rCUG compared to 
elav>rCAA, P<0.05 for elav>rCUG. 
 











CG6416  CG6416 CG6416 -0.92 
P=0.027 
-1.62   mesoderm  development 
(Zasp66) - cytoskeletal 
remodelling 
CG17290  CG17290 CG17290 -0.66 
P=0.031 
-1.60    
CG18107  CG18107 CG18107 0.73 
P=0.016 
-1.02    
CG4161  CG4161 CG4161 -1.34 
P=0.010 
-0.91    
CG13416  CG13416 CG13416 -0.67 
P=0.031 




dtr CG31623  -1.02 
P=0.030 
-0.75   synaptic  transmission 
CG6425  CG6425 CG6425 -0.73 
P=0.035 
-0.73    
Complement-
ation group C 
Mef2 CG1429  -0.90 
P=0.007 
-0.71  MEF2C transcription  factor, 
muscle  development 
Grip71  Grip71 CG10346  -0.82 
P=0.001 







CG6768  -0.55 
P=0.007 
-0.66  POLE DNA-dependent  DNA 
polymerase 
Cyp6a19  Cyp6a19 CG10243 -1.01 
P=0.010 
-0.65  CYP3A7 electron  carrier 
CG17177  CG17177 CG17177 -0.78 
P=0.048 
-0.63    
CG13300  CG13300 CG13300 -0.59 
P=0.014 
-0.59    
CG7906  CG7906 CG7906 0.95 
P=0.038 
-0.59    
CG9200  Atac1 CG9200  -0.62 
P=0.008 
-0.58  ZZZ3 histone  acetylation   229 











CG9817  CG9817 CG9817 -0.82 
P=0.023 
-0.57    
CG1961  CG1961 CG1961 -0.68 
P=0.040 
-0.56   nucleotidase 
CG10320  CG10320 CG10320 -0.63 
P=0.008 
-0.55  NDUFB3 NADH  dehydrogenase, 
electron transport chain, 
RNA import into nucleus 
Plum  bw CG17632  -0.51 
P=0.018 
-0.52   eye  pigment  precursor 
transport activity 
skpB  skpB CG8881  -0.54 
P=0.040 
-0.52  SKP1A ubiqutin-dependent 
protein catabolism, cell 
cycle? 
CG14034  CG14034 CG14034 -0.78 
P=0.024 
-0.50   phospholipase  activity, 
lipid metabolism 
CG12269  CG12269 CG12269 0.95 
P=0.021 




yip2 CG4600  0.64 
P=0.015 
0.54  ACAA2  lipid metabolism, fatty 
acid beta oxidation, 
mitochondrial 
CG9400  CG9400 CG9400 0.97 
P=0.014 
0.55   peptidase  inhibitor 
CG9079  Cpr47Ea CG9079  1.34 
P=0.003 
0.56   structural  component  of 
cuticle 
CG11400  CG11400 CG11400 0.55 
P=0.017 
0.56    
fragment K  alpha-
Est10 
CG1131  0.69 
P=0.041 
0.56  CES2 carboxyl  esterase 
CG17928  CG17928 CG17928 0.62 
P=0.013 
0.57    
CG11550  CG11550 CG11550 0.59 
P=0.045 
0.57    
CG34104  CG34104 CG34104 0.80 
P=0.004 
0.57    microtubule based G-
protein coupled signal 
transduction 
CG30026  CG30026 CG30026 0.76 
P=0.006 
0.58    
CG18249  CG18249 CG18249 0.55 
P=0.026 
0.59      230 











synaptobrevin  Syb CG12210  0.63 
P=0.025 
0.60  VAMP1 neurotransmitter 
secretion 
Inscuteable  insc CG11312  0.55 
P=0.050 
0.60  INSC cytoskeletal  adaptor, 
protein and RNA 
localisation, localisation 
is dynein dependent 
CG12262  CG12262 CG12262 0.64 
P=0.027 
0.60  ACADM  lipid metabolism, fatty 
acid beta oxidation, 
mitochondrial 
CG4576  CG4576 CG4576 0.53 
P=0.042 





Jhedup CG8424  0.83 
P=0.020 
0.63    degradation of juvenile 
hormone 
CG15414  CG15414 CG15414 0.64 
P=0.007 
0.63    
virus-induced 1  vir-1 CG31764  0.80 
P=0.023 
0.66   upregulated  in  response 
to viral infection, 
responsive to RNAi 
pathway components 
CG15293  CG15293 CG15293 0.83 
P=0.007 
0.66    
CG9396  CG9396 CG9396 0.86 
P=0.039 
0.66  BRP44  
CG9691  CG9691 CG9691 0.7 
P=0.018 
0.67    
CG14872  CG14872 CG14872 0.81 
P=0.031 
0.68    
CG18302  CG18302 CG18302 0.61 
P=0.007 
0.72  LIPA/LIPF lipid  metabolism 
lethal (2) 09851  l(2)09851 CG12792 0.89 
P=0.003 
0.72  GRWD1  glutamine rich, ribosome 
biogenesis 
CG6340  CG6340 CG6340 0.58 
P=0.036 
0.76    
CG12656  CG12656 CG12656 0.67 
P=0.026 
0.77    
CG3588  CG3588 CG3588 0.86 
P=0.044 
0.78      231 











CG16926  CG16926 CG16926 1.23 
P=0.006 
0.79    
CG17189  CG17189 CG17189 0.60 
P=0.041 
0.79    
CG18067  CG18067 CG18067 0.76 
P=0.006 
0.81    
serpin 1  Spn1 CG9456  0.73 
P=0.031 
0.81  SERPINB4 serine  protease  inhibitor 
Limpet  Lmpt CG32171  0.69 
P=0.019 




Ect3 CG3132  0.82 
P=0.039 
0.88  GLBL1  autophagic cell death 
CG12998  CG12998 CG12998 0.71 
P=0.023 
0.88    
bangles and 
beads 
bnb CG7088  0.82 
P=0.023 
0.88   gliogenesis 
CG4721  CG4721 CG4721 0.87 
P=0.046 
0.89   Metallo-endopeptidase 
CG7299  CG7299 CG7299 1.22 
P=0.032 
0.90    
CG14528  CG14528 CG14528 0.84 
P=0.015 
0.91   Metallo-endopeptidase 
CG9689  CG9689 CG9689 1.18 
P=0.022 
0.93    
CG17777  CG17777 CG17777 1.61 
P=0.009 
0.96    
Mth-like 2  mthl2 CG17795  1.05 
P=0.001 




Transferrin  Tsf1 CG6186  0.90 
P=0.048 
0.98    cellular iron ion 
homeostasis 
CG16836  CG16836 CG16836 1.09 
P=0.012 
1.04    
CG34020  CG34020 CG34020 1.14 
P=0.049 
1.08      232 











CG5428  CG5428 CG5428 1.30 
P=0.033 
1.28  SULT1E1 Sulfo-transferase 
CG10191  CG10191 CG10191 1.08 
P=0.039 
1.32  WDR51A  
CG6188  CG6188 CG6188 1.40 
P=0.001 
1.34  GNMT methionine  metabolism 
Cytochrome 
P450-4e3 
Cyp4e3 CG4105 1.57 
P=0.010 
1.35   electron  carrier 
CG32641 /// 
CG32640 
CG32641   CG32641  0.55 
P=0.048 
1.44    
CG5966  CG5966 CG5966 1.92 
P=0.001 
1.49  PNLIP triacylglycerol  lipase 
metchnikowin  Mtk CG8175  1.47 
P=0.009 
1.52   defense  response 
Turandot  TotA CG31509  3.14 
P=0.008 
2.66   stress  response 
Turandot C  TotC CG31508  4.16 
P=0.004 
3.19   stress  response   233 
Table C4: Genes altered in elav>rAUUCU and elav>rCAG flies compared to elav>+. 
Selected for Log2(ratio) >0.5 or <-0.5 for elav>rAUUCU and elav>rCAG compared to elav>+, 
P<0.05 for elav>rCAG. 
 













Ste12DOR CG32616 -2.88 
P=0.002 
-2.33   Spermatogenesis, 




Obp19c CG15457  -0.75 
P=0.029 
-0.9   Sensory  perception  of 
chemical stimulus 
CG32552  CG32552 CG32552  -0.55 
P=0.013 
-0.87    
CG13077  CG13077 CG13077  -0.55 
P=0.019 
-0.85  CYB561D2  
CG13117  CG13117 CG13117  -0.53 
P=0.015 
-0.84    
CG13895  CG13895 CG13895  -0.62 
P=0.016 
-0.62    
CG15545  CG15545 CG15545  -0.52 
P=0.029 
-0.62    
CG7031  CG7031 CG7031  -0.52 
P=0.022 
-0.58    
CG14959  CG14959 CG14959  0.81 
P=0.012 
-0.56   Chitin  binding 
CG11893  CG11893 CG11893  -0.81 
P=0.001 
-0.52    
Modifier67.2  mod(mdg4) CG32491  -0.76 
P=0.012 
-0.52   Regulation  of  chromatin 
assembly 
CG9686  CG9686 CG9686  0.55 
P=0.014 
0.54    
CG9186  CG9186 CG9186  0.58 
P=0.017 




IM2 CG18106  0.75 
P=0.017 
0.66   Immune  response 
CG4484  CG4484 CG4484  0.54 
P=0.039 
0.73  SLC45A1 Glucose  trans-
membrane transport 
CG9657  CG9657 CG9657  0.61 
P=0.030 





Hr38 CG1864  1.05 
P=0.040 
0.91  NR4A1/ 
NGFI-B 
Ligand-dependent 
nuclear receptor activity 
CG14528  CG14528 CG14528  0.85 
P=0.026 
1.04   Metallo-endopeptidase 
CG11825  CG11825 CG11825  0.70 
P=0.019 
1.17    
CG2540  CG2540 CG2540  0.56 
P=0.030 
1.18    
CG7526  CG7526 CG7526  -1.88 
P=0.024 
1.21    
CG14495  CG14495 CG14495  1.04 
P=0.002 
1.3      234 











CG9394  CG9394 CG9394  1.00 
P=0.002 
1.33   Lipid  metabolism, 
glycerol-phosphodiester 
phosphodiesterase 
CG11910  CG11910 CG11910  0.99 
P=0.047 
1.41    Insulin-like growth factor 
binding protein complex 
CG13704  CG13704 CG13704  0.73 
P=0.045 
1.56    
white  w CG2759  2.67 
P=0.002 
3.59  ABCG5  Eye pigment precursor 
transport, metabolic 
process   235 
Table C5: Genes altered in elav>rAUUCU and elav>rCUG flies compared to 
elav>+. Selected for Log2(ratio) >0.5 or <-0.5 for elav>rAUUCU and elav>rCUG 
compared to elav>+, P<0.05 for elav>rCUG. 
 













Ste12DOR CG32616  -2.00 
P=0.03 
-2.33   Spermatogenesis,  protein 
kinase regulator 
CG18646  CG18646 CG18646  -0.56 
P=0.047 
-1.55   GTPase  activity 
CG16752  CG16752 CG16752  -1.24 
P=0.006 
-1.51   Neuropeptide  receptor 
activity 
CG4078  CG4078 CG4078  -0.52 
P=0.046 
-1.44  RTEL1  Nucleotide excision repair 
CG40485  CG40485 CG40485  -0.65 
P=0.003 
-1.35   Oxidoreductase  activity 
CG12825  CG12825 CG12825  -0.59 
P=0.041 
-1.03    
CG40084  CG40084 CG40084    -0.89 
P=0.011 
-1.02    
CG40188  CG40188 CG40188  -0.76 
P=0.040 
-0.94    
CG13908  CG13908 CG13908 -0.95 
P=0.012 
-0.91    
CG32552  CG32552 CG32552  -0.86 
P=0.009 
-0.87    
CG13077  CG13077 CG13077  -0.79 
P=0.027 
-0.85  CYB561D2  
CG13117  CG13117 CG13117  -0.56 
P=0.009 
-0.84    
CG31781  CG31781 CG31781  -0.82 
P=0.010 
-0.81    
sickie  sick CG42589  -0.81 
P=0.015 
-0.79   Immune  response 
CG5010  CG5010 CG5010  -0.70 
P=0.026 
-0.78  CHCHD2  
CG31846  CG31846 CG31846  -0.77 
P=0.027 
-0.75      236 













hts CG9325  -0.62 
P=0.032 
-0.74  ADD1  Actin assembly, ring canal 
formation 
Cyp12a4  Cyp12a4 CG6042 -0.82 
P=0.050 
-0.73  CYP24A1 Electron  carrier  activity 
CG5883  CG5883 CG5883  -0.75 
P=0.005 
-0.71    Chitin metabolic process 
CG31814  CG31814 CG31814  -0.61 
P=0.014 
-0.67  HNT  
D-Titin  sls CG1915  -0.8 
P=0.029 






PQBP-1 CG31369  -0.73 
P=0.013 
-0.66    
CG7330  CG7330 CG7330  -0.70 
P=0.024 
-0.66    
CG13293  CG13293 CG13293  -0.55 
P=0.033 
-0.66    
mindmelt  mbl CG33197  -0.60 
P=0.022 
-0.66  MBNL1  Splicing factor, muscle and 
nervous system 
development 
CG15311  CG15311 CG15311  -0.66 
P=0.001 
-0.65   Diphosphatase 
CG32521  CG32521 CG32521  -0.8 
P=0.008 
-0.63    
sequoia  seq CG32904  -0.81 
P=0.041 
-0.58   Dendrite  morphogenesis 
CG1463  CG1463 CG1463  -0.62 
P=0.007 




Sbf CG6939  -0.54 
P=0.046 
-0.53  SBF2 DAG  signalling 
expanded  ex CG4114  -0.58 
P=0.023 
-0.52  FRMD6 Regulation  of  cell 
proliferation and 
differentiation 
fettucine  cic CG5067  -0.51 
P=0.011 
-0.52  CIC Transcription  factor  activity   237 













shep CG32423  -0.73 
P=0.002 
-0.52    
CG14614  CG14614 CG14614  -0.63 
P=0.017 
-0.51  WDR68  
Overflow  Dl CG3619  -0.56 
P=0.001 
-0.51  DLL1  Notch signalling pathway, 
neural development 
bruno  aret CG31762  -0.52 
P=0.014 
-0.51  CUGBP1  Regulation of alternative 
splicing and translation 
CG9449  CG9449 CG9449  0.60 
P=0.031 
0.53   phagocytosis 
CG9686  CG9686 CG9686  0.54 
P=0.016 
0.54    
CG8021  CG8021 CG8021  0.57 
P=0.035 
0.56    
CG9186  CG9186 CG9186  0.77 
P=0.031 
0.57    
CG10006  CG10006 CG10006  0.95 
P=0.001 
0.58  SLC39A6 Metal  ion  transporter 
Kua  Kua CG10723  0.91 
P=0.002 
0.67  KUA  
CG9449  CG9449 CG9449  0.60 
P=0.031 
0.76   phagocytosis 
Olfactory-
specific E 
Os-E CG11422  0.52 
P=0.046 
0.78   Sensory  perception  of 
chemical stimulus 
CG3603  CG3603 CG3603  0.59 
P=0.018 
0.82  HSD17B8 Oxidation  reduction 
CG17758  CG17758 CG17758  0.75 
P=0.017 
0.83  OTOP1  
CG32581   CG32581 CG32581    1.31 
P=0.003 




Hr38 CG1864  0.55 
P=0.028 





CG6465  CG6465 CG6465  1.01 
P=0.014 
0.98  ACY1  Hydrolysis of acetylated 
amino acids   238 













Ccp84Ag CG2342 0.54 
P=0.047 
1.02   Component  of  cuticle 
CG12179  CG12179 CG12179  0.74 
P=0.041 
1.12    
lethal (1) 
G0155 
Ykt6 CG1515  1.05 
P=0.012 
1.15  YKT6 Vesicle-mediated 





Pk17E CG7001  1.36 
P=0.003 




Obp8a CG12665  1.11 
P=0.001 





Rala CG2849  2.03 
P=0.018 
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Amendments: 
 
The following changes and additions have been made to this thesis: 
 
1.  Line 1, Page 155 should read “The principal aim of this study was…” 
 
2.  The following text should be inserted at the end of the Introduction (Page 26) to clarify 
the “working hypothesis” and specific hypotheses tested in this study: 
 
“This thesis investigates the role of hairpin-forming RNA species in pathogenesis of the 
expanded repeat diseases. It specifically tests the intrinsic toxicity of untranslated 
expanded repeat sequences and their ability to induce cellular dysfunction in a 
Drosophila model. The “working hypothesis” of this work is that expression of hairpin-
forming RNA species causes cellular dysfunction which contributes to pathogenesis in 
both the polyglutamine diseases and the untranslated repeat diseases. 
 
Several separate hypotheses have been tested in this thesis: 
•  In Chapter 3, a role for RNA editing in pathogenesis of CAG repeat RNAs is 
investigated. This hypothesis is based on the observation that RNA editing is 
essential for survival of a subset of neurons which are amongst those most 
affected in some of the expanded repeat diseases, as well as the prediction that 
the structure formed by CAG repeat RNA may be a target for editing. 
•  In Chapter 4 and 5, an investigation of cellular effects of expression of CAG and 
CUG repeat RNAs was performed by proteomic and microarray analyses 
respectively, based on the hypothesis that the similar structures of these RNA 
species may result in similar cellular outcomes. The ability of candidates from 
the microarray analyses to interact with expanded repeats in this model was 
then validated, as described in Chapter 6.  
•  Since the expanded repeat responsible for SCA10 is also predicted to form a 
similar hairpin secondary structure, a Drosophila model of expression of the 
associated repeat sequence, an AUUCU repeat, was also generated in the 
course of this study. Chapter 7 describes this model and investigates cellular 
effects of expressing this sequence.    274 
•  As a result of the outcomes of investigation of cellular effects of expression of 
different expanded repeat sequences, the hypothesis that CAG, CUG and 
AUUCU repeat RNAs perturb the Akt/Gsk3 pathway was tested. This data is 
described in Chapter 8 of this thesis.” 
 
 
3.  The following text should be inserted before the Discussion (Page 155) to reaffirm the 
outcomes of the thesis: 
 
“This study has produced data which supports the hypothesis that expression of 
expanded repeat RNAs is able to cause cellular dysfunction. This appears to be an 
intrinsic property of the expanded repeat sequences. 
•  A role for RNA editing in CAG repeat pathogenesis was not supported by the 
results described in Chapter 3. 
•  A number of candidates involved in expanded repeat pathogenesis were 
identified in Chapter 4 and 5. Several of these also showed an interaction with 
expanded repeat RNA, as described in Chapter 4 and 6. 
•  The SCA10 AUUCU repeat sequence was demonstrated to act in a similar 
manner to the CAG and CUG repeat sequences, both in its ability to form 
cellular foci and in the sort of cellular changes which expression produced. 
This data is described in Chapter 7. 
•  A role for the Akt/Gsk3 pathway in expanded repeat pathogenesis was 
supported by genetic validation in Chapter 8.” 
 
 
4.  The following text should be added to the end of the Discussion (Page 160): 
 
“While this study describes a number of cellular outcomes of expanded repeat 
expression in Drosophila, no evidence of neurodegeneration was observed in this model. 
The absence of severe effects in this model may suggest that these sequences are not 
highly toxic in Drosophila, possibly as a result of short lifespan. It may therefore be 
appropriate to further investigate neurodegenerative phenotypes, including ataxia, 
resulting from expression of hairpin RNAs in a mouse model.”   